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Abstract
Flavonoids are one of the largest groups of natural plant products and are 
found in most, if not all, fruits and vegetables. As dietary components, flavonoids have 
widespread biological properties and have been associated with several health benefits, 
including reduced risk of cancer and cardiovascular disease. The flavonol, quercetin, 
one of the most ubiquitous dietary flavonoids, is found principally as glycoside 
conjugates in plants and quercetin-3-glucosylrhamnoside (rutin) is one of the more 
common forms. To establish the role of rutin as a protective agent in vivo, it is critical to 
understand the chemical nature of the absorbed forms and their in vivo concentrations in 
the circulatory and excretory system. The bioavailability of rutin is not very well 
understood as reflected by the varying peak plasma concentrations {Cmax) and the time 
taken to reach the peak plasma concentration (Tmax) reported in the literature. This may, 
in part, be due to the analytical techniques used which include acid or 
glucuronidase/sulphatase treatments to release the parent aglycone prior to quantitative 
analysis by low resolution, isocratic reverse-phase HPLC. In addition, there has been 
some debate on the types of rutin catabolites produced as a result of colonic breakdown. 
There is therefore a need for further more detailed information on the absorption, 
metabolism and bioavailability of rutin.
The underlying objective in Chapter 3 was to investigate the metabolism and 
absorption of rutin in vivo after ingestion of tomato juice supplemented with 164 
pmoles (lOOmg) of rutin. Rutin was found to be extensively metabolised and made 
bioavailable to humans reflected in the identification of many phase II metabolites and 
catabolites. Using HPLC-photodiode array (PDA) detection, the phase II metabolites of 
rutin in the circulatory system were identified with an electronspray ionisation MS  ^ as 
isorhamnetin-3-glucuronide and quercetin-3-glucuronide. The Cmax of the two plasma 
metabolites ranged from 5.2-32 nM; with an average accumulation of 15 nM, which 
corresponds to 0.01-0.06% of the rutin ingested. In contrast, a total of nine rutin 
metabolites were detected in urine samples. In addition to the plasma metabolites, 
methylquercetin diglucuronide, three isomers of quercetin glucoside glucuronide, 
quercetin diglucuronide, quercetin-4-glucuronide and quercetin-3'-glucuronide were 
found to accumulate in the urine. There were considerable inter-individual variations in 
the excretion of the urinary metabolites where a range of 4981 ± 115 to 40 ± 1 nmoles 
of metabolites were excreted over a 24 h period after the ingestion of the rutin
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supplement. Rutin metabolites did not appear in the circulatory system until 4-5 h after 
ingestion indicating that absorption was occurring in the large rather than in the small 
intestine. More direct proof was provided in studies with ileostomy volunteers where 
92% of the rutin was found to pass through the small intestine and emerged without 
modification, in the ileal fluid. In the large intestine, rutin appeared to be rapidly 
catabolised by the colonic microfiora leading to ring fission and the appearance in urine 
of phenolic acids in amounts corresponding to 23% of rutin intake. Utilising both 
healthy humans and subjects with an ileostomy, three phenolic acids were identified as 
being potential ring fission products of rutin, namely, 3-hydroxyphenylacetic acid, 3,4- 
dihydroxyphenylacetic acid and 4-hydroxy-3 -methoxyphenylacetic acid.
To investigate the role of colonic microfiora in the breakdown of rutin, an in 
vitro faecal fermentation study was carried out as discussed in Chapter 4. Accumulation 
of quercetin in the fermentation vessel as early as 4 h after incubation indicated that 
deglycosylation was the initial step in the colonic breakdown of rutin. The addition of 
glucose to the fermentation media enhanced the deglycosylation process by almost 20 h. 
To identify and quantify further degradation products, which may be produced in 
smaller concentrations, 55 pmoles of quercetin spiked with 18 x 10^  dpm [^^CJquercetin 
(60 nmoles) was used as the substrate in in vitro fermentation trial. Utilizing the HPLC- 
MS  ^with atmospheric pressure chemical ionisation (APCI) and PDA detection, a range 
of intermediate products and catabolites of quercetin were identified. The first 
intermediate products of quercetin degradation were detected after 2 h of incubation and 
they were identified as taxifolin, alphitonin and an isomer of taxifolin. Subsequent 
fermentation products identified were 3,4-dihydroxyphenylacetic acid, 3- 
hydroxyphenylacetic acid, 3,4-dihydroxybenzoic acid, 4-hydroxybenzoic acid, 3 (3- 
hydroxyphenyl)propionic acid. The main catabolite to accumulate during in vitro 
fermentation of faecal samples with quercetin was 3,4-dihydroxyphenylacetic acid (60- 
97% conversion). Addition of glucose to the fermentation media enhanced both the rate 
of deglycolysation of rutin and the subsequent catabolism of quercetin, the released 
aglycone. It was envisaged that the presence of glucose altered the microfiora colony, 
enhancing the growth and the multiplication of bacterial strains responsible for the 
degradation of quercetin.
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The isoflavone, genistein is considered to be one of the most potent flavonoid 
compounds due to its pharmacological activities as a tyrosine kinase inhibitor and as a 
phytoestrogen. With limited consumption of genistein-rich food such as soybean, in 
Western cultures, the idea of genetically directing the synthesis of genistein in plants 
that do not synthesize isoflavones has gained widespread interest in recent years. The 
study in Chapter 5 aimed at achieving this objective. An attempt was made to direct the 
synthesis of genistein in arabidopis and in tomato by introducing isoflavone synthase 
(ITS), which is the key enzyme for the entry into the isoflavonoid biosynthetic pathway. 
The full length IFS cDNA from soybean roots was isolated and cloned into binary 
vectors, pGlasglow and pCHF3 habouring the CaMV 35S promoter and into pER8 
vector carrying an estrogen inducible G10-90 promoter. Using agrobacterium mediated 
transformation, the IFS gene was introduced in arabidopsis and tomato. Due to the 
nature of the pER8 construct and its G10-90 promoter, a 3-10 fold higher gene 
expression level was observed in arabidopsis transgenic plants transformed by pER8 
binary vector than those transformed with pGlasglow. High levels of gene silencing was 
observed when using the CaMV 35S in arabidopsis and total gene silencing was 
observed when the same promoter was used in tomatoes. HPLC-PDA-MS^ analysis of 
leaf extracts in the highly and moderately expressed IFS arabidopsis lines failed to 
detect the presence of genistein. Western blot analysis implied that IFS proteins were 
synthesized and accumulated in the leaves of arabidopsis and were present ‘freely’ in 
the cytoplasm rather than being membrane bound as they would in their natural 
environment. It was, therefore, hypothesised that the ‘free’ IPS was not able to access 
the substrate, naringenin which may be compartmentalized in a pre-existing 
multienzyme complex, and as a consequence, IFS was unable to synthesize genistein.
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1: Introduction
1.1 Functional food and health implications
An emerging trend in human healthcare is the focus on the link between diet 
and disease. Expanding knowledge of the role of physiologically active food 
components, from both plant and animal sources, has notably changed the role of diet in 
health. This new dimension of foods called “functional foods” provide an opportunity to 
combine high compliance food products with biologically active molecules as a strategy 
to consistently correct metabolic disturbances that lead to chronic disease (Salminen et 
al, 1998). The beneficial components, which are physiologically active in functional 
foods have been referred to by various terms such as phytochemicals, fimctional 
components, and bioactive conponents (Pennington, 2002).
Bioactive compounds typically occur in small amounts in foods. Inherently, 
bioactive compounds have more subtle effects than nutrients as they are more likely to 
influence cellular activities that modify the risk of disease (Kris-Etherton et al 2004). 
Functional food components have been associated with the prevention and/or treatment 
of at least four of the leading causes of death in the world: cancer, diabetes, 
cardiovascular disease, and hypertension. It is also associated with the prevention and/or 
treatment of other medical ailments including neural tube defects, osteoporosis, 
abnormal bowel function, and arthritis (Ahmad, 2002). A great deal of epidemiological 
evidence has indicated that the bioactive ingredients in finits and vegetables are 
responsible for the protective effects against numerous forms of cancer and 
cardiovascular diseases. Epidemiological and observational studies have consistently 
shown an inverse association between consumption of vegetables and fi*uits and the risk 
of human cancers and heart diseases (van’t Veer et a l, 2000; Jensen et a l, 2004). As a 
result of these studies there has been an active search to identify bioactive compounds 
particularly from fhiit and vegetables to determine their associated health effects and to 
elucidate their underlying biological mechanism of action.
Through intensive research in past decade, an impressive and growing number 
of bioactive compounds have been identified that have potentially important health 
benefits. To date there are approximately 120 naturally occurring foods that have been 
identified as containing bioactive components and could therefore be designated as 
functional (Pennington, 2002). These include a range of chemical compounds with
varying structures such as carotenoids, flavonoids, plant sterols, omega-3 fatty acids, 
allyl and diallyl sulfides, indoles (benzopyrroles), and phenolic acids. These compounds 
can act as antioxidants, antibacterial, antiviral, enzyme inhibitors and inducers, 
inhibitors of cholesterol absorption, decreasing platelet aggregation, inhibitors of 
receptor activities, and inducers and inhibitors of gene expression. (Pennington, 2002 
and Kris-Etherton et al, 2004). Due to the chemical and biological diversity of 
biological active compounds, the range of their molecular targets, and their possible 
interactions, the research in this field can be immensely complex. One of the more 
important groups of bioactive corrponents that will be focused on in the present study is 
flavonoids.
1.2 Flavonoids
Since ancient times, flavonoids appear to have played a major role in the 
successful medical treatments and their use has persevered up to now (Havsteen, 2004). 
Nutritionists became interested in flavonoids in the 1930’s when it was shown that 
flavonoids from citrus fruits decreased capillary permeability and had some antioxidant 
properties (Rusznyâk and Szent-Gyorgi, 1936). In the 1990’s flavonoids once again 
became popular, principally due to a combination of increased concern surrounding 
high levels of coronary heart disease and a reduction in its incidence by dietary 
components. Hertog et al (1993) in a study in the Netherlands, reported that 
flavonol/flavone intake was inversely associated with both mortality and with the 
incidence of myocardial infarction. Since then, the literature on flavonoids has increased 
tremendously. At present, flavonoids are one of the major foci of nutritional and 
therapeutic interest, especially in its involvement as cardioprotection, neuroprotection, 
and as chemopreventive agents (Havsteen, 2004).
1.3 Distribution and chemical form of flavonoids
The flavonoids are qualitatively and quantitatively one of the largest groups of
natural products known (Havsteen, 2004). Favonoids are distributed mainly in plants as 
they alone possess the ability to synthesize flavonoids. Since many flavonoids are 
pigments, their colors are undoubtedly associated with some of their important 
biological functions. As pigments, their electronic properties appear to include not only 
energy capture and transfer, but also in biological selectivity (Havsteen 2004). The 
latter is related with the attraction of suitable pollinators, e.g., insects and birds. In
addition to this, flavonoids are also associated with the selective activation of light- 
sensitive genes, where it is now evident that plants are using light not only as a source 
of energy, but also for gene regulation (Kirby & Styles, 1970).
Flavonoids are polycyclic structures consisting of 15 carbon atoms based on a 
C6-C3-C6 skeleton. In a few cases, the six-membered heterocyclic ring C occurs in an 
isomeric open form or is replaced by a five-membered ring such as in chalcone. 
According to the cyclization and the degree of unsaturation and oxidation of the three- 
carbon segment, they can be classified into several groups, the main ones being 
flavones, flavonols, flavan-3-ols, flavanones, isoflavones, and anthocyanidins (Figure 
1.1).
Flavone
o
Flavonol Isoflavme
Fiavan-3-oI
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Figure 1.1. The main generic structures of flavonoid
In most cases, the flavonoids are present as glycosides in vacuoles of flowers, leaves, 
stems or roots ((Iwashina, 2000). At present, about 400 flavone aglycones, 450 flavonol 
aglycones, 350 flavanone aglycones, 300 isoflavone aglycones, 19 anthocyanidins and 
250 chalcone aglycones have been reported (Iwashina, 2000). Flavonoid conjugation 
occurs in plants with additional substituent groups such as hydroxyl, methoxyl, methyl 
and/or glycosyl units. Occasionally, aromatic and aliphatic acids, sulphate, prenyl, 
methylenedioxyl or isoprenyl groups also attach to the flavonoid nucleus and their 
glycosides. Thus, more than 4,000 kinds of flavonoids have been reported as naturally- 
occurring compounds (Iwashina, 2000).
1.3.1 Flavonols
Flavonols are widespread in plant foods; the main flavonols are quercetin, 
kaempferol, isorhamnetin and myricetin (Figure 1.2). Of these the most common 
flavonol in the diet is quercetin. It is present in various fruits and vegetables, but the 
highest concentrations are found in onion (Hertog et al. 1992). Quercetin is present in 
plants in many different glycosidic forms and in onions, it is present principally as 
quercetin-4-glucoside and quercetin-3,4-diglucoside. Another widespread form of 
quercetin is quercetin-3-glucosyl-rhamnoside, more commonly known as rutin. Rutin is 
found abundantly in crops such as buckweed, tomatoes and asparagus. Other quercetin 
glycosides present in the diet are, quercetin galactosides (apples) and quercetin 
arabinosides (berries). Other flavonols in the diet include kaempferol (broccoli), 
myricetin (berries, maize) and isorhamnetin (onion and pears) (Peterson and Dwyer, 
1998).
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Ri=OH R2=0H: myricetin
R]=0 CH3  R2 =H: isorhamnetin
Figure 1.2. Structure of common flavonols.
1.3.2 Flavones
Flavones are structurally very similar to flavonols (see Figure 1.3) but differ 
from flavonols only in the absence of hydroxylation at the 3-position in the C-ring. The 
main flavones in the diet are apigenin and luteolin but since they are not so widely 
distributed (Crozier, 2003), their dietary intake is rather low. They are most prominent 
in cereals, herbs and vegetables such as celery, sweet red pepper and parsley (Peterson 
and Dwyer, 1998).
OH
HO
OH
Ri=H; apigenin 
Ri=OH luteolin
Figure 1.3. Structure of common flavones.
1.3.3. Flavanones
Flavanones are mainly represented by naringenin, hesperitin and eriodictyol. 
Two structural features, i.e., the absence of a double bond, and the presence of a 
chiral center at the carbon-2, characterize flavanones (Iwashina, 2000) (Figure 1.4). The 
flavanone structure is highly reactive and they have been reported to undergo 
hydroxylation, glycosylation and 0-methylation reactions (Crozier, 2003) (Figure 1.5). 
Flavonones are found principally in citrus fruit mainly as hesperitin and contribute to 
the flavour of citrus (Peterson and Dwyer, 1998). Naringenin is found in tomatoes and 
tomato-based products. Fresh tomatoes, especially the skin, also contain naringenin 
chalcone, which is converted to naringenin during the manufacture of tomato ketchup 
(Krause & Galensa, 1992).
Ri=H R2 =0 H: naringenin
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Figure 1.4. Structure of common flavanones
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Figure 1.5. Glycosides o f flavanones
1.3.4 Anthocyanidins
Anthocyanidins are widespread in higher plants (Timberlake, 1988). Nineteen 
types of naturally-occurring anthocyanidins have been reported (Iwashina, 2000). The 
common anthocyanidins are pelargonidin, cyanidin, peonidin, delphinidin, petunidin 
and malvidin (Iwashina, 2000) (Figure 1.6). These compounds are found in planta as 
their sugar-conjugated derivatives, called anthocyanins, a group of water-soluble 
compounds responsible for most floral, fruit and leaf pigmentation in nature (Clifford, 
2000). As pigments, they play an important role in attracting insects to flowers for 
pollination (Crozier, 2003). Anthocyanidins are also responsible for the red, blue or 
violet colour of edible fruits including grapes, plums and berries, with levels increasing 
during fruit maturation (Peterson & Dwyer, 1998).
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Figure 1.6. Structure of anthocyanidins
1.3.5 Flavan-3-ols
Flavan-3-ols are a complex in nature and range from the simple (+)-catechin 
and its isomer (-)-epicatechin, to the oligomeric and polymeric proanthocyanidins, also 
known as condensed tannins (Figure 1.7). Flavan-3-ols are widely distributed in the 
plant kingdom and are found abundantly in apricots, sour cherries, grapes and 
blackberries (Porter, 1988). The flavan-3-ols also contribute to the astrigent taste of tea 
and wine. In addition to forming complexes with other flavan-3-ols to produce 
proanthocyanidins, they also undergo estérification with gallic acid to form catechin 
gallates, and hydroxylation reactions to form gallocatechins (Figure 1.7). These forms 
of flavan-3-ols, particularly (-)-epigallocatechin gallate and (-)-epigallocatechin are 
abundantly found in green tea (Steward et al., 2005).
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Figure 1.7. Structure of flavan-3-ols (catechins and epicatechins)
1.3.6. Iso (lavoues
In contrast to most other flavonoids, isoflavones have a very limited 
distribution in the plant kingdom. Isoflavones are found primarily in leguminous species 
(Dixon and Steele, 1999; Graham, 1991). The commonly known isoflavones are 
genistein, daidzein and glycitein and they are principally found in soybeans, black beans 
and green split peas. Structurally isoflavones differ from the common flavonoid in the 
orientation of the B ring. They are characterised by having the B ring attached at the C3
rather than the C2 position (Figure 1.8). Isoflavones undergo various modifications, 
such as méthylation, hydroxylation, or polymerization and these modifications lead to 
simple isoflavonoids, such as isoflavanones, isoflavans, and isoflavanols, as well as 
more complex structures, such as rotenoids, pterocarpans, and coumestans (Dewick, 
1993). Isoflavones are popularly known for their estrogenic activity and have received 
much attention due to their putative role in the prevention of breast cancer and 
osteoporosis (Barnes, 2003).
Ri=OH R2 =H: genistem
R]=H R2 =H; daidzein
R]=H R2 = OCH3 : glycitein
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Figure 1.8. Structure of common isoflavones.
1.4 Important dietary flavonoids
Certain dietary flavonoids are particularly bioactive and have pronounced 
effects on human health. Two of the most potent flavonoids are quercetin and genistein. 
Both these compounds display a wide range of biological effects (discussed in Section 
1.5.2) and epidemiological studies suggest that both these compounds play an important 
role in disease prevention (discussed in Section 1.5.1). Quercetin, one of the most 
ubiquitous dietary flavonoids is principally found as glycoside conjugates in plants and 
one of the more common forms being rutin (Figure 1.9)
OH
OH
HO 0OH
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Figure 1.9. Structure of rutin
1.5 Evidence of health effects of flavonoids
1.5.1 Epidemiological studies
Epidemiologic studies suggest an inverse relationship between a high dietary 
intake of fruits and vegetables with many degenerative diseases such as cancer and 
cardiovascular disease (Steinmetz and Potter, 1996; Law and Morris, 1998; Riboli and 
Norat, 2003). It has been hypothesized that vegetables and fruits contain bioactive 
compounds, such as flavonoids, that have protective effects, independent of those of 
known nutrients and micronutrients (Arts and Hollman, 2005).
1.5.1.1 Cardiovascular disease
In the past decade a number of epidemiological studies have been carried out 
attempting to correlate high flavonoid intake with the risk of disease. To date, 12 cohort 
studies on flavonoid intake and the risk of coronary heart disease (CHD) and 5 cohort 
studies on the risk of stroke have been published (Arts and Hollman, 2005). Most, but 
not all, these studies have indicated some degree of inverse association (from borderline 
to relatively high levels) between flavonoid intake and fatal or nonfatal CHD, and 
reductions of mortality risk were up to 65%. An inverse association was found in the 
Zutphen Elderly Study (Hertog et al., 1993), the Finnish Mobile Clinic Study (Knekt et 
al., 1996), the Iowa Women’s Health Study (Yochum et al., 1999), the Alpha- 
Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study (Hirvonen et al, 2001) 
and the Rotterdam Study (Geleijnse et ah, 2002). In contrast negative or no association 
was found in three main studies, the Caerphilly Study (Hertog et al, 1997), the Health 
Professionals Follow-up Study (Rimm et a l, 1996) and in the Women's Health Study 
(Liu et al, 2000 Hennekens, 1992). In addition, case-control studies have also 
suggested that high flavan-3-ol and flavonol intake through the consumption of tea is 
beneficial (Sesso et al, 1999; Mukamal et a l, 2002). Further support for the benefit of 
higher flavonoid intake is provided by studies relating to red wine consumption to CHD 
(Pearson, 1996; Di Castelnuovo et al, 2002). As in the cohort studies, several case- 
control studies also demonstrated no relationship between flavonoid intake and 
cardiovascular risk (Vita, 2005).
1.5.1.2 Cancer
Studies relating flavonoid intake to cancer rates have assessed the relationship 
of food groups rich in these compounds to cancer risk. One of the most widely cited
studies, which provided a strong evidence for a protective role of flavonoids against 
cancer, was carried out by Knekt et al (1997) in the Finnish Mobile Clinic Health 
Examination Survey. In another study, Knekt et al (2002) investigated the dietary 
intakes of flavonols, flavones and flavanones against several chronic diseases. It was 
revealed that higher quercetin intakes were correlated with lower incidence of lung and 
breast cancer while the incidence of prostate cancer was lower with higher myricetin 
intakes. Higher quercetin intake also led to a significant reduction of the incidence of 
stomach cancer (De Stefani et a l, 2000). In a more recent study, six principal classes of 
flavonoids, namely, flavanones, flavan-3-ols, flavonols, flavones, anthocyanidines, and 
isoflavones were investigated against the incidence of breast cancer. A reduced risk 
was obtained with increasing intake of flavones and flavonols while no significant 
association was found with the other flavonoids (Bosetti et al, 2005).
Lower cancers incidences, including breast, prostate, and colon cancer is 
associated with Japanese and Chinese diets compared to those in Europe and the United 
States. Many investigators have suggested that this may be due to the level of 
consumption of soy foods in Japan and China. It has been proposed that soy foods, 
which contain high levels of isoflavones, are often associated with reductions in the 
incidence of cancer, although they do not always appear to be the primary protective 
component of the Asian diet (Birt et al, 2001). In line with this, consumption of 
fermented and salted soy paste was positively associated with gastric cancer (Hu et a l, 
1988) while prostate cancer rates were lowest among Hawaiian men of Japanese 
descent who consumed soybean curd (Severson et a l, 1989)
Although there has been studies that showed inverse correlation between the 
intake of flavonoids and cancer risk, other investigators had difficulties in assessing the 
relationship between the level of intake of flavonoids and protection against cancer 
(Hertog, et al, 1994, 1995; Garcia-Closas et al, 1998; Wu et a A, 1998).
1.5.1.3 Other chronic diseases
Due to the potent biological activities such as their antioxidant and 
antiinflammatory properties, the influence of high intakes of flavonoids was also 
investigated on other chronic diseases involving oxidative stress or inflammation, such 
as rheumatoid arthritis and chronic obstructive pulmonary disease. On studying the 
relationship between the intakes of different classes of flavonoids and rheumatoid
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arthritis, type 2 diabetes mellitus, cataracts, and asthma, Knekt et al. (2002) found a 
significant inverse association between high intakes of quercetin and the incidence of 
asthma. This finding supported an earlier cross-sectional study, in which intake of 
flavonoids specifically catechin was beneficially associated with pulmonary fiinction 
and symptoms of obstructive pulmonary disease (Tabak et al., 2001).
1.5.1.4 Confounding factors of epidemiological studies
Cohort and case control studies in epidemiology investigates the relationship 
between food intake and disease development and are critically dependent on the 
accurate measurement of the consumption of specific foods. However in most studies, 
due to lack of adequate food composition data, it is almost impossible to quantify the 
daily flavonoid intake. In most of the epidemiological studies mentioned above, only 
very few flavonoids were assessed and quantified in fruits and vegetables before they 
were correlated with the development of disease. In addition, inaccuracies in the 
analytical methods employed, or the small size of the investigations are also factors that 
may cause confounding results with epidemiological studies (Birt et a\., 2001).
Epidemiological studies can never prove causation; that is, it cannot prove that 
a specific risk factor actually causes the disease being studied. Epidemiological 
evidence can only show that this risk factor is associated (correlated) with a higher 
incidence of disease in the population exposed to that risk factor. The higher the 
correlation the more certain the association, but it cannot prove the causation. In 
addition, it also cannot prove which compounds in the food consumed were responsible 
for the observed health benefit. In conclusion, current epidemiological evidence is only 
suggestive that flavonoids may play a role in disease prevention, particularly in CHD 
and cancer.
1.5.2 Bioactivity and probable mechanism of action of flavonoids
A considerable body of literature supports a role for oxidative stress in the 
pathogenesis of age-related human diseases. More and more evidence indicates that a 
proper balance between oxidants and antioxidants is needed to maintain health and 
alterations to this balance may result in pathological responses causing functional 
disorders and diseases. In this context, flavonoids were thought to protect cell 
constituents against oxidative damage through direct scavenging of free radicals due to 
their antioxidant properties, which was evident through in vitro cell culture or cell free
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systems (reviewed in Heim et al., 2002). However, with the recent advances gained 
through research in the field of metabolism and absorption, it is clear that most 
flavonoids are modified during absorption from the small intestine, through conjugation 
and metabolism, and by the large intestine, mainly through the actions of the colonic 
microflora, and by subsequent hepatic metabolism of the components that are absorbed 
(Mullen et ah, 2004; Day et al, 2003a; Manach et al, 2004; Graefe et al, 2001). Thus, 
flavonoid metabolites that reach the cells and tissues are chemically, biologically, and in 
many instances, functionally distinct from the dietary form and such features underlay 
their bioactivity (Kroon et al, 2004). This, in addition to the fact that very low levels of 
flavonoids (<10 pM) are actually absorbed, implies that the concept of flavonoids 
functioning as hydrogen-donating antioxidants in vivo appear to be an oversimplified 
view of their mode of action (reviewed in Williams et a l, 2004; Halliwell et a l, 2005; 
Williamson and Manach, 2005). It was, therefore, hypothesised that cells respond to 
flavonoids mainly through direct interactions with receptors or enzymes involved in 
signal transduction, or through modifying gene expressions which may result in 
modification of the redox status of the cell that may trigger a series of redox-dependent 
reactions (Williams et al, 2004).
However, antioxidant and other protective effects of flavonoids and other 
phenolic compounds could occur before absorption, that is, within the gastrointestinal 
(GI) tract itself (Halliwell et al, 2005). This is due mainly to the fact that flavonoids in 
the GI tract are present at far higher concentrations after consumption of foods and 
beverages rich in polyphenols than their metabolites in the circulatory system 
(Watanabe et a l, 1998; Gee and Johnson, 2001).
1.5.2.1 Direct and indirect radical scavenging within the GI tract
The GI tract is unique compared to other organs in the body because it 
represents a critical defence barrier against luminal toxic agents and is constantly 
challenged by diet-derived oxidants, mutagens, and carcinogens as well as by 
endogenously generated reactive oxygen species (ROS) (Ames, 1983). To preserve 
cellular integrity and tissue homeostasis, the GI tract, specifically the large intestine, 
posses several physiological defense mechanisms such as maintaining high antioxidant 
concentrations (glutathione, tocopherol, and ascorbic acid), up-regulating antioxidant 
enzymes systems (glutathione peroxidase, glutathione reductase and superoxide 
dismutase), and inducing cell death by apoptosis to dispose of injured or spent
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enterocytes (Awe, 1999). During oxidative stress, an imbalance in the cellular 
prooxidant-antioxidant balance in favour of prooxidants occurs, which results in gut 
pathologies such as inflammation and cancer (Aw, 2003). Flavonoids and their 
metabolites/catabolites may become concentrated in the intestine due to minimal 
absorption in the upper GI tract and as such would be well placed to interact with the 
mucosal cells where they may exert their antioxidant capacity to scavenge free radical 
cations thereby assisting in the maintainence of a reduced redox state. An indication of 
the level of antioxidants in human large intestine was provided by Garsetti et al. (2000) 
who reported that the antioxidant levels obtained in faeces at 26.6 ± 10.5 mM Trolox 
was much greater than in plasma which contained 1.46 ± 0.14 mM Trolox. In addition, 
the total amount of antioxidants excreted over 24 h was found to be significantly and 
positively correlated to the consumption of beverages rich in polyphenols (Garsetti et 
al, 2000).
The antioxidant activity of flavonoids varies considerably among different 
backbone structures and functional groups. The difference in ROS scavenging between 
the flavonoids can be accounted for by the variation in the number and kind of 
functional groups present. Basically, there are three functional groups that are 
associated with an increase in the ROS scavenging potential among the flavonoids: the 
dihydroxy structure of the B ring; the C2-C3 double bond in concert with a 4-oxo 
function of the C ring; and the additional presence of both a 3- and a 5-hydroxyl moiety 
of the C and A rings, respectively (Bors et al, 1990) (Figure 1.10).
Figure 1.10. Chemical structure of quercetin indicating the number and types of 
functional groups present which accounts for its antioxidant activity
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Free radical scavenging capacity, which is primarily attributed to the high reactivities of 
hydroxyl substituents can be summarized in the following reaction:
F-OH+R-^F-O’+RH
where F -  flavonoid; R - free radical; F-0 - flavonoid radical 
The B ring hydroxyl configuration is the most significant determinant of scavenging of 
ROS and reactive nitrogen species (RNS). Hydroxyl groups on the B ring donate 
hydrogen and an electron to hydroxyl, peroxyl, and peroxynitrite radicals, stabilizing 
them and giving rise to a relatively stable flavonoid radical (reviewed in Heim et ah,
2002).
The stomach, small and large intestine are also known to have large amounts 
of peroxidases, which are capable of inducing lipid peroxidation (Miura et ah, 2002). 
This process causes damage to unsaturated fatty acids, thereby decreasing membrane 
fluidity, which may lead to many pathological events. However, this process can be 
quenched effectively by flavonoids. In addition to scavenging of ROS and RNS, the 
3'4'-catechol structure in the B ring of flavonoids strongly enhances inhibition of lipid 
peroxidation (Dugas et ah, 2000; Ratty and Das, 1988). In the large intestine, in 
addition to flavonoids, the presence of phenolic acids, which are the colonic catabolites 
of flavonoids can also provide additional protection through their anti-radical 
scavenging capacity. Phenolic acids such as 3,4,5-trihydroxybenzoic (gallic) acid and 
1,2,3-trihydroxybenzene (pyrogallol) with three hydroxyl groups bonded to the aromatic 
ring in an ortho position were found to posses the highest antioxidant activity, followed 
by those with two hydroxyl groups such as 3,4-dihydroxycinnamic (caffeic), 3,4- 
dihydroxybenzoic (protocatechuic) and 2,3 -dihydroxybenzoic (o-pyrocatechuic) acids 
(Sroka and Cisowski, 2003).
Flavonoids can also act indirectly as antioxidants by forming a “redox inactive 
complex” with metal ions such as Cu and Fe (Sugihara et ah, 1999; Sahu and Gray, 
1997). By removing and neutralizing these metal ions from the intestine, flavonoids 
inhibit oxidative damage by preventing Fenton type reactions, which is an important 
generator of ROS in vivo (Galey, 1997).
1.5.2.2. Interactions with intracellular signalling cascades
There is now emerging evidence that flavonoids may play an important role as 
modulators of intracellular signalling cascades, which are vital to cellular frmction
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(Williams et ah, 2004). Intracellular signaling cascades are the main routes of 
communication between the plasma membrane and regulatory targets in various 
intracellular compartments. These signalling cascades seems to consist of up to five 
tiers (levels) of protein kinases that sequentially activate each other by phosphorylation, 
which subsequently affects the activity of transcription factors and thereby gene 
expression (Seger and Krebs, 1995). The presence of these cascades enables the cells to 
respond to a variety of different stresses or signals which in turn regulate numerous cell 
processes, including growth, proliferation and death (apoptosis) (Williams et al., 2004). 
Flavonoids can exert modulatory effects in cells through selective actions at different 
components of the signalling cascades (Schroeter et a l, 2001, Kong et al., 2000; Matter 
et al., 1992). Intracellular concentrations of flavonoids required to affect cell signalling 
pathways are considerably lower than those required to impact on cellular antioxidant 
capacity, and flavonoid metabolites may still retain their ability to interact with cell 
signaling proteins, even if their antioxidant activity is diminished (Spencer et al., 2003a 
and 2003b; Williams et al., 2004). Modulation of the signalling pathway by flavonoids 
could provide protection against cancer and cardiovascular diseases through a number 
of mechanisms such as:
• Regulation of cell cycle: During the cellular division, DNA becomes more 
susceptible to damage. To counteract damage, mechanisms within the cell 
ensure that the cell cycle is transiently arrested at damage checkpoints to allow 
for DNA repair as defective cell cycle results in the propagation of mutations 
that contribute to the development of cancer. Chen et al. (2004) and Wang et al.
(2004), in separate experiments demonstrated that apigenin and epigallocatechin 
gallate could inhibit and arrest growth of tumour and cancer cells through 
regulating normal cell cycle progression.
• Apoptosis induction: Unlike normal cells, cancer cells proliferate rapidly and 
lose the ability to respond to cell death signals. Sah et al. (2004) demonstrated 
epigallocatechin gallate are able to induce apoptotic cell death in cervical cancer 
cell lines, thereby providing protective effects.
• Inhibition of tumor invasion and angiogenesis: Cancerous cells invade normal 
tissue and generate new capillaries by sprouting of pre-existing blood vessels via 
a process known as angiogenesis, to fuel their rapid growth. Luteolin, genistein.
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apigenin, and 3-hydroxyflavone were found to posses anti-angiogenesis 
properties, and the mechanism in which they act are thought to be at least in part 
via inhibiting the expression and activation of specific components of the 
signalling cascades (Bagli et a l, 2004; Kim, 2003).
Decreasing inflammation; O'Leary et al. (2004) and Sakata et al. (2003) 
demonstrated that flavonoids such as quercetin and hesperidin may exert their 
anti-inflammatory and immunomodulatory properties by suppressing the 
activation of specific protein kinases, thus inhibiting the production of 
cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) which 
are related to anti-inflammatory and anti-tumorigenic efficacies.
Decreasing vascular cell adhesion molecule expression; Atherosclerosis is 
characterized by the accumulation of cholesterol deposits in macrophages in 
arteries. This deposition leads to a proliferation of certain cell types within the 
arterial wall that gradually impinge on the vessel lumen and impede blood flow. 
This process requires the expression of endothelial adhesion molecules (Stocker 
and Keaney, 2004). Flavones and epigallocatechin-3-gallate were found to 
reduce the expression of these endothelial adhesion molecules (Choi et al., 2004; 
Ludwig et al., 2004).
Increasing endothelial nitric oxide synthase (eNOS) activity: eNOS is the 
enzyme that catalyzes the formation of nitric oxide by vascular endothelial cells. 
Nitric oxide is needed to maintain arterial relaxation as insufficient levels of it is 
associated with increased risk of CHD. Endothelium-derived nitric oxide 
bioactivity appears to be increased by supplementation with a number of 
polyphenols (Duffy and Vita, 2003). One of the mechanisms suggested is 
mediated through modulation of the protein kinase signalling pathway which 
activates production of eNOS (Anter et a l, 2005).
Decreasing platelet aggregation: Platelet aggregation contributes to both the 
development of atherosclerosis and acute platelet thrombus formation. It can 
therefore result in myocardial infarction or stroke. Inhibiting platelet aggregation 
is considered an important strategy in the primary and secondary prevention of 
cardiovascular disease. Hubband et a l (2003) and Pignatelli et a l (2000) 
demonstrated that polyphenols such as hydroxycinnamates, catechins and
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quercetin are able to inhibit platelet fiinction. The mechanism involved may be 
mediated, at least partly, through the modulation of the protein kinases 
signalling pathways (Deana et ah, 2003; Bucki et ah, 2003).
1.6 Bîoavaîlabilîty, absorption and metabolism of flavonoids
1.6.1 Bioavailability: concepts and methods of detection
The term ‘bioavailability’ and its underlying concept were initially introduced 
in the field of pharmacology, where bioavailability was defined by the Food and Drugs 
Administration (FDA) as ‘the rate and extent to which a drug reaches its site of action’. 
Because of the problems in the quantification of a compound at its ‘site of action’, this 
concept was modified to account for the fraction of an oral dose of a substance or its 
metabolite(s) that reaches the systemic circulation (Stahl et ah, 2002). Thus, 
bioavailability can be determined either in a single or multiple-dose experiment by 
measuring the peak blood concentration (Cmo%), the time to reach the peak concentration 
{Tmax), and the area under the blood concentration time curve (AUC). However the 
plasma pharmacokinetic parameters to determine bioavailability are limited by several 
factors. The concentration of the flavonoids in plasma does not represent bioavailability 
per se, as it actually represents a balance between intestinal absorption, breakdown, 
tissue uptake, and release from body stores (Yeum & Russell 2002). Flavonoids also 
tend to have a very low signal-to-noise ratio (Deprez & Scalbert 1999; Heaney 2001) 
and due to this, relatively large dosages of flavonoids, usually exceeding the typical 
daily intake, are generally needed for a significant increase in flavonoid concentrations 
over baseline levels in plasma (Yeum & Russell 2002). The assumption that the blood 
concentration and the biological activity of a compound are proportional is not always 
the case as suggested by Hoppe and Krennrich (2000).
Other methods used for the measurement of bioavailability include the balance 
method (Heaney, 2001). Here the differences between what is ingested and what is 
found in the faeces are measured. This method, however does not take into 
consideration bacterial transformation or degradation of the ingested compounds. 
Another more sensitive and reproducible method of measuring bioavailability is the 
tracer method using stable or radioactive isotopes. In this technique, the body 
distribution of labeled compounds is reflected by the absorption of the ingested 
compound including potentially unknown metabolites and the whole body auto­
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radiography can help to identify target tissues (Deprez & Scalbert 1999). Due to 
radiation hazard, radiolabelled flavonoids can only be fed to animals while stable 
isotopes can be administered in human intervention studies. However, in using this 
technique, number and the positioning of the radiolabelled atoms within the flavonoid 
molecule can very crucial in determining not only the strength of the signal but more 
importantly in the metabolic fraction that can be identified after metabolism or/and 
catabolism The amount of compound excreted into the urine is also sometimes used as 
a measure of absolute bioavailability. The urine increment method is based on the fact 
that plasma concentrations of the flavonoids are proportional to the amounts excreted in 
urine (Heaney, 2001). However, this only describes the minimum amount of compound 
absorbed since other routes of excretion, such as biliary excretion, are overlooked.
To-date there is no single approach that is recommended for measuring 
bioavailability of flavonoids. Due to differences in absorption mechanism, metabolism, 
intestinal enzymes, degradation by intestinal flora, stability of the flavonoid compound, 
body distribution and excretion pathways, each type of flavonoid may require one or 
more approach to accurately access its bioavailability (Walle et a l, 2003; Scalbert & 
Williamson, 2000). Other factors including the food matrix, the type of preparation, the 
individual the mucosal mass, intestinal transit time and rate of gastric emptying can also 
affect bioavailability of flavonoids (Erlund 2004). To gain a better understanding on the 
various parameters affecting bioavailability, researchers in this field have employed a 
number of different approaches. Using human intestinal cell culture, such as Caco-2 
cells and enzymatic studies, experimentations on bioavailability were carried out in 
vitro (Walle et al., 2003). In ex vivo conditions, investigators mainly employed rodent 
intestinal preparations while in vivo conditions both humæi and animal intervention 
trials were used to estimate bioavailability (Spencer et al, 2003).
It is also important to note that flavonoids do not need to enter the systemic 
circulation to be bioactive (Walle, 2004). Many of them are thought to exert their cancer 
preventive effects in epithelial cells. One such example is exhibited by the tea 
flavonoid, epicatechin-3-gallate, where it was demonstrated to be extensively taken up 
by the Caco-2 cells (Vaidyanathan and Walle, 2003).
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1.6.2. Absorption of flavonoids
Food components must, by definition, be made bioavailable in some form to 
exert biological effects. From recent advances made on flavonoid absorption and 
metabolism studies, it is apparent that a large number of flavonoids are absorbed. For 
example, micromolar plasma concentrations of different classes of flavonoids have been 
detected after consumption of flavonoid-rich onions, red wine and soya. These findings 
reveal that flavonoids are able to cross the intestinal barrier and reach micromolar 
concentrations in the bloodstream (Williamson and Manach, 2005).
1.6.2.1 Absorption of flavonoids, small or large intestine?
There are many factors that influence the extent and rate of absorption of 
ingested flavonoids. These include physiochemical factors of the flavonoid itself which 
include the molecular size and lingkage, lipophilicity, solubility and, pKa (Spencer
2003). Most polyphenols are present in food in the form of esters, glycosides, or 
polymers that cannot be absorbed in their native form. These substances must be 
hydrolyzed by intestinal enzymes or by the colonic microflora before they can be 
absorbed (reviewed by Manach et al, 2004). Depending on the type of lingkages, the 
flavonoids are either absorbed in the small or large intestine. Only aglycones and some 
glucosides can be absorbed in the small intestine, whereas flavonoids linked to a 
rhamnose moiety must reach the colon and be hydrolyzed by glycosidases of the 
microflora before absorption. This is supported by human intervention trials carried out 
by Graefe et al (2001) where absorption from rutin and quercetin glucosides were 
conpared. Peak plasma concentrations of quercetin, following ingestion of either onion 
or quercetin 4'-glucoside were similar i.e Cmax 7.0-7.6 pM and maximum absorption 
occurred 0.5-0.7 h after oral ingestion. Even with double the dose, the peak plasma 
concentration of quercetin from buckweed tea or rutin was significantly lower with a 
Cmax 1.0-2.0 pM and Tmax was delayed until 6-9 h after ingestion of rutin. Lower 
absorption rates in the colon than in the small intestine caused by a smaller exchange 
area and a lower density of transport systems, could result in rutin being absorbed less 
rapidly and less efficiently in the colon than quercetin glucosides, in the small intestine 
(Manach et al, 2004). The results of similar human intervention trials carried out by 
other investigators (Hollman et al, 1997; Hollman et a l, 1999; Olthof et al., 2000) are 
summarized in Figure 1.11. The results obtained imply that although the food matrix 
may influence absorption, the type of conjugate attached to the flavonoid skeleton, is
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the most important factor contributing to the overall bioavailability of the flavonoid 
moiety. To gain more information on the site of absorption from gastrointestinal tract, 
studies have been carried out with animals using quercetin and its glycosides (reviewed 
in Day and Williamson, 2003). All the results revealed similar patterns of absorption to 
those observed in human intervention trials where quercetin and quercetin glucosides 
were absorbed much earlier and in higher amounts than rutin.
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Figure 1.11. Summary o f published data. These data reveal the time taken to reach and T^ a.x in 
plasma after consumption o f rutin and quercetin glucosides. Q3G, quercetin 3-glucoside; Q4'G, 
quercetin-4'-glucoside. C„,ax' Maximum plasma quercetin concentration (pM ); Time taken to 
reach C^a:v(hours); ® Hollman el al., 1999; O lthof et al., 2000; Graefe et al., 2001 ;  ^ Hollman et a i,  
1997
1.6.2.2. Absorption variability between flavonoid aglycones
Absorption also differs greatly from one flavonoid to another. In a recent 
review by Manach et ai. (2005) the time to reach Cmax and the plasma AUC  were 
calculated for 18 major polyphenols. The plasma Cmax of total metabolites ranged from 
0.4-4 pM with an intake of 50 mg aglycone equivalents. Gallic acid and isoflavones are 
the most well-absorbed polyphenols, followed by catechins, flavanones, and quercetin 
glucosides, but with different kinetics. The least well-absorbed polyphenols are the 
proanthocyanidins, the galloylated tea catechins, and the anthocyanins.
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1.6.2.3. Effect of food matrix on absorption
Although the effects of the food matrix on the absorption of flavonoids have 
not been thoroughly examined, direct interactions with some components of food, such 
as binding to proteins and polysaccharides is known to occur, and these interactions may 
affect absorption. Schramm et al. (2003) demonstrated that absorption of flavan-3-ols 
could be increased significantly by concurrent carbohydrate consumption. In another 
study, Serafini et al. (2003) reported that addition of milk to black tea reduced the 
antioxidant potential, suggesting interactions of milk proteins with flavonoids. 
However, this effect was not consistent as subsequent studies showed that addition of 
milk to either black or green tea had no effect on the absorption of catechins, quercetin, 
or kaempferol in humans (reviewed by Manach et al, 2004). Similarly, some studies 
indicate that the presence of alcohol in wine can improve the intestinal absorption of 
polyphenols by increasing their solubility while other studies indicated otherwise. 
Donovan et al. (1999), for instance, reported that the plasma concentrations of catechin 
metabolites were similar after consumption of red wine or dealcoholized red wine. 
Indirect effects of food matrix on the pH, intestinal fermentations, biliary excretion, 
transit time etc. may also affect the gut physiology and thereby influence absorption of 
flavonoids (Erlund 2004).
1.6.2.4. Mechanism of absorption.
Due to the complexity of the in vivo environment, investigators have used two 
main approaches to gain information about the mechanisms of the gastrointestinal 
absorption of flavonoids. These involve the use of rat intestinal perftision models and 
human intestinal Caco-2 cell cultures (Walle et al., 2003). Since most dietary 
flavonoids are probably too hydrophilic to penetrate the gut wall by passive diffusion, 
membrane carriers have been suggested to be involved in their absorption. To date, the 
only active transport mechanism that has been described is a Na^-dependent saturable 
transport. Hollman et al. (1999) proposed that glucosides could be transported into 
enterocytes by the sodium-dependent glucose transporter SGLTl. This would imply that 
intact quercetin glucoside can be transported across the enterocyte and possibly could 
appear in the plasma. However, in human intervention studies, intact quercetin 
glucosides were absent in plasma after supplementation and this tends to weaken the 
SGLTl hypothesis (Day et al., 2001; Mullen et al, 2004). Walgren et a l (1998), using 
Caco-2 cell monolayer, demonstrated that quercetin was reasonably well absorbed but
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quercetin glucoside was initially absorbed via the SGLTl transporter but was later 
refluxed across the apical membrane. This opposing transporter to the SGLTl was 
proposed to be the multidrug resistance-associated protein 2 (MRP2) transporter 
(Walgren et ah, 2000).
The Caco-2 cell and rat intestinal perfusion studies have also pointed to an 
alternative mechanism of absorption of flavonoids, that is, hydrolysis of quercetin 
glucosides to release quercetin, which then could then be absorbed (Sesink et ah, 2003; 
Walgren et ah, 2000). Additional evidence supporting this pathway was produced by 
studies carried out in ileostomy volunteers in which the administration of quercetin 
glucosides resulted in complete hydrolysis within the small intestine, followed by 
effective absorption of quercetin (Walle et ah, 2000). In enzymatic studies, high levels 
of endogenous p-glucosidase activity have been demonstrated in both human and 
animal small intestine epithelial cells and in human liver (Day et ah, 1998). In rat 
intestinal cells, two B-glycosidases are present, cytosolic B-glucosidase (CBG) and 
lactase phlorizin hydrolase (LPH) (Sesink et ah, 2003; Day et ah, 2003). CBG has 
hydrolytic activity toward several flavonoid glucosides, but not quercetin-3-glucoside 
while LPH, an extracellular enzyme located at the brush border membrane of rat 
intestinal cells is able to hydrolyze flavonoid glucosides, including quercetin-3- 
glucoside (Day et ah, 2003). In contrast, quercetin-4'-glucoside is hydrolysed by both 
LPH and CBG (Day et ah, 2003). However, the hydrolytic step in vivo has yet to be 
established.
1.6.3. Metabolism — conjugation and nature of flavonoid metabolites
The term metabolism is used here to describe the typical modifications that 
occur during or after absorption (Kroon et ah, 2004). The gastrointestinal lumen, cells 
of the intestinal wall, and the liver are important sites of flavonoid metabolism. The 
metabolism of flavonoids is a matter of interest because metabolism may considerably 
change the function, activity of a compound and impact on its ability to enter cells 
(Kroon et ah, 2004). The primary defence mechanisms against toxic or xenobiotic 
compound are the enzymes that catalyse detoxification reactions and are classified as 
the phase I and phase II metabolising enzymes (Sanchez et ah, 2001).
Phase II metabolising enzymes are widely distributed among tissues such as 
the intestines, liver and the kidneys (Sanchez et ah, 2001). After absorption, flavonoids
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are metabolized by the phase II drug-metabolising enzymes, the uridine-5’-diphosphate 
glucuronosyl-transferases (UGTs), cytosolic phenol-sulfotransferases (SULTs), and 
catechol-O-methyltransferases (COMTs) (reviewed in Manach et a l, 2004). The 
resulting molecules are glucuronide and sulfate conjugates with or without méthylation 
across the catechol functional group, and many are multiple conjugates. A proportion of 
the flavonoid metabolites that resulted from intestinal conjugation are taken up and 
metabolized by the liver (O'Leary et a l, 2003) and then partially secreted in the bile. 
However, the metabolic fate of the flavonoid conjugates in the liver is not yet known. It 
has been postulated that after uptake by HepG2 cells, quercetin 7-glucuronide and 
quercetin 3'-0-glucuronide undergo two types of metabolism; méthylation of the 
catechol and deglucuronidation followed by 3’-sulfation (O’Leary et al, 2003). The 
detection of flavonoid metabolites of quercetin, luteolin, eriodictyol, and catechin in the 
bile of rodents showed that most flavonoids undergo enterohepatic recycling (Crespy et 
ai, 2003) and are secreted back into the intestinal lumen.
16.3.1. Colonic metabolism
Studies have suggested that the extent of absorption of dietary flavonoids in 
the small intestine is relatively small (10-20%) (Spencer, 2003). Flavonoids that are not 
absorbed in the small intestine or excreted by the enterohepatic cycling will be carried to 
the colon where they encounter the colonic microflora. Using animal models, human 
intervention trials and in vitro fermentation of the flavonoid with human faecal samples 
or anaerobic bacterial strains, investigators have atterrpted to identify the various 
catabolites produced in the colon after consumption of dietary flavonoids (Olthof et a l, 
2003; Aura et a l, 2002; Rechner et al, 2004; Labib et al, 2004; Braune et al, 2001; 
Bravo et al, 1994). Results from these various studies indicate that the enormous 
catalytic and hydrolytic potential of the microflora splits the flavonoid nucleus by ring 
fission, which results in the production of an array of catabolites (Spencer, 2003). 
Depending on the chemical structure of the flavonoids, various types of phenolic acids 
can be produced through the catabolic action of the microflora. The flavonols are 
catabolised to form hydroxyphenylacetic acids, the flavones and flavanones mainly 
produce hydroxyphenylpropionic acids, while the flavan-3-ols are known to produce 
phenylvalerolactones and hydroxyphenylpropionic acids (reviewed in Manach et a l, 
2004). Other than ring fission, the bacterial enzymes are also known to catalyze many 
other reactions including hydrolysis, dehydroxylation, déméthylation, decarboxylation
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and deconjugation (Scheline, 1999). In addition to the phenolic acids mentioned above, 
formation of benzoic acid, hippuric acid and hydroxyhippuric acids may also be a 
possible catabolites of flavonoids, in which the colon microflora and the liver were 
proposed to be active metabolic sites (Scheline, 1999).
The identification and quantification of microbial metabolites constitute an 
important field of research as some recent studies have revealed higher plasma 
concentrations and urinary excretion of microbial catabolites in humans compared to 
conjugated metabolites. (Gonthier et ah, 2003; Rechner et al., 2002). In addition, 
Halliwell et ai (2005) reported that concentrations of the colonic catabolites range from 
15-410 pM, compared to 0.7pM of flavonoids present in the colon. Halliwell et al
(2005) fiirther suggested that as a consequence of these high concentrations, phenolic 
acids might exert direct protective effects within the large intestine which could include 
binding of prooxidant iron, scavenging of reactive nitrogen, chlorine, and oxygen 
species, and perhaps inhibition of cyclooxygenases and lipoxygenases. In addition to 
this, microbial metabolites may also have physiological effects as indicated by studies 
carried out by Kim et al, 1998 in which hydroxyphenylacetic acids inhibited platelet 
aggregation.
1.6.4. Tissue uptake
Actual bioavailability of flavonoids occurs when their metabolites reach the 
site of action, which are the tissues or the organs. Therefore the determination of 
flavonoid metabolites in tissues or organ may be much more important than their 
concentrations in the circulatory system as it provides essential information about the 
potential site of accumulation of flavonoids. However, data in this topic is very limited, 
even when using animal models. Tissue or organ uptake of flavonoids is normally 
measured following in vivo feeding experiments. One such study that has provided 
evidence on this aspect was carried out by Abd El Mohsen et al. (2002). After oral 
ingestion of 100 mg kg'  ^ body weight per day of (-)-epicatechin, two metabolites, i.e., 
epicatechin glucuronide and 3’-0-methyl epicatechin glucuronide were found in the 
trace quantities in rat brain tissue. Using radiolabelled flavonoids, valuable information 
have also been obtained which allows the accumulation of flavonoids and their 
metabolites to be monitored in various organs and tissues following oral consumption. 
In a study utilising "^^C-labelled quercetin-4-glucoside in rats, only 6.4% of the 
recovered radioactivity was detected outside the gastrointestinal tract 60 min after
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consumption (Mullen et ah, 2002) suggesting limited absorption and low levels of 
metabolites in plasma and peripheral tissues. Flavonoids have also been detected in a 
wide range of other tissues and this is evident by a feeding trial carried out using 
[^H](-)-epigallocatechin gallate which led to the detection of radioactivity in various 
organs, including the liver, lung, pancreas, mammary gland, skin, brain, kidney, uterus 
and ovary, and testes (Suganuma, 1998). The isoflavone genistein was found to 
accumulate in the rat brain, liver, mammary, ovary, prostate, testis, thyroid and uterus 
after ingestion of genistein (Chang et al., 2000).
1.6.5. Elimination of flavonoids
There are three major pathways of flavonoid excretion, i.e, via the biliary and 
the urinary routes or through the faeces. Large, extensively conjugated metabolites are 
more likely to be eliminated in the bile, whereas small conjugates such as 
monosulphates are preferentially excreted in urine (Manach et a l, 2004). Using in situ 
perfusion of jejunum and ileum of rats, the relative magnitude of biliary excretion was 
found to vary from one flavonoid to another. For some flavonoids such as genistein, 
biliary secretion may be an important excretion route as it encompasses about 30% of 
the perfused dose while it encompasses only 1% and 6% of the dose in catechins and 
quercertin, respectively (Crespy et a l, 2003). Other than genistein, biliary excretion 
may also be a major pathway for the elimination of (-)-epigallocatechin gallate and 
eriodictyol (Kohri et al, 2001). However, biliary excretion of polyphenols in humans 
may differ greatly from that in rats because of the existence of the gall bladder in 
humans. To-date this possibility has not been investigated. Since intestinal bacteria 
possess 6-glucuronidases activity, it is able to release fi*ee aglycones fi*om conjugated 
metabolites secreted fi’om the bile resulting in reabsorption of aglycones produced via 
enterohepatic cycling. Evidence of enterohepatic cycling has been obtained with rats 
(Coldham et al, 2000) and with humans as a second Cmax plasma peak after ingestion of 
isoflavones (Watanabe et al, 1998; Setchell et al, 2001).
The urinary excretion of flavonoids has been discussed quite thoroughly in a 
recent review carried out by Manach et al (2005), where data from 97 studies were 
investigated for the kinetics and extent of polyphenol absorption and excretion among 
adults. Variation in the urinary excretion profile was obtained depending on the type of 
flavonoid ingested. The urinary excretion of anthocynanins ranged from 0.004% to
0.1% of the ingested dose while, the excretion of flavonols were slightly higher; the
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percentage excreted are 0.9% for rutin and 6.4% quercetin glycosides from onions. The 
excretion of flavanones was quite high at 4-30% of intake, and is even higher for 
isoflavones; the percentages excreted are 16-66% for daidzein and 10-24% for 
genistein. Data on the kinetics of excretion of the catabolites of flavonoids in humans 
are limited. Olthof et al. (2003) reported that after ingestion of rutin by humans, the 
total urinary excretion of microbial catabolites accounted for as much as 50% of the 
supplement. Following ingestion of (-)-epigallocatechin and (-)-epicatechin, catabolite 
excretion equivalent to 6-39% of intake was observed (Meng et al, 2002).
There have been conflicting reports on the excretion of flavonoids in the 
faeces Using radiolabelled quercetin, Ueno et al., 1983, found as much as 45% of 
the administered dose appeared in the faeces of rats. Coldham & Sauer (2000) found 
33% of intake excreted in urine and faeces, following an oral dose of -labelled 
genistein to rats. In human intervention studies, 5% of the ingested radiolabelled 
quercetin was excreted in the faeces (Walle et al, 2001). In vitro fermentation studies 
with quercetin glycosides and rutin using human faecal samples, there was a complete 
degradation to phenolic acids (Aura et a l, 2002, Rechner et al, 2003). The excretion of 
flavonoids in the faeces may differ between individuals, as it may be dependent on the 
activity of the colonic microflora, the degree of enterohepatic circulation, different 
intestinal transit time and the amount ingested.
1.7 Value of a varied diet
Not all plant foods contain all the essential nutrients or bioactive conpounds 
needed for human health, nor do they usually contain these compounds in sufficient 
concentrations or amounts to meet daily dietary requirements in a single serving 
(Grusak, 1999). In fact, scientific evidence from the various observational and 
epidemiological studies indicate that consumption of a complex and varied diet that is 
rich in nutrients and bioactive compounds are essential for achieving good health (Liu,
2004). This observations, however, raises one key question, that is, whether a purified 
bioactive compound has the same health benefit as the conpound when its source is a 
food or a mixture of foods. Evidences to-date points to the fact that the actions of the 
dietary supplements alone do not explain the observed health benefits of diets rich in 
finits and vegetables, because, taken alone, the individual bioactive corrpounds do not 
appear to have consistent preventive effects (Stephens et a l, 1996; Yusuf et a l, 2000). 
It is the additive and the synergistic effects of these bioactive compounds found in fiiiits
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and vegetables that are believed to be responsible for the protective effects as against 
diseases such as CHD and cancer (Liu, 2004).
Evidence of the benefits of food synergy was provided by an experiment 
carried out by Liu (2000). He demonstrated that a combination of fruits such as orange, 
apple, grape, and blueberry displayed a synergistic effect in antioxidant activity. The 
median effective dose (EC50) of each fhiit after combination was 5 times lower than the 
EC50 of each fruit alone, suggesting synergistic effects after the combination of the 4 
ftnits. In another study, Sakamoto (2000) emphasized the importance of consuming 
black tea together with soybean products as commonly carried out in a typical Japanese 
diet. In this study, thearubigen (a polyphenol in black tea) did not alter the in vitro 
growth of human prostate cancer cells when administered alone. However, a small 
amount (0.5 pg mL'^) of theambigen administered with genistein (20 pg mL'^), the 
major isoflavone in soybean, synergistically inhibited cell growth and increased the 
DNA distribution at the G2M phase of the cell division cycle by 34% compared with 
genistein alone (Sakamoto, 2000). Similar conclusions were derived by Temple and 
Gladwin (2003) when they reviewed > 200 cohort and case-control studies that provided 
risk ratios concerning intake of fruits and vegetables and risk of cancer. Their studies 
showed that the cancer-preventing action of finits and vegetables are most probably due 
to the many bioactive compounds that act in concert to prevent cancer rather than due to 
one or two potent anticarcinogens. It therefore can be concluded that consumption of 
vegetables and fruits to improve health have more beneficial effects that consuming 
dietary supplements, which do not contain the balanced combination of bioactive 
compounds.
1.8 Improving bioactive composition in plants to enhance human 
health
To ensure an adequate dietary intake of essential bioactive compounds, 
researchers have been interested in improving the bioactive composition and its 
concentration in plants. This would enable the increase of essential or potent bioactive 
components within the complex diverse array of other bioactive components present in 
the plant. Enhancement of bioactive compounds of plants can be tackled using a variety 
of approaches. Conventional breeding is one such approach, exemplified by the 
production of broccoli with an enhanced glucosinolate content (Faulkner et al., 1998).
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Glucosinolates are thought to have a role in the prevention of cancer by acting as 
inducers of the anti-carcinogenic marker en2yme, quinone reductase. Another major 
approach to bioactive component enhancement involves genetic modification. With the 
advent of GM technologies, molecular biologists, biochemists, botanists and medical 
researchers are linking in with plant breeding programmes to develop new varieties of 
fruit and vegetables that are tailor-made to produce higher levels of health-related 
bioactive compounds (Verrips et al., 2001). An example of which is the production of 
‘golden rice’, which has enhanced levels of the P-carotene in its grains (Beyer et al., 
2002).
1.8.1. Identification of target bioactive compounds for ‘biofortification’
Although the ability to manipulate plant metabolism is becoming well 
established, identifying which target bioactive compound for ‘biofortification’ can be 
problematical (Tucker, 2003). In Section 1.5.1.3, on discussing the confounding factors 
of epidemiological studies it was mentioned that such studies cannot prove causation 
and thus cannot attribute the beneficial effects of consumption of fruits and vegetables 
to any particular bioactive compound within these foods. In addition, the total content, 
or absolute concentration, of a given bioactive compound in a food is not always a good 
indicator of its useful nutritional quality, because not all of the bioactive compounds in 
food are absorbed and made bioavailable to the body as discussed in Section 1.6. In 
addition, most bioactive compounds undergo considerable metabolism upon ingestion, 
which change their chemical and biological nature and thus are functionally distinct 
from the dietary form and such features underlie their bioactivity.
Therefore to identify and choose the target bioactive compounds for 
enhancement, several factors should be taken into consideration, which include the 
absolute concentration, its bioavailability and the bioactivity of its metabolites. One 
such compound that excels in these respects is genistein, an isoflavone that is found 
primarily in leguminous species.
1.8.1.1 Genistein as the target bioactive compound for ‘biofortification’
Genistein (4',5,7-trihydroxyisoflavone) is biosynthetically the simplest form of 
isoflavone (Dixon and Ferreira, 2002). Major dietary sources of genistein for humans 
are soybean. Soybeans contain between 580 and 3800 mg isoflavones/kg fresh wt, and 
soymilk contains between 30 and 175 mg/L (Reinli and Block, 1996).
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Genistein’s many biological activities have made it a widely researched subject 
with over 3600 published studies in the last 10 years. Genistein, like the other 
flavonoids have the same biological activities and mode of action as discussed in 
Section 1.5.2. In addition, genistein is also known to have other pharmacological 
activities such as being a potent tyrosine kinase inhibitor and possessing phytoestrogen 
activity (Barnes et a l, 2000; Akiyama et al, 1987). Genistein shares structural 
similarities with the potent estrogen estradiol-17p and tamoxifen, a synthetic anti­
estrogen (Barnes et a l, 2000). These features confer its ability to bind estrogen 
receptors and sex hormone binding proteins. Genistein is able to bind to the estrogen 
receptor with an affinity 20-100 times lower than estradiol, thereby exerting its 
phytoestrogenic activity (Bames et a l, 2000). Its phytroestrogenic activity may confer 
its use in postmenopausal symptoms as indicated in a study where an isoflavone-rich 
diet was also observed to help approximately two thirds of post-menopausal women to 
better cope with hot flushes, in addition to potentially reducing the risk of CHD, which 
is elevated at post menopause (Dixon and Ferreira, 2002). Genistein’s anti-cancer 
property is based on its inhibition of DNA topoisomerase II and protein tyrosine kinase 
(Akiyama et al, 1987). Unlike other isoflavonoids, genistein exerts toxicity only at 
concentrations greatly in excess of those at which it first exerts its biological and 
pharmacological effects, making it a potentially important cancer chemoprevention 
dietary molecule (Dixon and Ferreira, 2002).
A number of studies have also been carried out on the bioavailability of 
isoflavones. After reviewing the kinetics and extent of polyphenol absorption from a 
total of 97 human intervention studies, isoflavones were found to be one of the most 
well-absorbed polyphenols (Manach et a l, 2005). In addition to the conjugated phase II 
metabolites, about 4-9 % of isoflavone intake is absorbed directly as aglycones without 
conjugation (Setchell et al 2001) and can therefore exert the biological activities as the 
aglycone. One of the most important colonic catabolite of isoflavone is equol and many 
in vitro studies and animal models has shown that equol is more estrogenic than its 
precursor (Setchell e ta l  2001). Another point worth noting is the evidence that high 
concentrations of isoflavones were found in breast tissue of premenopausal women and 
in prostate glands of men, where they are believed to exert their anticancer properties 
(Maubach et a l, 2003, Hong et al, 2002). To date, these are the only available data on 
polyphenol concentrations in human tissues.
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Isoflavones such as genistein are primarily found in leguminous species and 
their distribution is restricted to crop plants such as soybean. However, soybean is 
mainly consumed in the eastern and southeastern Asian regions of the world. In 
contrast, in United States and in Europe, its consumption is limited and restricted to 
ethic minorities. Due to the traditional limited consumption of soybean in Western 
cultures, the idea of genetically directing the synthesis of genistein in plants that do not 
synthesize them has gained widespread interest in recent years (Dixon and Steele, 1999; 
Winkel-Shirley, 2001).
1.8.12. Tomato as the target plant for genetic modification
In order to introduce isoflavone in target plants, certain dietary factors have 
first to be considered. Various ethnic groups worldwide should frequently consume the 
target plant in everyday diet as this becomes an excellent way to supply genistein to a 
vast population. In addition, it becomes more favourable if the target plant itself is a 
varied source of beneficial bioactive compounds and the addition of genistein will 
compliment and fortify the beneficial effects. One such plant is tomato. Tomato is one 
of the most produced and consumed vegetable worldwide, and a rich source of 
lycopene, P-carotene, folate, potassium, vitamin C, flavonoids, and vitamin E (Metha et 
ah, 2002). The carotenoid lycopene is one of the most researched bioactive confound 
in tomato. The results of clinical studies indicate that locopene in tomatoes is beneficial 
for the treatment and protection of prostate cancer (Chen et al., 2001; Kucuk et al., 
2001). A number of other clinical studies are also now underway investigating the role 
of tomatoes or lycopene in prostate cancer prevention or as an adjunct to therapy 
(Clinton, 2005). In addition to lycopene, the flavonoids in tomato, particular the 
flavonols, rutin and kaempferol (Stewart et al, 2000), are potentially health-protecting 
as a result of their high antioxidant capacity (Sugihara et a l, 1999; Dugas et a l, 2000; 
Duthie and Crozier, 2000).
Due to the reasons mentioned above, there are commercial interests to 
metabolically engineer tomatoes to enable them to produce the isoflavone genistein. 
Studies with soya indicate that substantial health benefits are associated with isoflavone 
consumption in Asian populations and for these to become available through tomato 
consumption could have a long-term favourable impact on health in the Western world.
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1.9. The challenge: engineering genistein synthesis in tomato.
1.9.1. The pathway leading to isoflavone biosynthesis — the phenylpropanoid
pathway
The phenylpropanoid biosynthetic pathway is a complex biological regulatory 
network that have evolved in vascular plants during their successful evolutions as land 
plants (Costa et al, 2003). This metabolic pathway is responsible for the synthesis of a 
wide variety of secondary metabolic compounds, including lignins, salicylates, 
coumarins, hydroxycinnamic amides, flavonoids, isoflavonoids and various plant 
pigments (Dixon & Paiva, 1995), all of which play key roles in the growth, 
development and survival of higher plants.
From the 1970’s to the 1990’s, there was rapid and substantial progress in 
research on the phenylpropanoid pathway focusing mainly towards a broad 
understanding of the metabolic pathway (Hahlbrock & Grisebach, 1975; Ebel & 
Hahlbrock, 1982; Heller & Forkmann, 1988). However, in more recent years, most 
research has been on specific metabolic steps mainly to fill the remaining gaps in the 
phenylpropanoid pathway. Lately, much effort has been directed at elucidating the 
phenylpropanoid biosynthetic pathway from a biochemical and a molecular genetic 
point of view by using approaches such as transposon tagging, positional cloning, co- 
immunoprecipitation, affinity chromatography, and two-hybrid experiments (Winkel- 
Shirley, 2001). As a result of using these new methodologies, the major steps involved 
in the phenylpropanoid pathway has been elucidated and nearly all the enzymes have 
been identified and characterizated (Winkel-Shirley, 2 0 0 1 ).
The gateway into the phenylpropanoid pathway requires the sequential action 
of three enzymes: phenylalanine ammonia-lyase (PAL), cinnamate 4-hydroxylase 
(C4H), and 4-coumarate: CoA ligase (4CL) (Hahlbrock & Grisebach, 1979). The enzyme 
phenylalanine ammonia-lyase (PAL) removes the amine group from the amino acid of 
phenylalanine and produces cinnamic acid. Cinnamic acid 4-hydroxylase (C4H), adds a 
hydroxyl group to form p-coumarate. The enzyme 4-coumarate:coenzyme A ligase 
(4CL) frirther activates the p-coumarate by attaching a CoA at the three-carbon side 
chain. The flavonoid biosynthetic pathway starts with the condensation ofp-coumaroyl- 
CoA with three molecules of malonyl-CoA to form the C15 flavonoid skeleton. This 
reaction is catalysed by chalcone synthase (CHS). In most species, the resultant C 15
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compound is naringenin-chalcone (Forkmann & Heller, 1999). Naringenin-chalcone is 
converted to the flavanone naringenin by the enzyme chalcone isomerase (CHI). 
Naringenin is a key central intermediate, as from this point onwards, the flavonoid 
biosynthetic pathway diverges into several side branches, each resulting in a different 
class of flavonoids, which include isoflavones, flavanones, flavones, flavonols, 
proanthocyanidins and anthocyanins. In most plants, a hydroxyl group is added to 
narigenin at the C3 position to form dihydrokaerrpferol in a reaction catalysed by 
flavanone 3-hydroxylase (F3H) (Forkmann & Heller, 1999).
In terms of engineering genistein synthesis in non-legumes, the next step in the 
phenylpropanoid pathway is very critical as the difference in the biosynthetic pathways 
of legumes and the non-legumes resides in this step (Yu & McGonigle, 2005). In the 
leguminous species, the flavanone, naringenin is converted into genistein (Figure 1.12), 
catalysed by the enzyme, isoflavone synthase (IFS). In addition to this step, chalcone 
reductase (CHR) and chalcone synthase (CHS) catalyses the conversion of p- 
coumaroyl-CoA to isoliquritigenin which IFS converts to the second isoflavone, 
daidzein (Dixon & Ferreira, 2002) (Figure 1.12). However in non-leguminous plants 
isoflavones are not synthesised in the phenylpropanoid pathway due to the absence of 
the CHR and IFS.
1.9.2. Isoflavone synthase discovery and mode of action
One of the major breakthroughs in our understanding of the isoflavonoid 
branch pathway was the isolation of the first IFS genes. Three laboratories 
independently reported the identification of the IFS gene. Shin-ichi Ayabe's laboratory 
(Nihon University, Fujisawa, Kanagawa, Japan) isolated IFS from a licorice cell lines 
that produces isoflavonoids upon elicitation (Akashi et al., 1999). At the same time, 
Richard Dixon’s group (The Noble Foundation, Ardmore) identified an IFS gene from 
soybean {Glycine max) by functional screening of P450 cDNAs in insect cells (Steele et 
al-, 1999). A group at DuPont Wilmington, identified the same gene using a similar 
screen in yeast (Jung et ah, 2000). Cloning of the IFS gene has now provided 
unprecedented opportunities for metabolic engineering to manipulate and modify the 
isoflavone synthesis in both legumes and non-legumes.
IFS or 2-hydroxyisoflavanone synthase is an exceptional enzyme because it 
catalyzes at least two unusual reactions with one protein: a hydroxylation and an
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intramolecular aryl migration reaction. It has been proposed that the flavanone first 
undergoes abstraction of hydrogen radical at C-3 followed by B-ring migration from C- 
2 to C-3 and subsequent hydroxylation of the resulting C 2 radical (Hashim et al., 
1990). IFS comes from the CYP93C subfamily of cytochrome P450s in plants and it is a 
membrane-bound enzyme attached to the outer surface of the endoplasmic reticulum 
(ER) by an n-terminal membrane anchor (Kochs & Grisebach, 1986).
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1.9.3. CHI- the other key enzyme in isoflavone synthesis.
The upstream enzymes of isoflavone synthesis in the phenylpropanoid 
pathway include PAL, C4H, 4CL, CHS, and CHI. Of these, the CHI is thought to be the 
rate limiting step for metabolically engineering genistein in non-legume plants as it 
catalyses the reaction which can divert its substrates either towards flavonoid 
(naringenin) or isoflavonoid production (liquiritigenin ) (Yu & McGonigle, 2005).
From recent studies, it has become apparent that there are multiple types of 
CHIs and their distributions are highly family specific (Shimada et a l, 2003). However, 
there are two major types of CHIs, CHI type 1 which is generally found in non-legumes 
and type H is found principally in leguminous species. Type 1 CHIs converts only 
naringenin chalcone to naringenin. In contrast, type II CHIs catalyses the metabolism of 
both isoliquiritingenin and naringenin chalcone, yielding liquiritigenin and naringenin 
respectively (Figure 1.13) (Shimada et al, 2003).
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Fig. 1.13: The flavonoid pathway in leguminous plants. Type I CHIs isomerize only 
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chalcone and isoliquiritingenin . Adapted from Shimada et a/. (2003).
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The genes that encode both types of CHIs have been cloned from various plant 
species (Kimura et al, 2001; Shimada et al., 2003). A high homology of amino acid 
sequences (>70%) was observed within the same type of CHI while the identity 
between type I and H CHIs was only about 50% homologous (Kimura et a l, 2001; 
Shimada et a l, 2003). This indicates that the different structures of CHI proteins may 
result in their different substrate specificities. Considering potential enzyme 
interactions, e.g., the interaction of type I CHI with the flavonoid pathway and type II 
c m  with the isoflavonoid pathway, it was proposed that introducing specific Cffls may 
be one of the key factors for metabolic pathway engineering of IFS in non-legume 
plants (Yu & McGonigle, 2005).
1.9.4 Transcriptional regulation
Transcriptional control is believed to play an important role in regulating the 
overall activity of phenylpropanoid metabolism in response to abiotic and biotic stress 
(Fahrendorf et al, 1995; Weisshaar and Jenkins, 1998). At least three types of 
transcriptional genes are known to regulate the flavonoid pathway. These include the 
MYB gene family, (Paz-Ares et al, 1987), a basic helix-loop-helix (bHLH) type 
transcriptional factor and a protein containing WD40 repeats (Mol et al, 1998). The 
formation of transcriptional factor complexes with each other and with the DNA 
conserved promoter elements is believed to be a fiindamental process in fine-tuning 
gene activity in the metabolic pathways (Wolberger, 1999). Due to their ability to 
manipulate and regulate the metabolic pathways, transcriptional factors have been used 
in gene transformation experiments. Since transcriptional factors are able to control 
multiple steps within a biosynthetic pathway, their use are believed to be more powerfiil 
than structural genes in manipulating metabolic pathways in plants (Broun, 2004). The 
potential benefit of using transcription factors to modify flux through flavonoid pathway 
was highlighted by a number of studies using the LC and Cl transcriptional factors. One 
such study was carried out by Bovy et a/. (2002), where overexpression of the maize 
transcriptional regulators LC and Cl in tomato, resulted in an increase in flavonols in 
the flesh of tomato finit. Total flavonol content of ripe transgenic tomatoes over­
expressing LC/Cl was about 20-fold higher than that of the controls where flavonol 
production occurred only in the skin (Bovy et al, 2002; Le Gall et a l, 2003).
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1.9.5 Metabolic channeling.
In addition to enzymatic and transcriptional control, there is also a need to 
balance the activities of the complex branched phenylpropanoid metabolic system, 
particularly where several branch pathways are active within the cell (Winkel-Shirley
1999). In the phenylpropanoid biosynthetic pathway, phenylalanine can be converted 
into a lignins, sinapate esters, stilbenes, and flavonoids. Metabolic channeling is 
envisioned to provide mechanism not only for sequestering unstable or toxic 
intermediates, but more inportantly, for controlling fluxes among the multiple branch 
pathways that often ftinction concurrently within the same cell (Winkel, 2004).
Metabolic channelling is the spatial organization of cooperating enzymes into 
macromolecular complexes, which enables the transfer of biosynthetic intermediates 
between catalytic sites without diffusion into the bulk phase of the cell (Winkel, 2004). 
The complexes allow for efficient control of metabolic flux, and protect unstable 
intermediates fi'om non-productive breakdown or access to enzymes fi’om potentially 
competing pathways. Through metabolic channelling, cellular metabolism may attain 
high localised substrate concentrations, regulate competition between branch pathways 
for common metabolites, coordinate the activities of pathways with shared enzymes or 
intermediates, sequester reactive or toxic intermediates (Winkel, 2004) and protect 
unstable intermediates fi'om non-productive breakdown (Dixon et a l, 2002). Such 
complexes may involve direct physical interactions between the various enzymes 
(Winkel-Shirley, 1999), or may be associated with the co-localization of enzymes on 
membranes or other surfaces (Liu & Dixon, 2001).
19.5.1 Metabolic channelling in the flavonoid and isoflavonoid biosynthetic
pathway
Evidence for direct interactions between several key flavonoid biosynthetic 
enzymes, CHS, CHI, and F3H was recently demonstrated in developing Arabidopsis 
seedlings using yeast two-hybrid assays and was further confirmed by affinity 
chromatography and immunoprécipitation assays (Burbulis & Winkel-Shirley, 1999) 
(Figure 1.14). The Dixon group suggest that metabolic channeling also occurs at the 
entry point into the isoflavonoid pathway which involves CHS, CHR, and CHI. In 
another experiment, Liu and Dixon (2001) demonstrated through biochemical 
fi-actionation and confocal microscopy, that isoflavone O-methyltransferase (lOMT)
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was localized in the ER membranes and is therefore envisaged to be closely associated 
with the membrane bound IFS (Figure 1.14). This complex was thought to facilitate 
rapid B ring méthylation resulting in formononetin (4'-0-methyldaidzein) and 
biochanin A (4'-0-methylgenistein) from the isoflavone, diadzein and genistein 
respectively (Akashi et al., 2003). With this concept of metabolic channelling, in 
leguminous plants, type I and type 11 CHIs may participate in distinct enzyme 
complexes devoted to producing, for example, anthocyanin pigments and isoflavonoids 
at different organs and/or in different subcellular locations (Shimada et a!., 2003).
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1.9.6. Manipulating flavonoid biosynthesis
The diverse functions of phenolic compounds in humans together with the 
increasing knowledge on the regulation of flavonoid biosynthesis by structural enzymes 
and transcriptional factors have made flavonoid biosynthetic pathway an excellent 
target for metabolic engineering. The cloning and the characterization of most of the 
genes in this pathway have opened up possibilities to develop plants with tailor-made 
optimised flavonoid levels and compositions. The metabolic engineering of flavonoid 
pathways began in 1987, and has rapidly become an accomplished research area in the 
past decade (Forkmann & Martens, 2001). A number of metabolic engineering studies 
within the framework of flavonoid biosynthesis was concentrated on the ornamental 
plant breeding to generate novel flower colors, in particular blue and yellow flowering 
cultivars (Forkmann & Martens, 2001; Martens et al, 2003). In addition, an atterrqyt was 
made also to increase the flavonoid content in tomatoes as demonstrated by the research 
carried out by Muir et al. (2001). Introducing the CHI gene from Petunia resulted in a 
78% increase of flavonols, mainly due to the accumulation of rutin. Similarly, 
expressing the maize transcriptional factors LC and Cl in potatoes also caused a marked 
increase in the accumulation of kaempferol in the tubers (de Vos et at., 2000).
1.9.6.1 Attempts made in the past to metabolically engineering IFS in non-
legume plants
In isoflavone biosynthesis, the cloning and characterisation of the IFS gene has 
paved way for the possibilities of introducing isoflavones into widely consumed crops 
such as potato, tomato and com, which will ultimately increase their nutritional value 
and bring the health benefits of isoflavones to more consumers. To engineer the 
isoflavone pathway in non-legume plants, the heterologous expression of IFS is an 
essential step because it is required to convert the naringenin, which is ubiquitous in 
higher plants, to isoflavone.
IFS has been successfully introduced into Arabidopsis, maize BMS cell 
cultures and tobacco (Jung et at., 2000). Transformation of the soybean IFS gene 
regulated by a 35S promoter into Arabidopsis was successful as genistein could be 
synthesized (Jung et ah, 2000). However, in tobacco, which has a tissue specific 
activation of the phenylpropanoid pathway, genistein was detected in the flowers but 
not in the leaves of the transformants. This indicates that the production of genistein in
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transgenic tobacco is regulated with a positive correlation to the activity of the 
anthocyanin branch of the phenylpropanoid pathway in only specific tissues (Jung et ah,
2000).
1.9.6.2 Constraints in metabolic engineering
Although there has been some success in the field of metabolic engineering in 
certain crops, due to the complexity of the flavonoid pathway, it nonetheless remains a 
challenging task to generate desired flavonoids. The final result of the engineering is 
dependent on a number of factors, including the approach used, the encoded fonction of 
the introduced transgene, the type of promoter used and on the activity and the 
regulation of the endogenous pathway (Broun, 2004; Lessard et ah, 2002). The desired 
results may not always be the case as seen in the stimulation of the flavonoid 
biosynthesis by the transcription factors LC and Cl in tomato which led to the induction 
of several flavonoid genes, but was not sufficient to induce F3'5TJ activity, which is 
essential for the production of anthocyanins. This was again repeated in an experiment 
carried out by Yu e/ ah (2000) where transcriptional regulation by the introduction of 
the maize Cl and R transcriptional factors in maize BMS cell cultures expressing 
soybean IFS yielded higher levels of flavonols but did not induce production of 
genistein (Yu et ah, 2000). Similarly, no increase in genistein level were detected in 
transgenic Arabidopsis lines when CHI was over-expressed with the aim on increasing 
the provision of the naringenin substrate for IFS. Nor was genistein production 
increased in transgenic Arabidopsis lines expressing the soybean IFS with a papI-D 
genetic background in which anthocyanin production was strongly up-regulated (Liu et 
ah, 2002).
1.9.7 The possibility of engineering genistein in tomatoes?
To date no attempt has been made to genetically engineer genistein synthesis 
in tomato. As with most non-leguminous plants, isoflavones are not synthesised in the 
tomato phenylpropanoid pathway due to the absence of the IFS gene. The pathway is, 
however, similar to that of Arabidopsis where the main substrate naringenin is present, 
thus, making it possible to engineer genistein synthesis. In tomato fruits, flavonoids 
accumulate in a tissue-specific manner (Krause & Galensa, 1992) and analysis at 
different ripening stages, showed that the accumulation of flavonoids in tomato fruit is 
not only regulated in a tissue-specific, but also in a development-dependent manner.
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Naringenin chalcone, the main flavonoid precursor was found to accumulate almost 
exclusively in skin and is simultaneously formed with colouring of the fruit, peaking at 
up to 1% on a dry weight basis (Muir et al., 2001). This may be advantageous in 
attempting to engineer genistein in tomato as naringenin chalcone is the precursor to the 
synthesis of naringenin, which is the crucial substrate for IFS to produce genistein. The 
tissue specific regulation and the development-dependent regulation of the flavonoid 
pathway in tomatoes may warrant the use of an inducible promoter, which will be 
utilised in attempting to engineer genistein synthesis in tomato in the present study.
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Chapter 2: Aims of Study
Currently, one of the main areas of investigation on flavonoid research is in 
the field of metabolism and bioavailability of flavonoids. This area demands an urgent 
examination of identification and quantification of in vivo metabolites as they are the 
key prerequisites to understanding and defining the role of beneficial flavonoids such as 
rutin in humans. Another area of research which is also gaining momentum is in the 
field of metabolic engineering where attempts are being made to increase levels of 
‘novel’ flavonoids such as genistein within the native plant or introduce them in crops 
that normally do not produce them. As such, this thesis is divided into two main parts. 
Part I (Chapters 3, 4 & 5) deals with the absorption, metabolism and bioavailability of 
the flavonol, rutin while Part II (Chapter 5) deals with attempts to engineer genistein 
into tomato and Arabidopsis.
Therefore, the present study was set out to achieve the following objectives;
1. To identify and quantify rutin metabolites in the circulatory and excretory
system and to provide quantitative pharmacokinetic data on the individual 
metabolites after consumption of rutin rich tomato juice
2. To determine the extent and site of absorption of rutin in humans
3. To identify specific degradation products of rutin in the colon by using an in
vitro faecal fermentation model and to determine their contribution to the 
total antioxidant activity of the colonic lumen.
4. To engineer into tomato and Arabidopsis, genistein synthesis, the key dietary 
component of soybean with the aim of ultimately producing plants with 
novel bioactive compound profiles.
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Chapter 3: Absorption and Bioavailability of Rutin
3.1 Introduction
The ubiquitous nature of polyphenolic compounds in plants ensures that they 
are found in substantial quantities in the diet. However, their potential health benefits 
are very much dependent upon their absorption and disposition in target tissues and 
cells. There are many reports of in vitro studies designed to elucidate the biological 
properties of flavonoids, however, these studies may not be readily extrapolated to in 
vivo situations. Therefore, an understanding of the metabolism and bioavailability of 
these conpounds m vivo is important. Hollman (2004) proposed that in the metabolism 
of flavonoids, two compartments should be considered; the first compartment consists 
of the small intestine, liver and kidneys while the colon constitutes the second 
compartment. But it is seems more appropriate that a third compartment which 
encompasses the circulatory system, cell and tissues be also included.
For aglycones and certain flavonoid glycosides such as quercetin glucosides, 
metabolism occurs in the first compartment where absorption from the gastrointestinal 
tract generally involves deglycosylation by luminal LPH and/or cleavage within the 
enterocyte by CBG (Day et al., 2003a; Nemeth et al., 2003). This is followed by 
metabolism of the aglycone, which leads to the appearance of quercetin sulphate and 
glucuronide conjugates in the circulatory system (Day et al., 2003b; Day et al., 2001). 
Flavonoids such as quercetin 3-rutinoside (rutin) where the conjugating moiety is a 
rhamnose-glucose disaccharide, are not cleaved by either LPH or CBG and therefore 
their metabolism occurs in the second compartment as they seemingly pass intact from 
the small intestine to the large intestine where they are hydrolyzed and possibly 
degraded by the colonic microflora (Olthof et al, 2003; Hollman et a l, 1995). At least 
part of the released quercetin is absorbed (reviewed by Manach et al., 2004). This was 
indicated, albeit indirectly, by the appearance of rutin metabolites in plasma, 4-8 h after 
intake, which implies absorption in the colon rather than the small intestines (Graefe et 
al, 2001, Erlund et al, 2000, Sawai et al, 1987). A more direct approach indicating the 
colon as the major site of rutin metabolism and absorption involves the use of human 
subjects with an ileostomy. Using this system, Hollman et al. (1995) showed that 83% 
of ingested rutin was present in the ileal fluid. In addition to the formation of phase II 
metabolites, a huge array of phenolic acid may also be formed through the degradation
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of the flavonoid ring structure by faecal bacteria in the colonic lumen. Thus, 
information on the site and extent of rutin metabolism can play a crucial role in 
determining the exact composition of metabolites produced which in turn impacts on its 
biological activities in vivo (DuPont et al, 2004).
Most flavonoids undergo considerable metabolism upon ingestion and are 
found in vivo as conjugates of glucuronate, sulphate, or methyl forms or as phenolic 
acids, which are ring fission catabolites (Kroon et al, 2004). To establish the role of 
flavonoids as protective agents in vivo, it is critical to understand the chemical nature of 
the absorbed forms and their in vivo concentrations in circulatory system and tissues as 
this may have a major impact on the contribution of flavonoids as dietary protective 
agents. This has pronçted researchers to make use of more accurate and reliable 
methods of identification. For instance, it is now known that identification of flavonols 
based on HPLC elution times and absorbance spectra is prone to produce inaccurate 
data as it lacks both the selectivity and sensitivity required when analyzing low levels of 
metabolites in plasma and urine. Traditionally, quantitative analysis of plasma and 
urine, post ingestion of rutin has involved acid or glucuronidase/sulphatase treatments 
to release to the parent aglycone prior to quantitative analysis by HPLC (Graefe et al, 
2001; Hollman et a l, 1997, Erlund et al, 2000). This analytical approach can fail to 
detect methylated derivatives and, other than a global figure for conjugating forms, 
provides little or no information on the number and identity of individual metabolites 
formed during either phase I or phase II metabolism.
With recent advances in analytical instrumentation, more powerful techniques 
such as the use of mass spectrometry in combination with high-resolution 
chromatography systems, especially reversed-phase HPLC, now enables structural 
information to be obtained for individual HPLC peaks without recourse to acid or 
enzyme treatment. It is possible for instance, to distinguish between metabolites such as 
quercetin glucuronides and quercetin glucosides without the need for reference 
compounds and also to differentiate between the different isomers. Some investigators 
have successfully used HPLC-MS technology to detect a range of quercetin metabolites 
in plasma and urine post ingestion of quercetin glycosides or onions in human 
intervention trials (Wittig et a l, 2001; Day et al, 2001; and Mullen et a l, 2004). 
Tandem MS (MS^) and MS  ^ offer significant advantages over single stage MS 
techniques (Mullen et a l, 2004). To date these analytical methods have not been used to
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unravel the complexities of the metabolism and absorption of rutin in human subjects. 
Olthof et al. (2003) used a GC-MS technique to identify and quantify the phenolic acid 
metabolites in the urine after ingestion of 440 mg (660 //moles) of quercetin-3- 
rutinoside but no attempt was made to detect the conjugated quercetin metabolites in 
either the circulatory system or urine.
This chapter reports on the use of HPLC with photodiode array (PDA) and 
MS  ^ detection with either an ESI (electrospray ionization) interface or APCI 
(atmospheric pressure chemical ionization) interface, to analyse human plasma, urine 
and ileal fluid collected fi'om six healthy human subjects and five volunteers with an 
ileostomy. The samples were collected at a series of time points over a 24 h period after 
the consumption of tomato juice fortified with 100 mg (164 pmoles) of rutin. With 
these procedures, it was possible to identify and quantify rutin metabolites in the 
circulatory and excretory system, determine the extent of absorption, provide 
quantitative pharmacokinetic data of the individual metabolites and finally to confirm 
the colon as the site of absorption of rutin-derived quercetin metabolites. The level of 
rutin in the tomato juice was chosen so that the amount ingested was the same as an 
earlier study in which onions rich in quercetin glucosides were fed to healthy human 
volunteers. This enabled direct comparisons to be made between the fate of quercetin 
glucosides and the quercetin-3-glucosylrhamnoside (rutin) conjugate.
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3.2 Materials and Methods
3.2.1 Study design
Six healthy human subjects, (five females and one male), and five volunteers 
with an ileostomy, and hence lacking a colon (four males and one female) who were 
non-smokers and not on any medication, participated in this study and gave their written 
consent. They were aged between 22 and 48 years and had a mean body mass index of
24.5 ± 1.1. All of the ileostomy volunteers had their operation at least 5 years prior to 
the study and had minimal resection of the small intestine, establishing that they were at 
least semi-physiologically normal. Subjects were required to follow a low flavonoid 
diet for two days prior to the study and this included avoiding most fi*uits, vegetables 
and beverages such as tea, coffee, finit juices, and wine. Food recommended was meat 
(excluding spices), pasta (without tomatoes), fiied or boiled potatoes, rice, milk and 
unflavored yogurt. On the morning of the study, the volunteers were asked to consume 
300 mL of tomato juice fortified with 164 pmoles (lOOmg) of rutin. Aliquots of the 
tomato juice were taken for qualitative and quantitative analysis of their flavonol 
content.
A cannula was inserted into the arm of each volunteer and venous blood 
samples withdrawn at 0, 2, 3, 4, 7, 8, and 24 h post-ingestion of the tomato juice. In 
keeping with previous reports (Graefe et al, 2001; Hollman et a l, 1997, Erlund et al, 
2000) and fi'om preliminary study carried out on feeding trial with rutin, it was clear 
that metabolism of rutin occurs only after 2 h of ingestion and therefore no blood 
samples were taken prior to this point. Ten ml of blood was collected in heparinised 
tubes at each time point and immediately centrifuged at 4000 g for 10 min at 4°C. The 
plasma was decanted firom the red blood cells and 1 mL aliquots were acidified to pH 3 
with 30 pL of 50% aqueous formic acid and 100 pL of ascorbic acid (10 mM) was 
added to prevent oxidation. The plasma samples were then stored at -80°C prior to 
analysis. Urine and ileal fluid was collected prior to supplementation and over 0-2, 2-5, 
5-8 and 8-24 h periods after the consumption of rutin-fortified tomato juice. The 
volume of each sample was recorded prior to storage of aliquots at -80°C. The stability 
of the stored samples were investigated by spiking the samples with 0.625 pg of 
catechin (internal standard) and then measuring its concentration before and after
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storage. The study protocol was approved by the Glasgow Royal Infirmary Local 
Research Ethics Committee.
3.2.2 Materials
The Del Monte tomato juice was purchased fi'om a local supermarket 
(Safeway Stores, Byres Road, Glasgow). HPLC grade methanol and acetonitrile were 
obtained fi'om Rathbum Chemicals (Walkerbum, Scotland). Formic acid was purchased 
fi'om Riedel-DeHaen (Seeize, Germany) and acetic acid firom BDH (Poole, UK). All 
other chemicals and reagents were obtained firom Sigma-Aldrich (Poole, Dorset, UK) 
unless otherwise stated. Quercetin-3-glucuronide was extracted from French beans 
{Phaseolus vulgaris) and purified by partitioning against ethyl acetate and firactionation 
using preparative reversed phase HPLC. Quercetin-3'-glucuronide, quercetin-4'- 
glucuronide, quercetin-7-glucuronide, quercetin-3'-sulphate and isorhamnetin-3- 
glucuronide were donated by Dr. Paul Needs and Dr Paul Kroon (Institute of Food 
Research, Norwich, UK).
3.2.3 Extraction of flavonoids from tomato juice
Aliquots of tomato juice were taken for quantitative analysis of their flavonol 
content. Triplicate samples of 5 mL of tomato juice were extracted with 5 mL of 50% 
methanol containing 1% formic acid and 20 mM sodium diethyldiothiocarbamate. (+)- 
Catechin was used as an internal standard. This mixture was placed on a basic orbital 
IKA (KS 130) shaker at 350 rpm for 30 min after which it was centrifuged at 4,000 g at 
4°C for 10 min. The supernatant was collected and the pellet further extracted twice 
with five mL methanol. The three supernatants were combined and reduced to dryness 
in a rotary evaporator (Thermo Savant SPFD SpeedVac, Hampshire, UK). The dried 
extract was dissolved in 125 p,L methanol to which 2375 pL of 1% formic acid was 
added and ten pL aliquots were analysed by HPLC-PDA-MS^. The extraction 
recoveries for the internal standard was 94 ± 4.5%.
3.2.4 Extraction of flavonoids from plasma
Triplicate samples of plasma were extracted using the method by Day et al. 
(2001) with slight modifications. Plasma (250 pL) was added dropwise to 600 pL of 
acetonitrile to precipitate the proteins. The mixture was vortexed for 30 s every 2 min 
over a 10 min period, before centrifuging at 16,000 g  at 4°C for 20 min. The 
supernatant was retained and the pellet re-extracted as described above but with
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methanol instead of acetonitrile. The two supernatants were combined and reduced to 
dryness in vacuo. Extracts were then dissolved in 25 pL of methanol plus 225 pL of 
1% formic acid in water and centrifuged at 13,000 g at 4°C for 2 min prior to the 
analysis of 250 pL aliquots of the supernatant by HPLC-PDA-MS^. (+)-Catechin was 
used as an internal standard with 0.625 pg being added to acetonitrile prior to the 
addition of the plasma. The extraction recoveries for the internal standard was 91± 5.3% 
while that of spiked samples was 85 ± 4.9%.
3.2.5 Extraction of flavonoids from ileal fluid
Ileal fluid was collected at the specified time points where all the content of 
the pouch were emptied. In the 8-24 h time point, the ileal pouch was emptied every 3 
h, except when the volunteers were asleep. This is to ensure that there was minimal 
bacterial growth and contamination. Immediately after collection, the ileal fluid was 
stored in -80°C. Prior to extraction, the ileal fluid was defrosted and thoroughly mixed. 
Triplicate 0.5 g samples were extracted with 3 mL of 95% methanol containing 1% 
formic acid and 20 mM sodium diethyldiothiocarabamate. Five pg (+)-catechin was 
added to the extraction mixture to act as an internal standard. Samples were 
homogenised for 5 min (Disruptor Genie, Scientific Industries) and then centrifuged at 
16000 g for 15 min. The supernatant was collected and the pellet re-extracted twice as 
described above. The three supernatants were combined and reduced to dryness in 
vacuo. Extracts were then made up to 1 mL with 50 pL methanol and 950 pL 1% 
formic acid. Aliquots of the centrifuged supernatant 20-100 pL were analysed by 
HPLC-PDA-MSl
3.2.6 Preparation of urine
Urine samples were defrosted, thoroughly mixed, centrifuged at 13,000 g at 
4°C for 2 min prior to injection of 200 pi aliquots of the supernatant into the HPLC- 
PDA-MS^ for analysis of flavonoids and phenolic acids.
3.2.7 HPLC with diode array and MS  ^detection
Samples were analysed on a Surveyor HPLC system comprising of a HPLC 
pump, PDA detector, scanning from 250 to 700 nm and an autosampler cooled to 4°C. 
(Thermo Finnigan, San Jose, USA). Separation was carried out using a 250 x 4.6 mm 
I D. 4 pm Synergi Max-RP column for flavonoids and (Phenomenex, Macclesfield,
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UK) eluted with a 65 min gradient of 5-43% acetonitrile in 1% formic acid at a flow 
rate of 1 mL min'^ and maintained at 40°C. Similar conditions were adopted for 
phenolic acid detection, but being more polar, a 250 x 4.6 mm I D. 4 pm Synergi 
Hydro-RP column and a 60 min gradient of 2-20% acetonitrile in 0.25% acetic acid was 
used. After passing through the flow cell of the diode array detector the column eluate 
was split and 0.3 mL min'^ was directed to a LCQ DecaXP ion trap mass spectrometer 
fitted with either an ESI interface or an APCI interface (Thermo Finnigan). Analyses 
utilised the negative ion mode for both flavonoids (ESI) and phenolic compounds 
(APCI) as this provided the best limits of detection. Analysis was carried out using full 
scan, data dependant MS  ^ scanning from m/z 100 to 1000. For the ESI interface, the 
capillary temperature was 250°C, sheath gas and auxiliary gas were 40 and 5 units 
respectively, and the source voltage was 5 kV for negative ionisation. For the APCI 
interface, the capillary tenperature was 130°C, vaporizer ten^erature was 350°C, 
sheath gas and auxiliary gas were 80 and 60 units respectively, and the source voltage 
was 6 kV for negative ionisation. Quercetin, rutin, quercetin-3-glucuronide were all 
quantified by reference to standard calibration curves at 365 nm. Other flavonols were 
quantified in quercetin-3-glucuronide equivalents. 3-Hydroxyphenylacetic acid and 3,4- 
dihydroxyphenylacetic acid were both quantified by reference to standard calibration 
curves at 280 nm. Other phenolic acids were quantified in either 3-hydroxyphenylacetic 
acid or 3,4-dihydroxyphenylacetic equivalents. In all instances peak identification was 
confirmed by co-chromatography and MS  ^fi'agmentation data.
3.2.8 Pharmacokinetic analysis of plasma metabolites
Maximum post-ingestion plasma concentration of rutin metabolites was 
defined as Cmax • The time to reach maximum plasma concentration {Tmœ) was defined 
as the time in hours at which Cmax was reached. The elimination half-life for the 
metabolites in hours was computed by using the following formula T1/2 = 0.693/Kg 
where Ke is the slope of the linear regression of the plasma metabolite concentrations.
3.2.9 Statistical analyses
Each sample was analysed in triplicate and data were presented as mean values 
± standard error (n=3).
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3.3 Results
3.3.1 HPLC-tandem mass spectrometry analysis of tomato juice
The levels of individual flavonoids were determined by HPLC-MS^ and diode 
array detection. Samples were analysed on a Surveyor HPLC system using a 60 min, 5- 
40% gradient of acetonitrile in 1% aqueous formic acid. In total nine compounds were 
identified in the tomato juice based on MS  ^data and at 365 nm. In keeping with the 
data of Woeldecke and Herrmann (1974), the major flavonol was rutin {peak 6 -  Figure 
3.1). The total amount of rutin in 300 mL tomato juice was 7.3 ± 0.9 mg (12.0 ±1.4 
pmoles). Smaller amounts of quercetin-3-rutinoside-7-glucoside (peak 4) and quercetin- 
rutinoside-pentoside {peak 5) were also detected in the juice. The results obtained fi'om 
the HPLC-PDA-MS^ are summarised below and presented in Table 3.1 and Figure 3.1
Peak 7 (tR =10.8 min, Xmax = 325 nm) had a [M-H]' at m/z 353 with MS  ^
yielding a charged fi'agment ion at m/z 191 and relatively intense secondary ion at 179. 
This peak is, 3-caffeoylquinic acid, according to the fragmentation scheme of Clifford 
et a l (2003).
Peak 2 (tR = 11.6, Xmax = 290 nm) had a [M-H]' at m/z 341, with MS  ^yielding a 
charged fragment at m/z 179 which corresponds to caffeic acid. Loss of 162 amu 
indicates cleavage of a hexose moiety. This fi'agmentation, therefore, is in keeping with 
the presence of a caffeic acid hexose conjugate.
Peak 3 (^ R = 15.9 min, Xmax = 325 nm) had a [M-H]' at m/z 353 with MS  ^
yielding a charged fragment ion at m/z 191 and weaker secondary ion at m/z 179. This 
peak co-chromatographed with and has the same MS  ^ spectrum as 5-caffeoylquinic 
acid.
Peak 4 (tR = 16.4 min, Xmax = 340 nm) had a [M-H]' at m/z 771, with MS  ^
yielding a charged fi'agment m/z 609 and m/z 301. These ions were formed by the 
successive loss of a hexose (162 amu cleavage) and a rutinose (308 amu cleavage) unit. 
This compound was tentatively identified as a quercetin-rutinoside-glucoside, possibly 
quercetin-3 -rutinoside-7-glucoside, as reported by Le Gall et al (2003).
Peak 5 (tR = 25.1 min, Xmax = 355 nm) had a [M-H]' at m/z 741, with MS  ^
yielding a charged fi'agment at m/z 609 and 301. These ions were formed by the
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successive loss of a pentose (152 amu cleavage) and a rutinose unit (308 amu cleavage). 
Peak 4 was identified as quercetin-rutinoside-pentoside.
Peak 6 (tR = 27.3 min, Xmax = 360 nm) was the main flavonoid present in the 
tomato juice. It had a [M-H]' at m/z at 609, which with neutral loss of 308 amu, 
corresponding in this instance to the loss of a glucosyl and a rhamnosyl unit, yielded an 
MS  ^ fragment corresponding to quercetin at m/z 301. This compound was identified as 
quercetin-3-rutinoside (rutin), which was confirmed by co-elution with an authentic 
standard.
Peak 7 (tR = 30.9 min, X^ iax = 360 nm) had a [M-H]' ion at m/z 593, with MS  ^
yielding a charged kaenpferol fragment at m/z 285, produced by cleavage of a 308 amu 
rutinosyl unit. This compound was identified as kaempferol-3-rutinoside.
Peak <? (tR = 31.4 min, Xmax = 325 nm) had a [M-H]' ion at m/z 515 and produced 
on MS  ^ a main fragment at m/z 353 and a minor one at m/z 173, in keeping with the 
presence of 3,4-dicaffeoylquinic acid (Clifford et al, 2003).
Peak 9 (tR = 49.5 min, Xmax = 280 nm) had a [M-H] at m/z 271 with MS  ^
yielding a charged fragment at m/z 151 and 177. This compound was identified as the 
flavanone, naringenin, which was confirmed by co-elution with an authentic standard.
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3.3.2 Identification and quantification of conjugated rutin metabolites in
plasma and urine of healthy volunteers with a colon
3.3.2.1 Identification of conjugated rutin metabolites
Plasma and urine collected at the different time points over a 24 h period from 
the healthy volunteers with a colon after ingestion of the rutin-spiked tomato juice were 
analysed by HPLC-PDA-MS^ detection. In the 365 nm traces obtained with plasma at 
0, 2 and 3 h samples and with urine at 0, 0-2 h samples no peaks that corresponded to 
any flavonol based compounds were detected. However, in the 4 h plasma samples and 
the 2-5 h urine samples onwards, small quantities of quercetin-based compounds were 
detected. A total of nine conjugated quercetin metabolites were detected in urine and 
two in plasma. Typical HPLC traces obtained at Ases nm are illustrated in Figure 3.3, 
their structures in Figure 3.2 and identifications based on MS  ^ spectra are summarised 
in Table 3.2. The different classes of metabolites that were detected can be summarised 
as follows:
Quercetin monoglucuronides. Three quercetin monoglucuronides were 
detected, each being characterised by a negatively charged molecular ion [M-H]' at m/z 
477, which on MS  ^fragments with a loss of 176 amu, corresponding to the cleavage of 
a glucuronide unit, to produce an ion at m/z 301 from quercetin. Co-chromatography 
with reference compounds facilitated the identification of quercetin-3-glucuronide (peak 
5), quercetin-4’-glucuronide (peak 8) and quercetin-3'-glucuronide (peak 9).
Quercetin diglucuronides. Peak 6 was present only in urine of subjects from 1 
and 2. It had a [M-H]' at m/z at 653 which yielded MS  ^fragments at m/z 477 ([M-H]'- 
176) and m/z 301 ([M-H]~352), loss of two glucuronide units, indicating the presence 
of a quercetin diglucuronide.
Isorhamnetin-3-glucuronide. This confound was detected in both urine and 
plasma and corresponded to peak 7, which was characterised by a mass spectrum with 
fragment ions at m/z values 14 amu higher than obtained with quercetin glucuronides 
and co-chromatograph with an authentic reference compound.
Methylquercetin diglucuronides. Peak 1, which yielded an MS  ^spectrum with 
fragment ions 14 amu higher than that of peak 6, was a methyl quercetin diglucuronide. 
It was only present only in the urine of volunteer 1 and 2.
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Quercetin glucoside glucuronides. Peaks 2, 3 and 4 which were detected in 
the urine had a [M-H]" at m/z 639 which on MS  ^yielded ions at m/z 477 ([M-H]"-162, 
loss of glucose), m/z 463 ([M-H]"-176, loss of a glucuronide unit) and m/z 301 
indicating that both compound are quercetin glucoside glucuronides
HO O
OH
0 ^ 0 T ; : ^ '^ 0 H
COOH
OH
HO; ""OH
COOH
OH
HO.
OH
HO O
Quercetin-3-glucuronide Quercetin-3 '-0-glucuronide
OH pH
COOH
HO O
I /OH
Quercetin-4’-0-glucuronide Isorhamnetin-3 -glucuronide
Figure 3.2. Structures of quercetin metabolites in plasma and urine of volunteers 
with a colon after consumption of rutin spiked tomato juice.
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3.3.2.2 Quantitative analysis of rutin metabolite accumulation in plasma
Two quercetin metabolites were detected in the plasma namely, quercetin-3- 
glucuronide and isorhamnetin-3-glucuronide. Isorhamnetin-3-glucuronide was however 
not detected in subject 6 (Table 3.3). The 0-24 h pharmacokinetic profiles of these two 
metabolites are illustrated in Figure 3.4. Neither compound was detected in plasma 
collected either immediately before ingestion, or after 2, 3 and 24 h. Quercetin-3- 
glucuronide was also not detected in the 8 h samples. A pharmacokinetic analysis of 
the data is summarised in Table 3.4. The major component was quercetin-3- 
glucuronide with a Cmax of 12 ± 2 nmoles while isorhamnetin-3-glucuronide had a Cmax 
of 4.3 ± 1.5 nmoles. In both instances the Tmax occurred more than 4 h after the 
ingestion of the rutin supplementation (Table 3.4). The levels of these two metabolites 
gradually declined after reaching Cmax (Figure 3.4) and they had a T//? with values of
5.7 ± 0.6 and 6.9 ± 0.3 h (Table 3.4). The longer Tm of isorhamnetin-3-glucuronide 
may be a consequence of it being produced by 3 -méthylation of quercetin-3- 
glucuronide. Due to inter-individual variations, the Cmax values of flavonols in the 
plasma is exhibited separately for each individual as presented in Table 3.4. Subject 1 
and 2 exhibited similar profiles with a higher Cmax for quercetin-3 -glucuronide than the 
other volunteers with values of 22 ± 6 and 24 ± 2 nM and with Tmax of 4 h. The Cmax of 
subjects 4, 5 and 6 was much lower ranging from 4.0 ± 1.0 to 5.2 ± 0.4 nM. Due to the 
low amounts of quercetin-3-glucuronide detected in these volunteers it was difficult to 
accurately calculate Tm values.
The pharmacokinetic profile of isorhamnetin-3-glucuronide was slightly 
different fi-om quercetin-3-glucuronide as there was a slower rate of decline after Cmax 
which is reflected in a later Tmax of 5.4 h and longer T1/2 of 6.9 h (Table 3.4). In addition 
to this the Cmax values were also lower than those of quercetin-3-glucuronide. Again, 
subject 1 and 2 exhibited higher Cmax values for isorhamnetin-3-glucuronide than the 
others (Table 3.4). The cumulative Cmax of the two plasma metabolites ranged ft-om 
5.2-32 nM; with an average accumulation of 15 nM, which corresponds to 0.01-0.06% 
of the rutin ingested (Table 3.5). This is broadly similar to the figures of 0.016% and 
0.09% obtained by Boyle et al (2000) after an ingestion of 500 mg of rutin. However, 
the values obtained in the current study is much lower than the figures of 0.18%, 0.15% 
and 0.09% obtained by Erlund et al (2000), Graefe et a l (2001) and Hollman et al 
(1997) respectively.
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Table 3.3. Concentration of two quercetin metabolites in the plasma of six human
A  O  ^  Vi  n f i h o r *  r » r \‘n o i i m - n + i n n  c n - r i ' n l i a f v i ^ n ' f + r \ r Y l Q ' f n
Metabolite (Peak number) Subject 4h 5 h 6 h 7h 8 h
Quercetin-3-glucuronide (5) 1 6 6 ± 17 42 ± 2 42 ± 2 14± 1 n.d.
2 73 ±7 30 ±2 30 ± 6 8 ± 2 n.d.
3 32 ± 0 38 ± 2 23 ± 1 8 ± 2 n.d.
4 16 ±5 13±2 6 ± 1 n.d. n.d.
5 n.d. 12 ±3 11±3 9 ± 2 n.d.
6 n.d. 14 ± 2 16 ± 1 n.d. n.d.
Mean 31 ±13 25 ± 5 22 ± 5 7 ± 2 n.tL
Isorhamnetin-3-glucuronide (7) 1 13 ±3 25 ± 1 29 ± 1 1 2  ± 1 n.d
2 17 ±2 18 ± 1 23 ± 7 8 . 8  ±0.7 1 0  ± 1
3 3.6 ±0.2 1 1 ± 1 1 0  ± 0 8.2 ± 1.4 6.0 ±0.5
4 6 . 6  ± 0 . 6 8 . 6  ±0.7 5.1 ±0.5 3.7 ±0.5 n.d.
5 5.4 ± 0.4 6.3 ±0.1 3.5 ±0.0 2 . 6  ± 0 . 2 n.d.
6 n.d. n.d. n.d. n.d. n.d.
Mean 7.6 ±2.5 11 ± 4 12 ± 5 5.9 ±1.8 2.6 ±1 .7
Data for the individual subjects are expressed as nmoles ± standard error (n = 3). Mean values are 
expressed as nmoles ± standard error (n = 6 ). No metabolites are detected in 0, 2, 3 and 24 h plasma 
samples, n.d. -  not detected. For MS  ^^ta and idaitification of peaks, refer to Table 3.2
Table 3.4 Pharmacokinetic parameters of quercetin metabolites in the plasma 
of human volunteers after the consumption of rutin supplemented
Metabolite Subject Tmax Tu2
Quercetin-3-glucuronide 1 22 ± 6 4 5.5
2 24 ± 2 4 5.1
3 13±1 5 5.5
4 5.2 ±1.5 4 5.4
5 4.0 ±1.0 5 8.6
6 5.2 ±0.4 6 4.5
Mean 12 ±2 4.7 ±0.3 5.7 ±0.6
IsorhamnetiQ-3 -glucuronide 1 9.5 ±0.1 6 5.98
2 7.7 ±0.3 6 7.65
3 3.8 ±0.2 5 7.30
4 2.9 ± 0 5 7.01
5 2 .1± 0 5 6.48
6 n.d n.d n.d
Mean 4.3 ±1.5 5.4 ±0.2 6.9 ±0.3
Cmax -  maximum concentration in plasma expressed in nM. Tmax -  time to reach Cmax 
expressed in h. Tyz -  the elimination half-life o f metabolites in h. Data presented as mean 
values ± standard error (n = 6 ). n.d. -  not detected.
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Table 3.5. Percentage rutin intake based on cumulative maximum 
concentration of quercetin-3-glucuronide and isorhamnetin- 
3-glucuronide in the plasma of human volunteers with a 
colon after consumption of tomato juice fortified with 164 
pmoles of rutin.
Subject Cumulative Cmax % of rutin 
ingested
1 31 0.05
2 32 0.06
3 6.5 0.03
4 8 1 0.01
5 6 0 0.01
6 5.2 0.01
Mean 14.8 ± 5 .2 0.03
Cmax -  maximum concentration in plasma expressed in nM. Data 
presented as mean values ± standard error (n = 6).
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Figure 3.4. Mean concentration of rutin metabolites in the plasma of six 
healthy human subjects 0-24 h following consumption of tomato juice 
supplemented with 164 pmoles of rutin. EiTor bars indicate standard error.
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3.S.2.3 Quantitative analysis of rutin metabolite excretion in urine
Nine rutin metabolites were detected in urine samples collected 0-2, 2-5, 5-8 
and 8-24 h after the ingestion of tomato juice fortified with 164 fimoles of rutin. All 
nine metabolites were present in the urine of subject 1 while eight of them were 
detected in subject 2 (Table 3.6). Due to high inter-individual variation the 
concentrations of these metabolites are presented separately for each individual. The 
urinary metabolites detected in this study are methylquercetin diglucuronide, three 
isomers of quercetin glucoside glucuronide, quercetin-3-glucuronide, quercetin 
diglucuronide, isorhamnetin-3-glucuronide, quercetin-4'-glucuronide and quercetin-3'- 
glucuronide. Excretion of rutin metabolites by volunteers 3-6, was much lower and 
limited to only the quercetin glucuronides and isorhamnetin-3-glucuronide. No 
methylquercetin diglucuronide, quercetin glucoside glucuronide or quercetin 
diglucuronide were detected in any of these subjects (Table 3.6).
There were considerable inter-individual variations in the excretion of the 
urinary metabolites as illustrated in Figure 3.5. A range of 4981 ± 115 to 40 ± 1 nmoles 
of total metabolites were excreted over a 24 h period after the ingestion of the rutin. The 
main urinary metabolites present in all the volunteers with the exception of volunteer 4, 
were the quercetin glucuronides {peaks 5, 8 and 9) with 3521 ± 171 to 29 ± 1 nmoles 
being excreted over the 24 h period. Substantial amounts of isorhamnetin-3-glucuronide 
was also detected in the urine of the volunteers with 686 ± 5 to 11 ± 0 nmoles being 
excreted.
In volunteers 1 and 2, the majority of the urinary rutin metabolites were 
excreted within the first five hours of tomato juice ingestion (Figure 3.6). However, this 
profile was completely different for volunteers 4, 5 and 6, where the majority of the 
urinary rutin metabolites were excreted only after 8 hours. An intermediate urinary 
excretion profile was observed for volunteers 3. Total urinary rutin metabolite excreted 
during the 0-24 h were 4981, 608, 310, 187, 141 and 40 nmoles respectively for the 
different volunteers (mean 1045 ±36) and these corresponded to 2.8% to 0.02% of rutin 
intake (mean 0.59% intake).
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Table 3.6. Concentration of rutin metabolites in urine of six healthy human subjects 
0-24 h after consumption of mtin supplemented tomato juice
Subject Metabolites (peak number) 2 - 5 h 5 - 8 h 8 - 2 4 h Total
1 Methylquercetin diglucuronide (7^ 94 ±5 35 ± 4 n.d 129 ± 9
Quercetin glucoside glucuronide (2) 216 ±30 n.d n.d 216±30
Quercetin glucoside glucuronide (3) 131 ±26 n.d n.d 131 ±26
Quercetin glucoside glucuronide (4) 112±10 9 ± 0 n.d 121 ± 9
Quercetin-3-glucuronide (5) 1122 ±90 70 ±26 n.d 1192 ±104
Quercetin diglucuronide (6) 147 ±27 28 ± 4 n.d 176 ±23
Isorhamnetin-3-glucuronide (7) 547 ± 5 140 ± 5 n.d 686 ± 5
Quercetin-4'-glucuronide (8) 1198±8 23 ± 3 n.d 1221 ±10
Quercetin-3'-glucuronide (9) 1108 ±62 n.d n.d 1108 ±62
Total quercetin glucuronides (5,8,9) 3428± 149 93 ±28 n.d 3521± 171
Total metabolites 4675 ±90 306 ±30 n.d 4981 ±115
2 Methylquercetin diglucuronide (7) 6 ± 0 1 5 ± 2 n.d 21 ± 2
Quercetin glucoside glucuronide (2) 11 ± 0 5 ± 1 n.d 16 ± 1
Quercetin glucoside glucuronide (3) 2 ± 1 n.d n.d 2 ± 1
Quercetin-3-glucuronide (5) 71 ±1 6 7 ± 2 4 ±  1 142 ± 2
Quercetin diglucuronide (6) 7 ± 1 12 ± 1 n d 1 8 ± 2
Isorhamnetin-3 -glucuronide (7) 30 ± 3 40 ± 1 6 0 ± 2 129 ± 3
Quercetin-4'-glucuronide (8) 87 ± 2 35 ± 1 n.d 122 ± 3
Quercetin-3'-glucuronide (9) 92 ±1 46 ± 0 19± 1 157 ±62
Total quercetin glucuronides (5,8,9) 250 ± 2 147 ± 3 2 2 ± 2 420 ± 5
Total metabolites 305 ±3 219 ± 3 82 ± 1 608 ± 4
3 Quercetin-3-glucuronide (5) 81 ± 6 43 ± 2 51 ±19 175 ±14
Isorhamnetin-3-glucuronide (7) 10 ± 0 20 ± 1 34 ± 1 6 4 ± 2
Quercetin-4'-glucuronide (8) 18± 1 18± 1 n.d 3 6 ± 0
Quercetin-3'-glucuronide (9) 10±1 17±1 10±1 37 ± 1
Total quercetin glucuronides (5,8,9) 108 ± 6 78 ± 1 62 ±20 248 ±15
Total metabolites 118 ± 6 97 ± 1 95 ±19 310 ± 1 4
4 Quercetin-3 -glucuronide (5) 16± 1 7 ± 0 n.d 23 ± 1
Isorhamnetin-3 -glucuronide (7) 21 ± 0 1 6 ± 0 82 ±1 120 ± 0
Quercetin-4'-glucuronide (8) 41 ± 1 n.d n.d 41 ± 1
Quercetin-3'-glucuronide (9) 4 ± 0 n.d n.d 4 ± 0
Total quercetin glucuronides (5,8,9) 61 ± 2 7 ± 0 n.d 68 ± 2
Total metabolites 82 ± 2 23  ± 1 82 ± 1 1 8 7  ± 2
5 Quercetin-3-glucuronide (5) 6 ± 2 1 2 ± 2 4 6 ± 3 6 4 ± 5
Isorhamnetin-3-glucuronide (7) 21 ± 0 17±1 2 7 ± 0 65 ± 0
Quercetin-4'-glucuronide (8) 1 ± 0 1 ± 0 n.d 2 ± 0
Quercetin-3'-glucuronide (9) 2 ± 0 6 ± 0 2 ± 0 10 ±1
Total quercetin glucuronides (5,8,9) 9 ± 1 20 ± 2 4 9 ± 3 77 ± 5
Total metabolites 30  ± 1 3 6  ± 2 75 ± 3 141 ± 5
6 Quercetin-3-glucuronide (5) n.d 3 ± 0 24 ± 1 2 7 ± 1
Isorhamnetin-3-^ucuronide (7) 4 ± 0 7 ± 0 n.d 1 1 ± 0
Quercetin-3'-glucuronide (9) n.d n.d 2 ± 0 2 ± 0
Total quercetin glucuronides (5,8,9) n.d 3 ± 0 26±  I 2 9 ± 1
Total metabolites 4 ± 0 1 0 ± 0 2 6  ± I 40 ± 1
Data for the individual subjects are expressed as nmoles ± standard error (n=3). n.d -  not detected
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Figure 3.5. Inter-individual variation in the concentration o f  urinary 
m etabolites in healthy subjects with a colon after ingestion o f  rutin 
supplem ented tomato juice
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Figure 3.6. Excrétion of urinary rutin metabolites in healthy subjects after 
ingestion of tomato juice fortified with 164 jumoles of rutin
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3.3.3. Identification and quantification of rutin metabolites in the ileal fluid,
plasma and urine of ileostomy volunteers
3.3.3.1 Quantitative analysis of ileal fluid
Ileal fluid was collected before consumption of tomato juice supplemented 
with 164 pmoles rutin and subsequently collected at 0-2, 2-5, 5-24 h. Using the MS  ^
and diode array detection, ileal fluid samples were analysed using a 60 min, 5-40% 
gradient of acetonitrile in 1% aqueous formic acid. In total six phenolic compounds 
were identified in the ileal fluid based on MS  ^ data and Amax at 365 nm (Figure 3.7). 
Most of these compounds were derived from the consumption of tomato juice as can be 
seen by comparing the chromatograms of tomato juice and ileal fluid illustrated in 
Figure 3.7. No conjugated rutin metabolites were detected in any of the ileal fluid 
samples for all the time points. Rutin, however was detected in an unmodified form and 
amounted to a total mean of 151 ± 5 pmoles which corresponded to 92 ± 3% of rutin 
intake (Table 3.7). Most of the rutin (70%) was excreted in the ileal fluid 2-5 h post 
ingestion of tomato juice.
3.3.3.2. Quantitative analysis of plasma
Plasma was collected before ingestion of rutin and subsequently collected at 
2, 3, 4, 5, 6, 8 and 24 h. Using the HPLC-MS^ and diode array detection, plasma 
samples were extracted for flavonoids and were analysed at 365 nm using a 60 min, 5- 
40% gradient of acetonitrile in 1% aqueous formic acid. None of the quercetin 
metabolites detected in the plasma of healthy volunteers (Table 3.3) were present in 
detectable quantities in the 0-24 h plasma samples collected from subjects with an 
ileostomy.
3.3.3.3 Quantitative analysis of urine
Urine was collected before ingestion of rutin and subsequently collected at 0- 
2, 2-5, 5-8 and 8-24 h. Using the HPLC-MS^ and diode array detection, urine samples 
were analysed at 365 nm using a 60 min, 5-40% gradient of acetonitrile in 1% aqueous 
formic acid. None of the quercetin metabolites detected in the urine of healthy 
volunteers (Table 3.6) were present in detectable quantities in the 0-24 h urine samples 
collected from subjects with an ileostomy.
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Table 3.7. Amount of rutin in the ileal fluid of five ileostomy 
subjects 0-24 h after consumption of rutin spiked 
tomato juice
Subject 0 - 2  h 2-5 h 5-24 h Total
1 2 1 ± 1 132 ± 1 4.7 ±0.0 158 ± 1
2 6 ± 0 109 ± 7 40 ± 1 155 ± 6
3 1 1  ± 1 118±3 6 ± 1 135 ± 1
4 1 ± 0 1 0 0  ± 6 43 ± 0 149 ± 1
5 n.d 119±2 37 ± 1 156 ± 3
Mean 8 ± 5 115±7 26±11 151 ± 5
% intake 5 ± 1 70 ± 4 16 ± 7 92 ± 3
Data for the individual subjects are expressed as pmoles ±  standard 
error (n = 3). Mean values are expressed as pmoles ±  standard 
error (n = 5). N o rutin was detected at time 0. n.d - not detected
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Figure 3.7. Gradient reversed-phase HPLC with detection at 365 nm o f phenolics in tomato 
juice and ileal fluid The ileal fluid chromatogram is obtained from volunteer 1 after 
consumption o f tomato juice fortified with 164 pmoles o f  rutin, i. s.-internal standard
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3.3.4 Identification and quantitative analysis of rutin catabolites in urine of 
volunteers with and without a colon.
3.3.4.1 Identification of urinary phenolic acids
The levels of individual phenolic compounds were determined by HPLC-MS^ 
and diode array detection. Samples were analysed on a Surveyor HPLC system using a 
60 min, 2-20% gradient of acetonitrile in 0.25% aqueous acetic acid. The column eluate 
being directed first to a diode array absorbance monitor and then to a mass spectrometer 
with an APCI interface operating in full scan MS  ^mode. The absorbance at 280 nm 
trace contained a large number of peaks which were present in the 0 h blank and others 
which could not be identified (Figure 3.8). However, fi*om the MS  ^data, a total of six 
phenolic acids were identified in urine of healthy volunteers with a colon and three in 
volunteers without a colon (Figure 3.8). The major component in the urine was 4- 
hydroxyhippuric acid. The overall results obtained are presented in Table 3.8 and 
summarised below. The structures of the compounds are illustrated in Figure 3.9.
Peak 1 (^ R = 13.6 min, Àmax= 260 nm) had a [M-H]’ at m/z 194 with MS  ^
yielding two charged fragments, a main one at m/z 100 and a smaller ion at m/z 93. The 
mass spectrometric data and co-chromatography with an authentic standard confirmed 
that this compound is 4-hydroxyhippuric acid.
Peak 2 (^r = 15.9 min, X.niax= 280 nm) had a [M-H]’ at m/z 167 with MS  ^
yielding two charged fragments, a main one at m/z 123 and a smaller ion at m/z 108. 
The mass spectrometric data and co-chromatography with an authentic standard 
confirmed that this compound is 3,4-dihydroxyphenylacetic acid.
Peak 3 = 26.8 min, .^max= 270 nm) had a [M-H]’ at m/z 151 with MS^
yielding three charged fragments, a main one at m/z 107 and two smaller ions at m/z 93 
and 121. The mass spectrometric data and co-chromatography with an authentic 
standard confirmed that this compound is 3 -hydroxyphenylacetic acid.
Peak 4 {t^ = 29.1 min, ^max= 280 nm) had a [M-H]’ at m/z 181 with MS  ^
yielding one charged fragment at m/z 137. The mass spectrometric data and co­
chromatography with an authentic standard confirmed that this compound is 4-hydroxy-
3-methoxyphenylacetic acid.
6 8
Peak 5 (^ R = 33.2 min, 300nm) had a [M-H]' at m/z 194 with MS^
yielding a charged fragment at m/z 150. The mass spectrometric data and co­
chromatography with an authentic standard confirmed that this confound is 3- 
hydroxyhippuric acid
Peak 6 (/r = 39.1 min, 300nm) had a [M-H]' at m/z 194 with MS^
yielding a charged fragment at m/z 150. The mass spectrometric data and co­
chromatography with an authentic standard confirmed that this compound is 2- 
hydroxyhippuric acid
Table 3.8. HPLC-MS^ identification of phenolic acids detected in urine 
samples of volunteers with and without colons
Peak fp (mini Compound
[M-H]' MS  ^fragments 
(m/z) ions (m/z)
1 13.6 4-hydroxyhippuric acid 194 100, 93
2 15.9 3,4-dihydroxyphenylacetic acid 167 123, 108
3 26.8 3-hy droxypheny lacetic acid 151 107, 93, 121
4 29.5 4-hydroxy 3-methoxyphenylacetic acid 181 137
5 32.2 3-hydroxyhippuric acid 194 150
6 38.1 2 -hydroxyhippuric acid 194 150
Peak numbers and HPLC retention times and the peaks refer to HPLC trace in Figure 3.8; 
/r - retention time; [M-H]' - negatively charged molecular ion
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Figure 3.8. 2-20% gradient HPLC chromatogram of urine sample obtained from donor 1 
from healthy volunteers with a colon (A) and from an ileostomy volunteer (B), 8-24 h 
after ingestion o f tomato juice fortified with 164 pmoles o f rutin The MS^ fragmentation 
profile for each peak is also illustrated. For the identification o f peaks, refer to Table 3.8
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Figure 3.9. Structures of phenolic acids detected in the urine
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3.3.4.2 Quantitative analysis of urinary phenolic acids
3.3.4.2.1 Healthy volunteers
Six urinary phenolic acids were detected in healthy human subjects with a 
colon in amounts that facilitated quantitative analysis (Table 3.9). These catabolites 
consist of 2-hydroxyhippuric acid, 3-hydroxyhippuric acid, 4-hydroxyhippuric acid, 3- 
hydroxyphenylacetic acid, 3,4-dihydroxyphenylacetic acid and 4-hydroxy-3 -methoxy- 
phenylacetic acid. The main urinary metabolite excreted was 4-hydroxyhippuric acid 
(peak 1) with a total mean excretion of 65 ± 6 fimoles, 0-24 h after ingestion of rutin.
The excretion profile of all these metabolites were similar where there was a 
gradual increase in the excretion over the 0-24 h time points (Figure 3.10). The 
excretion was however, highest 8-24 h after rutin intake (Table 3.9). Total 0-24 h 
phenolic acid excretion after rutin intake for the individual volunteers were 179, 115, 
112, 81, 167 and 126 pmoles and the mean value of 130 ± 15 pmoles corresponded to 
74% of rutin intake. The 3-hydroxyphenylacetic acid, 3,4-dihydroxyphenylacetic acid 
and 4-hydroxy-3-methoxy-phenylacetic acid corresponded to only 23% of intake.
3.3.4.2 2 Deal volunteers
In contrast to the volunteers with a colon, only three phenolic acid catabolites, 
that is, 2-hydroxyhippuric acid, 3-hydroxyhippuric acid and 4-hydroxyhippuric acid, 
were detected in human subjects with an ileostomy (Table 3.10). No phenylacetic acid 
derivatives were detected in any of the urine samples from these subjects. The 
excretion of these catabolites had a similar profile to that of the healthy volunteers with
4-hydroxyhippuric acid being the main catabolite excreted in the urine with an average 
of 30 ± 7 pmoles being excreted over the 24 h period after the ingestion of rutin.
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Table 3.9. Concentration of phenolic acids in the urine of six healthy human subjects
Metabolite Subject 0-2 2-5 5-8 8-24 Total
2-OH-hippuric acid (peak 6) 1 0.4 ±0.2 0.9 ±0.0 3.7±0.1 7.8 ±0.4 13±1
2 0.2 ±0.0 0.7 ±0.1 3.2 ±0.0 4.0 ±0.6 8.2 ±0.7
3 0.6 ±0.0 0.8 ±0.1 0.7 ±0.0 0.9 ±0.0 2.9±0 .9
4 0.1 ±0.0 0.1 ±0.0 1.2 ±0.2 2.9 ±0.2 4.3 ±0.3
5 0.4 ±0.1 1.4 ±0.1 1.7 ±0.2 0.6±0.1 4.0 ±0.1
6 0.2 ±0.0 0.6 ±0.0 1.2±0.1 0.2 ±0.0 2.3 ±0.1
mean 0.3 ±0.1 0.8 ±0.2 2.0 ±0 .5 2.7 ±1.2 5.7 ±1.6
3-OH-hippuric acid (peak 5) 1 0.9 ±0.0 3.7 ±0.1 2.0 ±0.1 6.5 ±0.2 1 3 ± 0
2 1.1 ±0.0 3.1 ±0.1 3.1 ±0.2 5.5 ±0.3 1 3 ± 0
3 2.1 ±0.1 5.2 ±0.1 2.8 ±0.0 9.0 ±0.1 1 9± 0
4 0.4 ±0.1 1.2±0.1 1.0 ±0.1 1.9±0.2 4.5 ±0.1
5 2.4 ±0.1 1 5 ± 0 5.2 ±0.0 20 ±1 43 ±1
6 0.6 ±0.0 3.2 ±0.1 0.8 ±0.1 9.8 ±0.5 14 ±1
mean 1.2 ±0.3 5.3 ±2.1 2.5 ± 0 .7 8.7 ±2.5 18 ± 5
4-OH-hippuric acid (peak 1) 1 3.6±0.1 7.3 ±0.3 26 ±1 40 ± 3 78 ± 1
2 1.9±0.1 4.4 ±0.5 28 ± 0 47 ± 2 81 ±3
3 4.0 ±0.1 5.1 ±2.2 14 ± 0 24 ± 1 48 ± 2
4 4.1 ±0.2 4.8 ±0.1 12 ± 0 27 ± 0 48 ± 0
5 2.9 ±0.1 1 2 ± 0 26 ± 1 25 ±1 66 ± 2
6 0.1 ±0.0 0.7 ±0.0 0.7 ±0.4 46 ±1 66± 1
mean 2,8 ±0.6 5.8 ±1.6 18 ± 4 35 ± 4 65 ± 6
3-OHPA acid (peak 3) 1 t.a. 0.5 ±0.1 0.4 ±0.1 1.1 ±0.0 2.0 ±0.2
2 0.1 ±0.1 0.4 ±0.0 2.2 ± 0.0 3.2 ±0.0 6.0 ±0.1
3 0.5 ±0.0 0.6 ±0.0 0.2 ±0.0 0.3 ±0.0 1.6±0.1
4 0.2 ±0.0 0.4 ±0.0 0.8 ±0.0 2.3 ±0.1 3.7 ±0.1
5 0.2 ±0.0 0.1 ±0.0 1.4 ±0.2 2.6 ±0.2 4.3 ±0.1
6 0.1 ±0.0 0.6 ±0.0 1.8 ±0.1 6.5 ±0.4 9.0 ±0.2
mean 0.2 ±0.1 0.4 ±0.1 1.1 ±0.3 2.7 ±0.9 4.4 ±1.1
3,4-DiOHPAacid (peak!) 1 n.d. 2.5 ±0.0 6.7 ±0.5 20 ±1 27 ±1
2 n.d. n.d. 2.2 ±0.2 n.d. 2.2 ±0.2
3 n.d. 2.9 ±0.1 2.2 ± 0.2 7.8 ±0.2 13 ±1
4 n.d. n.d. 2.6 ±0.2 1 2 ± 0 1 4 ± 2
5 n.d. n.d. 1.8±0.1 14 ± 1 1 6 ± 0
6 n.d. n.d. 3.2 ±0.3 16± 1 20 ± 0
mean n.d 0.9 ±0.6 3.1 ± 0 .7 12 ± 3 15 ± 3
4-OH-3-methoxy-PA acid (peak 4) 1 1.0±0.1 4.2 ±0.2 13± 1 27 ± 2 45 ± 0
2 n.d. n.d. 4.3 ±0.1 n.d. 4.7 ±0.1
3 n.d. 3.5 ±0.1 5.5 ±0.1 19±1 28 ±1
4 n.d. n.d. 4.7 ±0.2 1.1 ±0.0 5.8 ±0.2
5 n.d. 3.8 ±0.1 6.8 ±0.5 7.9 ±0.4 21 ± 0
6 2.1 ±0.1 2.9 ±0.3 2.7 ±0.1 6.7 ±0.1 14 ±1
mean 0.9 ±0.5 2.4 ±0.8 6.1 ± 1 .4 10 ± 4 20 ± 6
Data for individual subjects expressed as jumoles ± standard error (n = 3). Mean values 
expressed as pmoles ± standard error (n = 6). For MS^  data and identification of peaks, 
refer to Table 3.8; n.d. -  not detected, t.a- trace amounts; n.d. -  not detected
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Table 3.10. Concentration of phenolic acids in the urine of five human 
subjects with an ileostomy 0-24 h after the consumption of 
tomato juice supplemented with 164 [umoles rutin
Metabolite Subject 0 - 2 2-5 5-8 8-24 Total
2-OH-hippuric acid 1 0.3 ±0.0 0.7 ±0.0 1.2 ±0.0 5.2 ±0.0 7.4 ±0.0
2 n.d. n.d. n.d. n.d. n.d.
3 1 9± 0 6.2 ±0.2 26± 1 9.5 ±0.5 61 ±1
4 1.7±0.1 0.4 ±0.0 6.1 ±0.7 6.9 ±0.3 15±1
5 1.8±0.1 1.8 ±0.0 4.5 ±0.1 12 ± 0 21 ± 0
mean 4.5 ±3.6 1.8 ±1.1 7.6 ± 4 .7 6.8 ±2.1 21 ±11
3-OH-hippuric acid 1 2.3 ±0.0 3.3 ±0.2 1.6±0.1 9.0 ±0.4 1 6± 0
2 3.0 ±0.2 1.2±0.1 3.7 ±0.5 9.3 ±1.9 17 ± 2
3 0.3 ±0.0 0.6 ±0.0 8.1 ±0.6 1.1 ±0.5 10 ±1
4 3.0 ±0.1 0.4 ±0.0 3.7 ±0.2 n.d. 1 4 ± 0
5 n.d. n.d. n.d. n.d. n.d.
mean 1.7 ±0 .7 1.1 ±0.6 3.4 ±1.4 3.9 ±2.2 10 ± 3
4-OH-hippuric acid 1 0.9 ±0.0 4.1 ±0.3 8.0 ±0.4 2 9 ± 4 42 ± 4
2 1.7 ±0.0 0.9 ±0.1 6.1 ±0.7 29 ±3 37 ± 4
3 5.3 ±0.1 5.7±0.1 8.9 ±0.5 2 2 ± 4 42 ± 4
4 1.4 ±0.0 0.3 ±0.0 3.9 ±0.5 0.8 ±0.1 6.4 ±0.7
5 4.8 ±0.1 3.3 ±0.4 3.3 ±0.1 1 3 ± 0 24 ±1
mean 2.8 ±0.9 2.9 ±1.0 6.0 ±1.1 19 ± 5 30 ± 7
Data for individual subjects expressed as pmoles ±  standard error (n = 3). 
Mean values expressed as pmoles ± standard error (n = 6 ). For MS^ data and 
identification of peaks, refer to Table 3.8. n.d. -  not detected
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3.4 Discussion
From the metabolite profiles of rutin in the plasma and urine, it is clear that 
rutin is extensively metabolised in the human body. Following the release of the 
aglycone, quercetin is subjected to glucuronidation and méthylation as these can be 
found in the circulatory and the excretory system. However, there is no evidence of any 
sulphation occurring. Glucuronidation seems to be the dominant metabolic pathway in 
the metabolism of rutin as quercetin glucuronide is the major metabolite appearing in 
the plasma and excreted in the urine post ingestion of rutin.
3.4.1 Phase II metabolism
The metabolites quercetin-3-glucuronide and isorhamnetin-3-glucuronide 
appeared in plasma after ingestion of rutin with a cumulative Cmax value of 15 nM, and a 
Tmax value of > 4 h (Table 3.4). These values differ markedly from those reported by 
Mullen et al. (2005) when onions containing quercetin-4’-glucoside and quercetin-3,4- 
diglucoside were consumed and a Tmax value of < 1 h and a Cmax value of 463 nM were 
obtained for the same metabolite. The difference in the post-absorption kinetic 
behaviour of the quercetin glucosides and that of rutin is believed to stem from the 
sugar moiety attached to quercetin. In contrast to quercetin glucosides, in rutin, the 
rutinose moiety is not cleaved by either LPH or CBH associated with the wall of the GI 
tract (Day and Williamson, 2001). As a consequence, most of the rutin passes through 
the small intestine without modification and enters the colon of healthy subjects or 
emerges in the ileal fluid in the case of subjects with an ileostomy. The longer time
taken to reach the large intestine is reflected in the increased Tmax value. In the large
intestine, rutinose is cleaved by the gut microflora. The microbial enzymes involved in 
the deglycolysation of the rutinoside moiety from quercetin, such as a-rhamnosidases 
and p-glucosidase have been detected in the human colon (Aura et al., 2005).
After the initial deglycosylation of rutin, quercetin metabolites that appear in 
plasma are the result of conversions occurring in the lumen of the large intestine. 
Relatively low concentrations of quercetin metabolites were detected in the plasma after 
ingestion of rutin. The peak concentration of quercetin metabolites in plasma was about 
30 times lower than when an equivalent dose of quercetin glucosides were ingested 
(Mullen et al, 2005). The relatively low a-L-rhamnosidase activity compared to p- 
glucosidase may be partly responsible for the lower Cmax values observed in the plasma
76
(Graefe et al., 2001). In contrast to the metabolism in the small intestine, the extent of 
quercetin absorption and the further breakdown into ring fission products depend 
largely on the composition of the colonic microflora of individual subjects and their 
intestinal transit times. The dependency of the metabolism of rutin on the composition 
of the microflora in the large intestine also explains the inter-individual variations 
observed both in plasma concentrations and in particular, the urinary excretion of 
quercetin metabolites. The more quercetin is degraded by the colonic microflora, the 
less it accumulates with only trace amounts absorbed in the intestinal lumen and hence 
lower amounts are recovered in plasma and urine as conjugated quercetin metabolites. 
This phenomenon was most pronounced in volunteers 4, 5 and 6 (Table 3.4 and 3.6). 
The argument presented here is also in agreement with the findings of other researchers 
where the absorption of quercetin showed low inter-individual variations compared with 
that of rutin (Erlund et al., 2000). However, it should be noted that low accumulation of 
rutin metabolites in the plasma could also be related to reduced breakdown of rutin or 
differences in the rate of absorption within the colonic lumen of that of individual 
volunteers.
The plasma pharmacokinetic profile of isorhamnetin-3-glucuronide was 
slightly different in that it had a longer Tm and a delayed Tmax compared to that of 
quercetin-3-glucuronide. The reason for these two metabolites displaying different 
pharmacokinetic profiles could be due to differing enzyme specificities and/or varying 
rates of efflux from the enterocyte into the bloodstream although deposition in body 
tissues and a slow release in the bloodstream could also be factors of influence. Another 
possibility is that the major plasma metabolite, quercetin-3-glucuronide is produced in 
the large intestine, passes into the portal vein and is further converted to other 
components, including isorhamnetin-3-glucuronide in the liver. This is in line with the 
investigations carried out by O’Leary et al. (2003) where by using the HepG2 hepatic 
cell model, it was demonstrated that 32% of quercetin-3-glucuronide was methylated to 
3- methylquercetin glucuronide.
No evidence of sulphation of quercetin was detected in this study, which is in 
contrast with results obtained from studies on bioavailability of quercetin glycosides 
where quercetin-3-sulphate was found to be the major plasma metabolite after 
consumption of onions (Mullen et al, 2004, Day et al, 2001). The lack of sulphation 
of quercetin in the colonic lumen could be due to the lack of the flavonol-specific
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sulphotransferase (SULTs) activitiy. Although high SULTs activities are present in the 
colon (Harris et a l, 2000), no sulphate phase II conjugates of flavonoids, were 
recovered in the perfusate of the colonic lumen when using a rat model. In fact, the 
phase II conjugates were found to be region-dependent, with the highest recovery in the 
jejunum, followed closely by the duodenum, the ileum, and none in the colon (Liu and 
Hu, 2002).
In contrast to rutin, the absorption of quercetin glycosides (after hydrolysis) 
from the small intestine into the bloodstream appears to be much more effective (Crespy 
et a l, 1999). In the small intestine enterocytes, quercetin is metabolised to the 
corresponding glucuronides, sulphates or methylated to isorhamnetin. This assumption 
is reported by in situ experiments with rat intestines, in which quercetin was rapidly and 
extensively conjugated to quercetin sulphate and quercetin glucuronide (Crespy et al, 
1999). However, the activity of UDP-glucuronosyltransferase (UGT), the conjugating 
enzymes, which transfer the glucuronosyl group from the UDP-glucuronic acid to the 
flavonoid moiety were found to decrease slightly from proximal to distal small intestine, 
whereas in the large intestine a sharp fall in activity was observed (Peters et a l, 1991). 
If this also occurs in humans, it could explain the low quercetin glucuronide Cmax values 
obtained in the present study.
In summary, the lower bioavailability of rutin and the lack of quercetin 
sulphate conjugates in the circulatory system and urine could be due to any of following 
reasons:
• Lack of UGT and SULT activities or possibly the lack of specific isoforms of 
UGT and SULT for the phase II metabolism of flavonols
• Lack of quercetin intestinal transporters
• Low a-L-rhamnosidase activity
• Enzyme-dose effect. Concentration of quercetin present at any time in the large 
intestine is dependent on the enzymatic activities of the microflora for both the 
deglycolysation and also the ring cleavage. Any quercetin formed can be acted 
upon immediately by the microflora resulting in catabolism to phenolic acids 
and thus accumulation of quercetin in the large intestine may be insufficient to 
facilitate significant SULT activity.
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Table 3.6 summarises the 24 h urinary excretion of the flavonol metabolites detected 
after consumption rutin and presents clear evidence of substantial phase II metabolism 
as only two of the urinary metabolites were detected in plasma (Table 3.3). Quercetin-
3 -glucuronide and quercetin-4-glucuronide were excreted in substantial amounts in the 
urine but were not detected in plasma. The virtual absence of these urinary metabolites 
together with other urinary metabolites such as methylquercetin diglucuronide, 
quercetin glucoside glucuronide and quercetin diglucuronides in plasma could indicate 
that after metabolism in the liver and/or kidney, they are rapidly removed from the 
circulatory system via excretion by the kidneys.
3.4.2 Ileostomy model
Five healthy ileostomy volunteers were chosen in this study as analysis of ileal 
fluid collected after supplementation provides information on the absorption and 
metabolism occurring in the small intestine. By measuring the level of phenolics in ileal 
fluid we are able to calculate how much has been absorbed by the small intestine and 
what amount goes through to the colon in healthy subjects. In addition to this, any 
conjugated metabolites formed as a result of enterohepatic recycling from Phase II 
metabolism may also be detected in the ileal fluid. Analysis of plasma and urine data 
revealed no phase II metabolites of rutin. Further analysis of the ileal fluid showed that 
no significant absorption had occurred in the small intestines. Ninety-two % of the rutin 
ingested was excreted in the ileal fluid, implying that the site of the absorption is not the 
small intestine but the large intestine. The results in this study is in broad agreement 
with the findings of Hollman et al. (1995) who obtained only 17 ± 15% absorption of 
rutin in ileostomy subjects when supplemented with 164 pmoles of rutin.
The validity of the ileostomy model has been questioned as it has been 
hypothesized that the distal part of the small bowel in ileostomy subjects has an active 
microbial population (Norman et al., 2001). Bacterial fermentation was however, 
minimized with the frequent emptying of ileostomy bags and the rapid freezing of the 
ileal fluid. In addition, the ileal fluid did not smell or look faecal. The fact that 92% of 
the rutin ingested was excreted in the ileal fluid, suggest that bacterial fermentation in 
the ileal fluid was minimal.
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3.4.3. Ring fission catabolites
The 0.02-2.8% recovery of the ingested rutin as metabolites in urine clearly 
does not account for the vast majority of the consumed rutin. The most likely fate of 
these compounds is that they are broken down to low molecular weight phenolic acids 
by the colonic microflora (Olthof et al, 2003). Under strictly controlled dietary 
conditions, a total of six potential rutin catabolites were detected in the urine with 
significant excretion increases post-supplementation of rutin (Table 3.9).
In healthy subjects with a colon, hydroxyhippuric acids, and 3- 
hydroxyphenylacetic acid, 3,4-dihydroxyphenylacetic acid and 4-hydroxy-3-methoxy- 
phenylacetic acid were all detected in urine after ingestion of tomato juice spiked with 
rutin. This is in agreement with investigations carried out by Olthof et a l (2003), 
Rechner et al (2001) and Gonthier et al (2003). Rechner et a l (2001) further proposed 
that hydroxyhippuric acid is a good indicator for bioavailability and metabolism of 
phenolic compounds. In subjects without a colon, we recovered hydroxyhippuric acids 
but none of the hy droxypheny lacetic acids. This difference can be explained by the fact 
that the hydroxyphenylacetic acid derivatives are most likely the ring fission products of 
rutin and are, therefore, formed principally in the colon while the presence of 
hydroxyhippuric acids in urine of ileostomy volunteers suggests their synthesis is not 
restricted to only the colon. Hydroxyhippuric acid may also originate in the oxidative 
attack on exogenous benzenoid compounds by detoxifying enzymes system of the 
endoplasmic reticulum or microsomes (Gelboin et a l, 1972). However, bacterial action 
cannot altogether be excluded as possible source of these compounds (Spencer et al,
2003). This is supported by the higher levels of hydroxyhippuric acids observed in the 
volunteers with a colon (Tables 3.9 and 3.10). However, when considered with the data 
obtained from the ileal fluid, it is clear that the hydroxyhippuric acids detected in ileal 
subjects were not derived from the metabolism of rutin but most probably from other 
compounds present either in the tomato juice or food consumed during the period of the 
study. This is in agreement with the investigation carried out by Olthof et a l, 2003 
where it was shown that hippuric acids, are important catabolites in humans after 
ingestion of tea, but not after ingestion of rutin.
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3.4.4. Extent of metabolism
The plasma concentration of quercetin metabolites accounts for only 0.01- 
0.016% of the rutin ingested while the hydroxyphenylacetic derivatives corresponded to 
24% of intake. The fraction that was not recovered in the urine was likely to be either 
metabolized to non-phenolic compounds that were not detected, deposited in body 
tissues, excreted with the faeces or degraded to carbon dioxide (Walle et al, 2001). 
Distribution and accumulation of metabolites in other tissues may constitute an 
important part of the unaccounted rutin metabolites as available data, essentially from 
animal studies, indicate that some polyphenol metabolites may accumulate in certain 
target tissues rather than just equilibrate between blood and tissues (Manach et al,
2004). Since human subjects were used in this study, the possible deposition of 
metabolites in body tissues such as the liver, kidneys and brain, is not possible for 
obvious reasons. Another possibility is that the metabolites of rutin could have been 
taken into cells or tissues and released back into the bloodstream at concentrations 
below the limit of detection of the analytical method used in this study or as metabolites 
or degradation products that were not identified.
3.4.5 Methodology
Most of the earlier studies on the bioavailability of flavonoids either used 
enzyme or acid hydrolysis of samples to release aglycones, prior to HPLC to determine 
levels in plasma and urine. However, the current study with human volunteers in which 
unhydrolysed extracts were analysed by HPLC with PDA and full scan data dependent 
MS  ^ detection, provided a far more detailed and realistic picture of the fate of rutin 
within the body than it was possible to obtain in earlier investigations. A total of 15 
urinary metabolites were detected and quantified. This HPLC-MS^ technique which 
employed in these analyses used either an APCI or an ESI interface and such 
methodology has been available for over a decade and is now firmly established as the 
primary analytical tool for screening studies related to bioavailability and drug 
discovery (Ackermann et a l, 2002). The ESI, regarded as the softer more versatile 
method of ionisation, is able to ionise extremely polar/non-volatile molecules such as 
the flavonols or conjugated metabolites. However, ESI does not ionise phenolic acids. 
In contrast, APCI provides more robust ionization through a heated nebulizer, which 
facilitates solvent evaporation and subsequent ionisation of phenolic acids.
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3.5 Conclusion
The data obtained in this study revealed that extensive modification of rutin 
occurs following its ingestion and the appearance of metabolites in the bloodstream and 
urine. The large intestine or the colon has been verified as the major site for the 
metabolism of rutin. The absorbance of rutin at this site involves a complex 
combination of deglycosylation, glucuronidation and méthylation processes. Microfloral 
degradation introduces an additional complexity to the intestinal disposition and 
biotransformation of rutin in \ivo. Evidence obtained from this trial suggests that the 
colonic microflora play a very crucial role in the catabolism of rutin producing large 
quantities of 3,4-dihydroxyphenylacetic acid, which is the major catabolite in the urine.
However, before any further steps can be taken to study the potential 
biological effects at the tissue and cellular level, more data is needed on the 
concentrations and exact metabolic forms produced in the colonic lumen after ingestion 
of rutin. One way this can be done is though in vitro fermentation of rutin with colonic 
microflora. Detailed study on this aspect is revealed in the following chapter.
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Chapter 4: Colonic Metabolism of Rutin
4.1 Introduction
Most flavonoids and polyphenolic compounds are present in plant-derived 
food as glycosides that undergo hydrolysis before absorption. Depending upon the 
linkages, they are both hydrolysed and subsequently absorbed either in the small or the 
large intestines (Murota and Terao, 2003). In recent years, major advances have been 
made in elucidating structural changes and understanding the mechanism of absorption 
of flavonoids across the small intestine using both Caco-2 cell models and isolated 
preparations of rat small intestine (Spencer, 2003). Such studies have however 
suggested that the extent of absorption of dietary polyphenols in the small intestine may 
be relatively small (10-20%) (Spencer et al, 1999; Kuhnle et al, 2000) This is partly 
due to the fact that majority of the absorbed polyphenols in the enterocytes and/or the 
liver may transport back out into the lumen either directly or via the bile and ultimately 
will reach the large intestine where they encounter the colonic microflora (Spencer, 
2003). Identifying structural changes of polyphenol compounds and the mechanism of 
absorption in the large intestine is, therefore, the key to not only defining their 
bioavailability but also their biological activities in humans.
The micro flora in the colon, which can amount to ~1 0 ^^  microorganisms/mL 
has an enormous catalytic and hydrolytic potential that can result in a huge array of new 
metabolites (Spencer, 2003). The hydrolytic power of the micro flora enzymes is able to 
catalyze the breakdown of the Ce-Cs-Ce flavonoid skeleton itself to simpler molecules 
such as phenolic acids. Phenolic confounds, which include unabsorbed compounds 
from the diet and products of microbial metabolism by the gut microflora; account for 
the major components of the lower GI tract (Halliwell et a l, 2005). Depending on the 
diet consumed, a huge array of phenolic acids such as phenylacetic acid, 3- 
phenylpropionic acid, caffeic acid, ferulic acid, 3-hydroxyphenylacetic acid, benzoic 
acid, 3-(4-hydroxy)phenylpropionic acid, 3,4-dihydroxyphenylacetic acid, 4 -  
hydroxyphenylacetic acid and 3,4-dihydroxyphenylpropionic acid were found in faecal 
water. Halliwell et al (2005) reported that concentrations of these phenolic acids range 
from 15-410 pM, which was much higher than the 0.7pM of flavonoids present in the 
colon. Halliwell et al (2005) further suggested that as a consequence of these high 
concentrations, phenolic acids might exert direct protective effects within the large
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intestines which could include binding of prooxidant iron, scavenging of reactive 
nitrogen, chlorine, and oxygen species, and perhaps inhibition of cyclooxygenases and 
lipoxygenases.
The identification and quantification of microbial metabolites is still in its 
infancy (Manach et a l, 2004). To date there has been some debate in the identification 
of specific degradation products of rutin and also in elucidating the catabolic pathways 
involved. Aura et al (2002) and Rechner et al (2004) identified quercetin, 3,4- 
dihydroxyphenylacetic acid, 3-hydroxyphenlyacetic acid and 3(3- 
hydroxyphenyl)propionic acid as the colonic catabolites of rutin. In addition to this, 
Justesen and Arrigoni (2001) also identified 3,4-dihydroxybenzoic acid, 3,4- 
dihydroxybenzaldehyde, 2,4,6-trihydroxybenzoic acid, 2-(3,4-dihydroxyphenyl)ethanol,
4-hydroxyphenylpropionic acid and 3,4-dihydroxytolene as the possible catabolites of 
rutin but did not detect quercetin (Justesen et a l, 2000 and Justesen and Arrigoni, 
2001). Using a pig caecum under anaerobic ex-vivo conditions, Labib et al (2004), 
found that quercetin was metabolized to phloroglucinol, 3,4-dihydroxyphenylacetic 
acid, and 3,4-dihydroxytoluene. In studies using the anaerobic bacterial strain, 
Eubacterium ramulus, which is a key organism for flavonoid degradation, Braune et al 
(2 0 0 1 ) demonstrated that alphitonin and taxifolin are intermediates in the conversion of 
quercetin to 3,4-dihydroxyphenylacetic acid. Structures of the possible catabolites of 
rutin and quercetin are illustrated in Figure 4.1.
This chapter reports on the use of an in vitro faecal fermentation system to 
investigate the role of colonic microflora in the metabolism of rutin. The aims being i) 
to identify specific degradation products ii) to obtain information on possible catabolic 
pathways involved in their formation and iii) to determine their contribution to the total 
antioxidant activity of the colonic lumen.
84
OHHO.
OH
Phloroglucinol
OH
OH
COOH
3,4-Dihydroxybenzoic acid
OH
OH
H,C"
3,4-Dihydroxytoluene
OH
OH
OHO
OH
COOH 
4-Hydroxybenzoic acid
OH
HO' OH
COOH
3,4-Dihydroxybenzalddiyde 2,4,6-Trihydroxybenzoic acid
OH
CH2COOH CH2COOH CH2CH2COOH
3-Hydroxyphenylacetic acid 3,4-Dihydroxyphen>1acetic acid 3-(3-Hydroxyphenyl)propionic acid
OH OH
OH
CH2CH2COOH CH2CH2OH
4-Hydroxyphen)dpropionic acid 2-(3,4-Dihydroxyphenyl)ethanol
OH
O H
HO.
OH
OH O
Taxifolin
OH
OH
OH
Alphitonin
Figure 4.1. Structures of possible biodégradation products of rutin and quercetin
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4.2 Study model
The in vitro fermentation model adopted in this study is based on faecal 
incubation with conditions designed to simulate events taking place in the human colon 
(Edwards et al., 1996). In vitro studies circumvent some of the problems encountered 
with in vivo studies: the collection of faeces is simple and retention of fermentation 
products within the system makes their identification and quantification easier 
(Christian et a!., 2003). The fermentations were performed under strictly anaerobic 
conditions.
4.3 Materials and method
4.3.1 Materials
14[4- C]Quercetin was synthesized by Chemsyn Science Laboratories (Lenexa, 
KS 66215, USA) (Figure 4.2). The specific activity was 52.9 mCi mmol'\
OH
OH
HO.,
OH
OH O
Figure 4.2. Radiolabelled [4-*'^ C] quercetin
Standards of rutin, taxifolin, 2-hydroxyphenylacetic acid, 3- 
hydroxyphenylacetic acid, 4-hydroxyphenylacetic acid, 3,4-dihydroxyphenylacetic acid,
4-hydroxybenzoic acid, 3,4-dihydroxybenzoic acid, 3,4-hydroxybenzaldehyde, 3,4- 
dihydroxyphenylpropionic acid, gallic acid and phloroglucinol were purchased from 
Sigma Aldrich Chemical (Poole, Dorset, UK). 3-(2-Hydroxy)phenylpropionic acid and
3-(3-hydroxy)phenylpropionic acid were purchased from Fluorochem (Derby, UK).
Analytical grade chemicals were used in preparing the buffer, macromineral, 
micromineral and reducing solutions. Ammonium bicarbonate, sodium bicarbonate, 
cysteine hydrochloride, sodium sulphide, magnesium sulphate, calcium chloride.
86
sodium hydrogen phosphate anhydrous, potassium dihydrogen phosphate anhydrous, 
manganese chloride, cobalt chloride, ferric chloride were obtained from BDH 
Laboratory Supplies (Poole UK). Resazurin and tryptone were purchased from Sigma- 
Aldrich while sodium hydroxide was purchased from Riedek-DeHaen (Seelze, 
Germany).
The HPLC solvents, methanol and acetonitrile (HPLC grade) were purchased 
from Rathbum Chemicals Ltd. (Walkerbum, Scotland). Formic acid was purchased 
from Riedek-DeHaen) while acetic acid was from BDH. All other chemicals and 
reagents were obtained from Sigma-Aldrich unless otherwise stated.
4.3.2 Fermentation medium
The fermentation media was prepared by mixing 2 g of tryptone in 400 mL of 
distilled water and 100 pL of micromineral solution (consisting of 13.2 g of CaCl2.2 
H2O, 10.0 g of MnCl2. 4 H2O, 1.0 g C0 CI2 .6  H2O, FeCls.ô H2O and distilled water up to 
100 mL). This solution was agitated to dissolve the chemicals and then 200 mL of 
buffer solution (2 g of NH3.CO3, 17.5 g of Na2.2 C0 3 , and 500 mL of distilled water), 
200 mL of macromineral solution (2.85 g of Na2HP0 4 -H2 0 , 3.1 g of KH2PO4 .H2O, 0.3 
g of MgS0 4 .7 H2 0  and 500 mL of distilled water) and 1 mL of 0.1% (w/v) of resazurin 
solution (a redox indicator) were added. This medium was adjusted to pH 7 using HCl 
and subsequently boiled for a few minutes to sterilize it and remove oxygen. Reducing 
solution (312.5 mg of cysteine hydrochloride, 2 mL of 1 M NaOH, 312.5 mg of sodium 
sulphide and 47.5 ml distilled water) was added at 0.5 mL for every 10 mL of medium 
after which oxygen-free nitrogen (OFN) was admitted until anaerobic conditions 
(observed through a colour change from pale indigo to colomless) were achieved.
4.3.3 Subjects
Faecal samples were obtained from two males and a female volunteer; A, B 
and C. As a matter of practicality and time constraints, faecal samples from only three 
volimteers were used in the present study. Subjects were non-smokers, aged between 
26-37 and had not consumed antibiotics for at least three months prior to the study. The 
volunteers were required to avoid all alcohol and food rich in polyphenols 48 h prior to 
faecal collection. Faecal samples were collected and processed within 30 min of 
passage.
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4.3.4 In vitro fermentation
The in vitro fermentation method used in this study was adopted from 
Edwards et al. (1996). For each subject, 6.4 g of freshly voided faecal sample was 
homogenized with 20 mL phosphate buffer to obtain a 32% faecal slurry. Five mL of 
the slurry was added to 44 mL of the pre-reduced fermentation media in 100 mL 
fermentation bottles (Figure 4.3). Each batch culture consist of 50 mL of the above 
slurry mixture together with one of the following substrates ;
a) 28 pmoles of rutin
b) 28 pmoles of rutin plus 0.5 g glucose
c) 55 pmoles of quercetin plus 18x10^ dpm [^"^Cjquercetin (60 nmoles)
d) 55 pmoles of quercetin plus 18 x 10^  dpm [^^Cjquercetin (60 nmoles) and
0.5 g glucose
e) Control -  no substrate
A single absorbance peak at 365 nm and a single radioactive peak, which corresponded 
to the retention time of quercetin were obtained when 10^  dpm of [^^Cjquercetin was 
analysed by HPLC. The amount of rutin used in this study corresponds to the results 
obtained from the previous chapter, i.e after consuming 175 pmoles of rutin, 
approximately 75% of it was excreted out in the ileal fluid within five hours of 
ingestion. Assuming that the colon volume content is about 300 mL, the final 
concentration of rutin in the colon is 560 pM. To obtain this concentration in in vitro 
fermentation studies, 28 pmoles of mtin was dissolved in 50 mL fermentation medium. 
Glucose was added to the fermentation media so that the test conditions were more 
representative of the real life situation as rutin is normally consumed through ingestion 
of rutin containing food or beverages.
The results of the in vitro fermentation study with rutin indicated that the first 
degradation product to be formed was quercetin. This is in agreement with the findings 
of Aura et al. (2002) and Rechner et al. (2004). To identify and quantify further 
degradation products, which may be produced in smaller concentrations, 55 pmoles of 
quercetin spiked with 18x10^ dpm [ '^^Cjquercetin (60 nmoles) was used as the substrate 
in the in vitro fermentation trial.
After adding in the substrate, the fermentation bottles were sealed air-tight and 
purged with OFN. They were then placed horizontally in a shaking water bath at 60
8 8
strokes/min and incubated at 37°C for 48 h, aiming to simulate the conditions in the 
colonic lumen (Christian et al, 2003). Aliquots of the fermented faecal samples (3-5 
mL) were collected after 0, 2, 4, 6 , 24, 30 and 48 h and stored immediately at -80°C.
4.3.5 Measurement of fermentation products
4.3.5.1 Extraction of polyphenols
Triplicate 250 pL samples of faecal slurry were extracted twice with 500 pL 
MeOH in 1% formic acid and 20 mM sodium diethyldithiocarbamate (antioxidant). To 
calculate the extraction recovery, 250 pg gallic acid was used as an internal standard. 
For each extraction, samples were homogenised for 5 min with a Disruptor Genie 
(Scientific Industries, UK) and then centrifuged at 16000 g for 10 min. Supernatants 
were combined and reduced to dryness in vacuo. Extracts were then re-suspended in 25 
pL methanol plus 225 pL 1% formic acid in distilled water and centrifuged at 16000 g 
at 4°C for 5 min prior to the analysis of 200 pL aliquots of the supernatant by HPLC- 
PDA-MS^. Analyte recovery was calculated by comparing the response of samples 
spiked with the internal standard prior to extraction and its recovery of it after 
extraction. The extraction recoveries for the internal standard was 93+ 3.3%. The 
precision and accuracy of the assay were evaluated by analyzing standard solutions of 
rutin and 3,4 dihydroxyphenyl acetic acid, everyday, over the period of the study. 
Significant changes in the ionization peaks were overcome with the re-tuning of the 
MS .^ Calibration plots of peak area versus concentration for all the analytes were 
obtained by linear regression analysis of at least four data points per concentration range 
of 5 ng to 300 ng using UV absorbance at 365 nm for flavonol and 280 nm for phenolic 
acids.
4.3.5.2 HPLC with diode array and MS  ^ detection with on-line radioactivity 
detection for metabolite identification
Samples were analysed on a Surveyor HPLC system comprising of a HPLC 
pump, PDA detector, scanning fi-om 250 to 700 nm and an autosampler cooled to 4°C. 
(Thermo Finnigan, San Jose, USA). Separations were carried out using a 250 x 4.6 mm
I.D. 4 pm Synergi Max-RP column (Phenomenex, Macclesfield, UK) for flavonols and 
eluted with a 60 min gradient of 5-40% acetonitrile in 1% formic acid at a flow rate of 1 
mL min'  ^ and maintained at 40°C. Analysis of phenolic acids used a 250 x 4.6 mm I.D. 
4 pm Synergi Hydro-RP column (Phenomenex) eluted with a 60 min gradient of 2-20%
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acetonitrile in 0.25% acetic acid at a flow rate of 1 mL min"\ After passing through the 
flow cell of the PDA detector, the column eluate was split and 0.3 mL min’^  was 
directed to a LCQ DecaXP ion trap mass spectrometer fitted with an ESI for the 
analysis of flavonols or to an APCI interface (Thermo Finnigan) for the analysis of 
phenolic acids. Analyses utilised the negative ion mode for both flavonols (ESI) and 
phenolic compounds (APCI) as this provided the best limits of detection. For detection 
of radioactivity, the column eluate was first directed to a radioactivity monitor (Model 
9701, Reeve Analytical, Glasgow, UK) fitted with a 200 pL heterogenous flow cell, 
before being split to enter the LCQ DecaXP ion trap mass spectrometer. Analysis was 
carried out using full scan, data dependant MS  ^scanning from m/z 100 to 1000. For the 
ESI interface, the capillary temperature was 350°C, sheath gas and auxiliary gas were 
60 and 10 units respectively, and the source voltage was 4 kV for negative ionisation. 
For the APCI interface, the capillary temperature was 130°C, vaporizer temperature was 
350°C, sheath gas and auxiliary gas were 80 and 60 units respectively, and the source 
voltage was 6  kV for negative ionisation.
Quercetin, rutin, taxifolin, 3-hydroxyphenylacetic acid, 3,4- 
dihydroxyphenylacetic acid were all quantified by reference to standard calibration 
curves at 365 nm for flavonols and 280 nm for phenolic acids. Other phenolic acids 
were quantified in either 3-hydroxyphenylacetic acid or 3,4-dihydroxyphenylacetic 
equivalents. In all instances, peak identification was confirmed by HPLC retention 
times and MS  ^fragmentation data.
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Figure 4.3. Flow chart of the in vitro fermentation method
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4.3.6 Antioxidant assays
4.3.6.1 Determination of the antioxidant activity using the FRAP assay
The ferric reducing antioxidant power (FRAP) assay, described by Benzie et 
al. (1996), was used to estimate the antioxidant activity of the faecal samples and that of 
specific flavonol and phenolic acid standards. This method measures the ability of a 
solution to reduce a ferric-tripyridyl-triazine complex (Fe^^-TPTZ) to the ferrous form, 
Fe^ ,^ producing a blue colour with absorption at 593 nm. The reaction is non-specific 
and any half-life reaction, which has a lower positive redox potential under reaction 
conditions, than the Fe^/Fe^^-TPTZ half-life reaction will drive the Fe^-TPTZ 
reduction. In the FRAP assay excess Fe^  ^is used and the rate limiting factor of the Fe^ -^ 
TPTZ, and hence the colour formation, is the reducing ability of the sample. The 
absorbance at 593 nm was measured with a Unicam UV500 Spectrophotometer. Thirty 
pL of sample was added to the freshly prepared FRAP reagent (acetate buffer, pH 3.6; 
FeClg, TPTZ in 40 mM HCl). Absorbance was measured at 593 nm after 4 min and 
compared to a 0-1 mM Fe^  ^standard curve.
4.36.2 Determination of the antioxidant activity using the ABTS
decolourisation assay
The ABTS^ (2,2'-azinobis-[3-ethylbenzothiazoline-6-sulfonate]) assay is 
based on the method of Koleva et al. (2001) and Dapkevicius et al. (2001) and was used 
in combination with the HPLC to analyse faecal samples in order to identify individual 
catabolites with antioxidant activity. This on-line HPLC antioxidant detection system is 
based on procedures developed by Stewart et al. (2005). A 2 mM ABTS stock solution 
containing 3.5 mM potassium persulphate was prepared and incubated at room 
temperature in darkness overnight to allow for stabilisation of the radical. The next 
morning, the stock solution was diluted 8 -fold with 0.1 M potassium phosphate buffer at 
pH 8 .
The HPLC system comprised of an HPLC pump, an auto-injector with sample 
cooler, a column oven linked to a photodiode array detector (Thermo Finnegan). 
Samples, 2 0  - 30 pL in volume, were analysed with the same column and solvents used 
for HPLC-PDA-MS^ analysis. HPLC eluent leaving the PDA arrived at a “T” piece, 
where the ABTS^ reagent was added. ABTS^ solution was delivered by a LC-10-AD 
VP pump, connected to a GT-154 Vacuum Degasser (Shimadzu, Kyoto, Japan) at a
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flow rate of 0.5 mL/min. After mixing by passing through a 1.5 m x 0.4 mm (i d.) loop, 
absorbance was measured by a UV-detector at 720 nm (Nemphlar Bioscience, Lanark, 
UK). Data were analysed using ThermoFinnigan ChromquestTM chromatography 
software (Version 4.0) (Figure 4.4)
Injector
HPLC-
pump
HPLC
Column ABTS'"
solution
Sample HPLC
pump
PDA
dectecor
Reaction
loop
Detector at 
720 nm
Figure 4.4. Schematic diagram o f the on-line antioxidant system used in this study. HPLC 
separation followed by an on-line post column detection of radical scavenging compounds based on 
a model oxidation system: ABTS*+ bleaching and decreasing absorbance at 720 nm upon its 
reduction by an antioxidant
4.3.7 Statistics
Each sample was analysed in triplicate and data were presented as mean values 
± standard error (n=3). Where appropriate, data were subjected to statistical analysis 
using analysis of variance (ANOVA) to determine the significance of the observed 
treatment/response relationship. Multivariate correlation analysis of appropriate data 
was performed according to Pearson’s Correlation. All statistical analyses were 
performed using Minitab software (Minitab Inc., Addison-Wesley publishing Co, 
Reading, MA).
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4.4 Results
4.4.1 Deglycosylation of rutin
Analysis of the faecal samples of rutin fermentation revealed clear donor- 
dependent variations in degradation patterns. The data are presented in Figure 4.5 in 
which seven fermentation time points are presented over a 48 h period following 
incubations with 28 pmoles of rutin. Identification of metabolites was obtained fi"om 
HPLC-MS^ analyses. The first fermentation product of rutin to be detected, was 
quercetin. Quercetin-3-glucoside was not detected as an intermediate indicating the one 
step removal of the rutin moiety rather than an initial cleavage of rhamnose followed by 
the loss of glucose as observed in faecal incubation with cyanidin-3 -rutinoside (Aura et 
al, 2005). The addition of glucose to the fermentation medium enhanced the 
deglycosylation process by almost 20 h. Quercetin was detected in the faecal samples 4 
h after fermentation and complete degradation of rutin occurred within 24 h in the 
presence of glucose. However, the degradation pattern of rutin and the formation of 
quercetin differed between the faecal donors when glucose was not present. In the 
absence of glucose, higher amount of quercetin was observed in samples fi'om donors B 
and C. This was especially evident in the case of faecal samples fi^ om the donor C where
7.5 pmoles of quercetin was present at the 48 h time point. This effect was not observed 
in the samples from donor A (Figure 4.5). Since quercetin is the first degradation 
product of rutin, subsequent incubations were carried out using quercetin as the 
substrate.
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Figure 4.5. Individual fermentation profiles of rutin in faecal samples 
from three donors, demonstrating the different degradation patterns of rutin 
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4.4.2 Radiolabelled intermediate products after deglycosylation of rutin
When high a concentration of quercetin amounting to 55 pmoles (1.1 mM) 
was added directly into the fermentation medium, it was foimd to be imstable. Within 
15 min, only 1.4% remained in the fermentation medium containing glucose and 2.3% 
in the absence of glucose. This may be due to its pro-oxidant properties as suggested by 
Awad et al (2 0 0 2 ). Quercetin can undergo rapid oxidation especially through reactions 
with H2O2, resulting in its conversion to semiquinone free radicals and to a wide variety 
of unidentified reaction products (Krishnamachari et al., 2002) (see Figure 4.6). Long et 
al. (2000) demonstrated that at concentrations of 1 mM of quercetin in cell culture 
media produced substantial quantities of H2O2 which increased with concentration and 
time. Geneiation of H2O2 could explain the rapid oxidation of quercetin in the 
fermentation media even though oxygen free conditions were maintained throughout the 
fermentation period. This phenomenon was, however, not so pronounced when 
quercetin was formed from rutin as indicated in Figure 4.5. The contrasting effect seen 
here could be due to differing concentrations of quercetin involved. When present in 
high concentrations, the quantities of H2O2 produced would appear to be sufficiently 
high to cause most of the quercetin to be oxidised while this did not appear to occur to 
the same extent at lower concentrations of quercetin which was produced from rutin via 
deglycosylation (see Figure 4.5, donors B & C, without glucose). A number of other 
studies have also substantiated that pro-oxidant properties of quercetin is only observed 
when present in high amounts (Cao et al, 1997, Galati, et al., 2 0 0 1 )
In the present study, evidence indicates that quercetin may have been oxidised 
to more polar compounds as indicated by analysis using HPLS-MS^ with APCI and the 
on-line radioactivity detector (Table 4.1 & Figure 4.7). Being more polar, these 
‘oxidised’ quercetin compounds were separated by HPLC using a 2-20% acetonitrile 
gradient. These oxidised forms of quercetin retained their radioactivity where most was 
associated with peak 3 while only smaller amounts could be detected in peak 1, 2 and 3 
(Figure 4.6 and 4.7). The oxidised quercetin compound in peak 2 with a m/z of 299 may 
be a quinone methide as it is more stable than 0-Quinone (Awad et al, 2002). The 
structure of this compound is illustrated in Figure 4.6. However, this compound 
appeared only transiently in the faecal samples 15 min after incubation and was present 
in trace and non-quantifiable amounts. The inter-individual degradation profiles of the 
quercetin and of its other oxidized forms are presented in Table 4.2. As with rutin, the
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degradation of quercetin and its oxidised forms were enhanced by the addition of 
glucose, which resulted in almost all the quercetin being degraded within 6  h of 
fermentation (faecal samples from donor A and B). However, it must be noted that after 
15 min of incubation only 1 0 % of the residual quercetin and its oxidised forms were 
identifiable while the remaining 90% could not be accounted for. Oxidised quercetin 
such as quinone methide and O-quinone are highly reactive intermediates and have the 
affinity to form adducts with various conpounds (Awad et al. y 2 0 0 0 ) and also rapidly 
polymerize (Awad et al. 2002). This may explain the appearance of a number of 
unidentified radioactive peaks particularly in the first 4 h of incubation as observed in 
Figure 4.9. In addition, its possible attachment to diverse compounds of varying 
molecular weight present in the fermentation media also makes detecting and 
identifying these compounds a less than straight forward task.
CH OH
HO.
OH
OH O
Quinone methide 
Molecular weight:300 
CisHsOt
Adopted from Awad et al (2002)
(9-Quinone 
Molecular weigjit:300 
CisHgOy
OH
HO. OH
OH OH
OH
OH
HO,
OH OH
Unidentified ‘oxidised’quercetin 
Molecular weight:318 
CisHioOs
Unidentified ‘oxidised’quercetin 
Molecular weight:334
ClsHioOg
Adopted from Krishnamachari et a l (2 0 0 2 )
Figure 4.6. Possible oxidised intermediate products formed during the in vitro fermentation of quercetin.
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Table 4.1. HPLC-MS^ identification of ‘oxidised’ quercetin metabolites detected in 
faecal samples after 15 min of fermentation
Peak (min) Oxidised Quercetin [M-H] (m/z) MS  ^fragments ions (m/z)
1 9.3 Quercetin + [H] + [O] 318 274, 244, 199, 200
2 14.8 Quinone methide 299 271,277,255
3 37.1 Quercetin + [O] 317 231,255, 187, 191,302
4 50.0 Quercetin + 2[0] 333 315, 300, 181, 151
Peak numbers and HPLC retention times refer to HPLC trace in Fig. 4.5. /r - retention 
time; [M-H]' - negatively charged molecular ion. APCI.
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Figure 4.7. HPLC chromatogram (A) and radioactivity (B) of faecal samples from 
donor A at time 0.15 h as analysed by HPLC-MS-radiodetector. Radiolabelled 
compounds are numbered according to the order of elution. (For MS^ data and 
identification and quantification of peaks 1-4, refer to Table 4.1)
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Table 4.2. Accumulation of quercetin and ‘oxidized quercetin’ structures 0.15- 
6  h following in vitro fermentation of faecal samples from three donors with 55 
nmoles of quercetin
Donor Metabolite Glucose 0.15 h 2 h 4h 6 h
A Quercetin - 1.4 ±0.1 1.3 ±0.1 0.7 ±0.0 n.d.
+ 0 . 8  ± 0 . 0 0.7 ±0.0 0.5 ±0.0 n.d.
Quercetin+[H]+[0] - 2 . 6  ± 0 . 0 3.9 ±0.1 4.1 ±0.1 3.1 ±0.1
+ 2 . 6  ± 0 . 1 n.d. n.d n.d.
Quercetin+[0] - 0.7 ±0.0 0.7 ±0.1 0 . 6  ± 0 . 0 0.5 ±0.1
+ 0 . 8  ± 0 . 0 0.3 ± 0.0 n.d. n.d.
Quercetin+2[0] - 0 . 2  ± 0 . 0 0 . 2  ± 0 . 0 n.d. n.d.
+ 0 . 2  ± 0 . 0 n.d. n.d. n.d.
B Quercetin - 1 . 1  ± 0 . 0 0.9 ±0.0 0.5 ± 0.0 n.d.
+ 0 . 8  ± 0 . 0 0.9 ±0.1 n.d. n.d.
Quercetin+[H]+[0] - 3.1 ±0.1 3.9 ±0.2 4.1 ±0.1 3.5 ±0.1
+ 3.4 ±0.1 n.d. n.d. n.d.
Quercetin+[0] - 1 . 0  ± 0 . 0 5.5 ±0.0 0.5 ±0.0 0.5 ±0.1
+ 0 . 8  ± 0 . 0 0.4 ±0.0 n.d. n.d.
Quercetin+2[0] - 0.3 ± 0.0 0 . 2  ± 0 . 0 0 . 2  ± 0 . 0 n.d.
+ 0.3 ± 0.0 n.d. n.d. n.d.
C Quercetin - 1 . 1  ± 0 : 1 1 ,6 ± 0 . 1 1.5 ±0.0 0.5 ±0.1
+ 0 . 8  ± 0 . 0 1 .6 ± 0 .l 0.5 ± 0.0 n.d.
Quercetin+[H]+[0] - 4.1 ±0.3 2.7 ±0.0 n.d. n.d.
+ 4.5 ±0.1 4.2 ± 0.3 1.4 ±0.0 n.d.
Quercetin+[0] - 0.7 ± 0.0 1 .6 ± 0 . 1 1 . 1  ± 0 . 0 1 . 8  ± 0 . 1
+ 0.7 ± 0.0 0.9 ±0.0 0.3 ± 0.0 n.d.
Quercetin+2[0] - 0.4 ± 0.0 0.4 ±0.0 0.3 ± 0.0 n.d.
+ 3.7 ±0.1 3.2 ±1.0 0.9 ± 0.0 0.3 ± 0.0
Data for individual donors are expressed as pmoles ± standard error (n=3); n.d - 
not detected; + : incubated with 500 mg glucose; - : incubated without glucose. 
No quercetin or its oxidized compounds were detected at 24 h, 30h and 48 h 
after fermentation.
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4.4.3 Intermediate metabolites and phenolic acids formed after degradation of 
quercetin
4.4.3.1 Identification of intermediate metabolites and phenolic acids
Analysis by HPLC- MS  ^with APCI and PDA detection revealed the presence 
of intermediate products and catabolites of quercetin resulting from fission of the Ce-Cs- 
Cô structure. The results obtained are illustrated in Figure 4.8 & Table 4.3 and 
summarised below. The structures of the compounds are illustrated in Figure 4.1.
Peak 1 (^ R = 14.7 min, Aonax= 255nm) had a [M-H]' at m/z 153 with MS  ^
yielding a charged fragment at m/z 109. The mass spectrometric data and co­
chromatography with an authentic standard confirmed that this compound is 3,4- 
dihydroxybenzoic acid
Peak 2 (/r = 15.5 min, ^max= 280 nm) had a [M-H]' at m/z 167 which on MS  ^
yielded a major ion at m/z 123 and two smaller fragments at m/z 108 and 164. The mass 
spectrometric data and co-chromatography with an authentic standard confirmed that 
this compound is 3,4-dihydroxyphenylacetic acid
Peak 3 (/r = 21.0 min, Xm&x^  245nm) had a [M-H]' at m/z 137 with MS  ^
yielding a charged fragment at m/z 93. The mass spectrometric data and co­
chromatography with an authentic standard confirmed that this compound is 4- 
hydroxybenzoic acid
Peak 4 (^r = 26.6 min, A^x= 270 nm) had a [M-H]' at m/z 151 with MS  ^
yielding a major ion at m/z 107 and two smaller ions at m/z 93 and 121. The mass 
spectrometric data and co-chromatography with an authentic standard confirmed that 
this compound is 3-hydroxyphenylacetic acid.
Peak 5 {tR = 28.2 min, Xrmx= 295 nm) had a [M-H]' at m/z 303 with MS  ^
yielding three charged fragments, a main one at m/z 285 and two smaller ones at m/z 
117 and 241. From the mass spectrometric data, this compound may be an isomer of 
taxifolin, alphitonin, previously identified as a quercetin degradation product by Braune 
etal. (2 0 0 1 ).
Peak 6 (/r = 38.2 min, ^max= 270 nm) had a [M-H]' at m/z 165 with MS  ^
yielding a charged fragment at m/z 121. The mass spectrometric data and co­
chromatography with an authentic standard confirmed that this compound is 3-(3- 
hydroxyphenyl)propionic acid.
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Peak 7 (^r = 47.7 min, A,max= 295 nm) had a [M-H]' at m/z 303 with MS^ 
yielding three charged fragments, a main one at m/z 285 and two smaller ones at m/z 
117 and 241. The mass spectrometric data and co-chromatography with an authentic 
standard confirmed that this compound is taxifolin.
Peak 8 (/r = 50.3 min, 295 nm) had a [M-H]' at m/z 303 with MS^
yielding three charged fragments, a main one at m/z 285 and two smaller ones at m/z 
117 and 241. From the mass spectrometric data, this compound appears to be an isomer 
of taxifolin.
In addition to these catabolites, trace amounts of phloroglucinol were detected 
in the faecal samples from donor B at 4 h (with glucose) and 6  h (without glucose). This 
catabolite was also detected in small amounts in faecal samples of donor C but was only 
observed at 24 h (with glucose). This catabolite eluted at 7.2 min with a [M-H]' at m/z 
125 with MS  ^yielding a major ion at m/z 57 and a smaller fragment at m/z 81. Analysis 
of a phloroglucinol standard confirmed the identity of this peak as it yielded the same 
mass spectrum and also co-chromatographed with the catabolite peak.
Table 4.3. HPLC-MS^-APCI identification of phenolic acids detected in faecal 
samples after fermentation with 55 p,moles of quercetin
Peak /R (min) Compound [M-H]
(m/z)
MS  ^fragments 
ions (m/z)
1 14.7 3,4-dihydroxybenzoic acid 153 109
2 15.5 3,4-dihydroxyphenylacetic acid 167 123, 108, 164
3 2 1 .0 4-hydroxybenzoic acid 137 93
4 26.2 3-hydroxyphenylacetic acid 151 107, 93, 121
5 28.2 alphitonin 303 285, 117, 241
6 38.2 3-(3-hydroxypheny)propionic acid 165 1 21
7 47.7 taxifolin 303 285, 117, 241
8 50.3 isomer of taxifolin 303 285, 117, 241
Peak numbers and HPLC retention times and the peaks refer to HPLC trace in 
Figure 4.8; /r - retention time; [M-H]' - negatively charged molecular ion.
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Figure 4.8. 2-20% gradient HPLC chromatogram of fermented faecal samples 
(with glucose) at time points indicated in the respective chromatograms obtained 
from donor B (chromatogram A-D) and donor C (without glucose; 
chromatogram E), with diode array detector operating at absorbance 260 nm. 
The absorbance at 280 nm was saturated for most of the peaks, and therefore 
absorbance at 260 nm was used both for quantification and illustration. For MS  ^
data and identification of peaks, refer to Table 4.3 for the detection of phenolic 
acids.
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4.4.S.2 Quantitative estimates of quercetin catabolites
4.4.3.2.1 Taxifolin and related compounds
Taxifolin, the first intermediate metabolite formed during the degradation of 
quercetin was observed in faecal samples after 2 h of fermentation and peaked in the 4 h 
sample. The amount produced varied between the individual donors. It was significantly 
higher in faecal samples of donor B and only appearing transiently in faecal samples 
fi'om donor A and C (Table 4.4). Three isomers of taxifolin were identified in the fecal 
samples (Table 4.3, Figure 4.8). Taxifolin (peak 8) and its isomer (peak 9) retained their 
radioactivity whereas no radioactivity was detected on alphitonin (peak 6) (Figure 4.9). 
The synthesis of alphitonin involves a ring opening and recyclization mechanism 
(Schoefer et al, 2003) and during this process it could have lost its radioactivity.
Table 4.4. Accumulation of taxifolin and its isomers 0-48 h following in-vitro 
fermentation of faecal samples fi’om three donors with 55 pmoles of quercetin
Donor Metabolite Glucose 2  h 4h 6 h 24 h
A alphitonin - 0 . 1  ± 0 . 0 0 . 1  ± 0 . 0 0 . 1  ± 0 . 0 t.a.
+ t.a. 0 . 1  ± 0 . 0 n.d. n.d.
taxifolin - n.d. t.a. ta. 0 . 1  ± 0 . 0
+ 0 . 1  ± 0 . 0 0 . 2  ± 0 . 0 n.d. n.d.
Isomer of taxifolin - n.d. n.d. 0 . 0 1  ± 0 . 0 0 n.d
+ n.d. t.a. n.d n.d.
B alphitonin - 0 . 1  ± 0 . 0 0 . 1  ± 0 . 0 0 . 1  ± 0 . 0 n.d.
+ t.a. 4.7 ±0.0 n.d n.d
taxifolin - 0 . 1  ± 0 . 0 0.3 ± 0.0 0.7 ±0.0 t.a.
+ 0.4 ± 0.0 5.6 ±0.2 n.d. n.d.
Isomer of taxifolin - n.d. t.a. 0 . 1  ± 0 . 0 n.d
+ ta. 0 . 8  ± 0 . 0 n.d. n.d.
C alphitonin - t.a. n.d. n.d. n.d
+ 0 . 1  ± 0 . 0 n.d. n.d. n.d.
taxifolin - n.d. n.d. n.d. n.d
+ n.d. n.d. n.d. n.d.
Isomer of taxifolin - n.d. n.d. n.d n.d.
+ n.d. n.d. n.d. n.d.
Data for individual donors are expressed as pmoles + standard error (n=3); n.d.- not 
detected; + : with 500 mg glucose; - : without glucose; t.a. - trace amounts. N o  
taxifolin or its isomers were detected at 0, 30 and 48 h after fermentation.
103
1400
£c 1000'
ooo<N
^  600  _(L>O
S  200
X)
<
o
>  150 —
B
150 —
O
cS 50 -
50 55 6035 40 4530
Figure 4.9. HPLC chromatogram (A) and radioactivity (B) o f taxifolin and its isomers 
obtained from the faecal samples of donor B at time 4 h as analysed by HPLC-MS^- 
radiodetector. Radiolabelled compounds are numbered according to the order of elution. 
(For MS^ data and identification and quantification of peaks 5, 7 and 8, refer to Table 
4.3). X- appearance of unidentified peaks
104
4.4.3.1.2 Phenolic acids
Five phenolic acids were identified and quantified in the faecal samples. A 
sixth, phlorogucinol appeared only in trace amounts and, therefore, was not quantified. 
Generally, the rate of catabolism was dependent on the individual differences in colonic 
microflora and the presence of glucose, which enhanced the rate of breakdown. The 
bio-degradation to the phenolic acids was slower in the faecal samples from donor C 
compared to those from donors A and B. The data obtained are presented in Table 4.5.
3.4-Dihydroxyphenylacetic acid appeared within 2 h of fermentation (faecal 
samples from donor A & B) and gradually increased in quantity in the fermentation 
media without glucose. The rate of increase was more rapid in the presence of glucose 
(Figure 4.10). 3,4-Dihydroxyphenylacetic acid was the most abundant metabolite 
formed during the degradation of quercetin and accounted for 60-97% of the breakdown 
products when glucose was present. Its maximum amount ranged between 33 to 53 
pmoles (Table 4.5). This metabolite was however not present in the faecal samples from 
donor C (without glucose) and only appeared in the 24* hour of fermentation when 
glucose was present (Table 4.5).
3-HydroxyphenyIacetic acid, a dehydroxylation product of 3,4- 
dihydroxyphenylacetic acid first appeared after 24 h (donor B) and 48 h (donor C) 
(Table 4.5). This metabolite accounted for 15-20% of the breakdown products of 
quercetin in the presence of glucose.
3.4-Dihydroxybenzoic acid was observed transiently in the faecal samples of 
donors A and B (Figure 4.10) but more abundantly, up to 37 pmoles, in samples from 
donor C (Table 4.5). This metabolite started appearing in the faecal samples as early as 
in the second hour of fermentation.
4-Hydroxybenzoic acid, a dehydroxylation product of 3,4-dihydroxybenzoic 
acid, appeared in the faecal samples 2-4 h later than its parent compound (Figure 4.10) 
and as detected in low amounts ranging from 1.1 pmoles (donor A) to 2.2 pmoles 
(donor C) (Table 4.5).
3-(3-Hydroxyphenyl)propionic acid, appeared in the faecal samples in 
varying amounts. This catabolite appeared after 2-4 h of fermentation in the faecal 
samples of donor A but was not present until 6-24 h in the faecal samples of donor B 
and C (Table 4.5). It was detected in relatively low quantities with the highest amount,
3.3 pmoles, found in faecal samples from donor C after 48 h fermentation (Table 4.5).
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In summary, in the absence of glucose, a high percentage of quercetin was 
degraded to 3,4-dihydroxyphenylacetic acid in faecal samples from donors A and B and 
appears to be further catabolised to 3-hydroxyphenylacetic acid by donor B However in 
faecal samples from donor C, these catabolites did not accumulate and most of the 
quercetin was catabolised to 3,4-dihydroxybenzoic acid and subsequently to 4- 
hydroxybenzoic acid. The rate of breakdown of quercetin and accumulation of 3,4- 
dihydroxyphenylacetic acid was enhanced in the presence of glucose. But glucose did 
not have much effect on the levels of other catabolites such as 3,4 dihydroxybenzoic 
acid, 4-hydroxybenzoic acid and to 3-(3-hydroxyphenyl)propionic acid. Without the 
addition of the flavonol, quercetin or rutin, none of the catabolites were detected in any 
of the faecal samples fermented over a 0-48 h period.
Results from section 4.4.2 implies that upon dissolving 55 pmoles of quercetin 
in the fermentation media, most of it was oxidised or converted to unidentified 
quercetin adducts. The 60-97% conversion of the substrate to 3,4- 
dihydroxyphenylacetic acid in the presence of glucose, therefore, strongly suggests that 
in addition to the residual quercetin remaining in the fermentation media, the oxidised 
forms of quercetin together with the unidentified quercetin adducts must have also been 
catabolised by the colonic microflora to produce 3,4-dihydroxyphenylacetic acid and 
other phenolic acids.
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4.4.4. Recovery of radioactivity after 48 hours of fermentation
The recovery of the radioactivity of the fermentation medium at the different 
time points was monitored using a scintillation counter. A faster rate of decline of 
radioactivity was observed in the first six hours of the faecal fermentation (Table 4.6) 
where about 25% of the radioactivity was lost. This is in keeping with the rapid 
biodégradation of quercetin occurring within the first few hours of fermentation. 
Depending on the absence or presence of glucose, a total of 40-44% of total 
radioactivity was lost after 48 h of fermentation (Table 4.6). The conversion to gaseous 
fermentation products may account for the loss of radioactivity as suggested by Walle et 
al (2001) who found that 52% of oral dose of quercetin was lost as [^ "^ CJcarbon 
dioxide in exhaled gases. Since no radioactivity was present in any of the phenolic acids 
formed as a result of the biodégradation of quercetin, the residual radioactivity detected 
(56-60%) most probably came fi'om other unidentifiable compounds, illustrated as peak 
A in Figure 4.11. These small molecular weight compounds were present in all the 
faecal samples and could not be identified using the HPLC-MS^ system. They may be 
the end products of the biodégradation of ring A of the quercetin structure such as the 
acetates and butyrates as indicated by Griffiths and Smith (1972).
Table 4.6. Recovery of radioactivity in faecal samples after fermentation with 55 
pmoles of quercetin (18 xlO^dpm)
Donors glucose % recovery o f
2h 4h 6h 24 h 30 h 48 h
1 - 96 ±0 84 ± 2 73 ±0 70 ±3 62 ± 1 56 ± 1
+ 84 ±0 80 ±0 68 ±1 69 ±0 67+1 58 ±1
2 - 94+1 84 ±0 71 ±2 68 ±1 67 ±0 64 + 0
+ 86 ±2 81+0 76 ±1 67 ± 1 63+0 46 + 0
3 - 95 ± 1 85 ±1 84±2 64 ± 1 65 ±0 61 ±0
+ 91 ±0 85 ±0 78 ±0 67 ±0 68 ±1 63 ±0
Mean - 95±1 84 ±1 76±4 67 + 2 65 + 1 60 ±2
+ 87 + 2 82 + 2 74 ±3 68 ±1 66 + 2 56 ±9
Data for individual donors are expressed as % [ C] remaining in the fermentation 
media ± standard error (n = 3).
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Figure 4.11. Radioactivity (millivolts) of faecal samples from 3 
donors 48 h after fermentation with 55 pmoles o f quercetin as analysed 
by LC-MS^-Radiodetector. Unidentified radiolabelled compound (A) is 
eluting at 5.6 mins.
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4.4.5 Relationship between the colonic catabolites of rutin and antioxidant
activity
4.4.5.1 Total antioxidant activity
The antioxidant activity of the 0-48 h fermentations in the absence of substrate 
(A) and with the addition of 55 pmoles quercetin at 0 h (B), was measured with the 
FRAP assay. To obtain the FRAP values of the residual quercetin and its catabolites 
produced as a result of fermentation, B  was subtracted from A  for the corresponding 
time points. On addition of quercetin, the FRAP value was 2.2 but this value rapidly 
declined as the quercetin became oxidised in the fermentation media. The resultant 
FRAP values ranging from 0-3.3 mM Fe^  ^measured from 0.15—48 h are illustrated in 
Table 4.7. The relationship between the concentrations of total colonic metabolite 
products with the reducing ability in the FRAP-derived antioxidant assay of individual 
faecal samples from the three donors were analysed using Pearson’s correlations. 
FRAP-derived antioxidant activity was highly and significantly correlated (P<0.001) 
with the total colonic catabolite products produced as a result of in vitro fermentation of 
quercetin in all the faecal samples except for the one derived from donor C (without 
glucose) (Table 4.7). This could be due to the absence of 3,4- dihydroxyphenylacetic 
acid, in faecal samples from donor C incubated without glucose.
I l l
Table 4.7. Total colonie metabolite content and antioxidant capacity of fermented 
faecal samples after incubation with 55 pmoles of quercetin
Pearson’s
Time Total correlations
Donor Glucose (h) Metabolite* FRAP** r_________ p_
A w/o
w
B w/o
w
w/o
w
2 6.3 ± 0.3 0.5 ±0.0
4 7.9 ±0.1 0 . 8  ± 0 . 1
6 7.8 ±0.1 0 . 6  ± 0 . 0
24 40 ±1 2.4 ± 0.2
30 34 ±2 1 . 0  ± 0 . 1
48 47 ±2 2 . 0  ± 0 . 0
0.15 4.6 ±0.0 0.3 ± 0.0
2 2 . 6  ± 0 . 0 0.3 ± 0.0
4 8 . 6  ±0.3 0 . 8  ± 0 . 1
6 35 ±2 1.9 ±0.0
24 44 ±1 3.3 ±0.1
30 49 ± 1 3.2 ±0.1
48 46 ± 1 2 . 8  ± 0 . 1
2 6.5 ±0.2 0 . 2  ± 0 . 0
4 8.9 ±0.1 0 . 1  ± 0 . 0
6 9.8 ±0.2 0 . 2  ± 0 . 0
24 33 ± 1 2.7 ±0.1
30 35 ±2 2.5 ±0.1
48 18±0 0.3 ±0.0
0.15 5.5 ±0.0 0.5 ±0.1
2 3.9 ±0.0 0 . 1  ± 0 . 0
4 30 ±2 1.7 ±0.1
6 54 ±1 2 . 1  ± 0 . 1
24 33 ±2 2 . 6  ± 0 . 1
30 37 ± 2 2 . 2  ± 0 . 1
48 15±0 0 . 0  ± 0 . 0
2 8 . 0  ± 0 . 1 0 . 8  ± 0 . 0
4 4.8 ±0.0 0.4 ± 0.0
6 8 . 1  ± 0 . 1 0 . 1  ± 0 . 0
24 39 ± 0 0.7 ±0.0
30 37 ± 0 0 .6 ± 0 . 0
48 37 ± 2 2 . 1  ± 0 . 1
0.15 1 0  ± 0 0 . 8  ± 0 . 0
2 1 1  ± 0 0.7 ± 0.0
4 3.2 ±0.0 0 . 0  ± 0 . 0
6 0.5 ±0.0 0 . 0  ± 0 . 0
24 33 ±2 2 . 2  ± 0 . 1
30 25 ±1 1.4 ±0.0
48 46 ±2 2.3 ±0.0
0.885 0.000
0.936 0.000
0.760 0.000
0.969 0.000
^Amount o f residual quercetin plus total metabolites produced at the time intervals 
specified above, expressed as pmoles; '’FRAP antioxidant capacity o f fermentated 
faecal sanples expressed as mM Fe^  ^ . On addition o f quercetin, the antioxidant 
capacity o f faecal samples at time 0 is 2.2. All data expressed as mean values ±  
standard error, where n = 3. w -  incubated with glucose; w /o -  incubated without 
glucose
1 1 2
4.4.5 2 Antioxidant activity of individual catabolites
In order to investigate the antioxidant capacity of the individual catabolites, 
the standards of these compounds at 1 mM were compared with each other and with 
their parent compounds (rutin and quercetin). Of the compounds analysed, only 
quercetin, rutin, 3,4-dihydroxyphenyacetic acid, 3,4-dihydoxybenzoic acid and taxifolin 
had antioxidant activity in the FRAP assay. No reaction was observed with 3- 
hydroxyphenylacetic acid, 4-hydroxybenzoic acid, phloroglucinol and 3-(3- 
hydroxyphenyl)propionic acid. Quercetin and 3,4-dihydroxyphenylacetic exhibited the 
highest reducing ability in the FRAP antioxidant assay with values ranging from 1.7 - 
1.9 mM (Table 4.8).
Table 4.8. FRAP values of 1 mM flavonols and phenolic acid standards
Flavonol/phenolic acid standard FRAP
Rutin 1.0±0.fr
Quercetin 1.9 ± o r
Taxifolin 0.9 + 0.P
3,4-Dihydroxyphenylacetic acid 1 . 8  + O.r
3-Hydroxyphenylacetic acid 0 . 0
3,4-Dihydroxybenzoic acid 1.0±0.fr
4-Hydroxybenzoic acid 0 . 0
3-(3-Hydroxyphenyl)propionic acid 0 . 0
Phloroglucinol 0 . 0
FRAP values are expressed as mM Fe^ .^ Data expressed as mean values ± standard 
error, where n = 3. Means followed by different superscript letters are significantly 
different at p < 0 .0 1 .
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4.4.S.3 Contribution of individual catabolites to the total antioxidant capacity
The concentrations of each of the catabolites, 3,4- dihydroxyphenylacetic acid, 
taxifolin and 3,4-dihydroxybenzoic acid, during the in vitro fermentation at various time 
intervals was used to calculate FRAP values from the standard calibration curves of 
each individual compound. From this, the contribution of each of these catabolites to the 
total antioxidant capacity of the faecal samples was then determined.
Taxifolin
Taxifolin did not contribute significantly to the total antioxidant capacity of 
the faecal samples. This is due to the fact that very low amounts of antioxidant activity 
was observed in most of the faecal samples except for that from donor B (with glucose) 
at the 4 h time point which gave a FRAP value of 0.2. This value is equivalent to a total 
of 11 pmoles (5.6 + 4.7 + 0.1 pmoles of taxifolin, alphitonin and isomer of taxifolin 
respectively) as revealed in Table 4.4 (Donor B, 4 h + glucose).
3.4-Dihydroxybenzoic acid
3.4-Dihydroxybenzoic acid did not contribute to the total antioxidant capacity 
of the faecal samples of donor A and B, due to low level accumulation (0.15-0.95 
pmoles) in these samples. In donor C, only those samples incubated without glucose 
accumulated higher amounts of 3,4-dihydroxybenzoic acid (up to 37 pmoles) and 
produced FRAP values of up to 0.7 which in turn was responsible for most of the 
antioxidant activity observed in the faecal sample (Table 4.9).
3.4-Dihydroxyphenylacetic acid
3.4-Dihydroxyphenylacetic acid is the main metabolite which plays a major 
role in the contribution of total antioxidant activity in the faecal samples (Table 4.9). 
This is evident in all the faecal samples except for faecal samples from donor C 
(without glucose). The high antioxidant activity observed in the faecal sanples is 
attributed to the large amounts 3,4-dihydroxyphenylacetic acid present. In faecal 
samples from donor A, high concentrations of 3,4-dihydroxyphenylacetic acid 
amounting to 38-48 pmoles corresponded to high FRAP value of 2.4-3.0 and this in turn 
was responsible for most of the antioxidant activity observed in the faecal sample 
(Table 4.9) Similarly in donor B, a high FRAP value of 2.5 corresponded to 53 pmoles 
of 3,4-dihydroxyphenylacetic acid which again contributed to most of the antioxidant 
capacity exhibited in the faecal sample (Table 4.9).
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4.4.S.4 Relationship between antioxidant activity and the content of 3,4-
dihydroxyphenylacetic acid in the faecal samples
Since 3,4-dihydroxyphenylacetic is the main contributor to the total 
antioxidant activity of the faecal samples, the relationship between concentration of this 
metabolite with the reducing ability in the FRAP-derived antioxidant assay of individual 
faecal samples from the three donors were analysed using Pearson’s correlations. 
FRAP-derived antioxidant activity was highly significantly correlated with the 
concentration of 3,4-dihydroxyphenylacetic produced as a result of in vitro fermentation 
of quercetin (Table 4.10). This is also illustrated graphically in Figure 4.12.
Table 4.10. Correlation of 3,4-dihydroxyphenylacetic acid content 
with its antioxidant capacity of individual faecal 
samples from the three donors.
Donor Glucose Pearson’s correlations 
r P
1 - 0.814 0.000
+ 0.975 0.000
2 0.974 0.000
+ 0.872 0.000
3 + 0.868 0.002
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Figure 4.12. Relationship between antioxidant activity (expressed as FRAP in mM 
Fe  ^ ) and 3,4-dihydroxyphenylacetic acid (expressed as pmoles) at specific time 
points after in vitro fermentation of faecal samples obtained from three donors with 
55 pmoles of quercetin. All data expressed as mean values ± standard error, where 
n = 3.
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4.4.5 5 Illustration of the contribution of individual catabolites to the autioxidant 
capacity of the faecal sample using the ABTS^ on-line decolorisation 
assay.
To illustrate and confirm the contribution of the antioxidant capacity of 
individual catabolites in the faecal samples, 20 pL of selected faecal samples were 
analysed by gradient HPLC system with the on-line ABTS^ antioxidant detector system. 
The major antioxidants in most of the samples were associated with the presence of 3,4- 
dihydroxyphenyacetic acid. However, in the faecal sample of donor B (with glucose), 4 
h after fermentation, taxifolin and its isomers were observed to reach its maximum level 
(11 pmoles) and the antioxidant capacity of this compound together with that of 3,4- 
dihydroxyphenyacetic acid (18.5 pmoles) is as illustrated in Figure 4.13-B. The 
antioxidant peaks observed in the ABTS chromatogram before 10 min corresponded to 
unidentified compounds that were also present in faecal samples when no substrates 
(quercetin) was added (Figure 4.13-A).
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4.5 Discussion
4.5.1 Methods, material and model used
To assess the colonic metabolism of rutin, an in vitro fermentation model was 
adopted. This method involves faecal incubation with a substrate, aiming to simulate 
events occurring in the human colon. In vitro fermentation has been used by other 
researchers to study colonic catabolism of flavonoids (Aura et al., 2002, 2005; Rechner 
et a l, 2004, and Justesen et a l, 2000) but in most cases, the experimental approach used 
varied with respect to the inoculum size, type of media, anaerobic conditions, choice of
buffer and mixing rate. All these factors can affect the bacterial ecotypes, which in turn
affects the catabolism of the flavonoid (Edwards et al, 1996). In this study, a slight 
modification of the method derived by Edwards et a l (1996) was adopted. The mixing 
rate chosen was 60 strokes min'  ^ which was considered to be gentle and not vigorous 
and was important to disperse the rutin/quercetin substrate throughout the fermentation 
media. In contrast with the other researchers who used 100-167 gL'  ^ of faecal inocula 
(Aura et a l, 2002; Rechner et a l, 2004), in this study a relatively large amount of 
inoculum, 320 gL % was used to provide a large initial bacterial population which 
ensured a better survival rate of the bacterial species (Edward et al, 1996). In addition 
to this, the effect of glucose as a carbon source on flavonoid degradation was also 
investigated.
The main limitations of the in vitro method is that it may not fiilly depict the in 
vivo conditions. The removal of faecal material may alter the bacterial composition and 
thus may not represent the actual colonic microflora, which in turn may not depict the 
catabolism process that is occurring in the colon. The accumulation and retention of the 
degradation products in the fermentation vessel makes collection, identification and 
quantification of the metabolites easier but is not representative of the events that occur 
in vivo. The actual concentration of a metabolite at any time interval is dependent on the 
combined rates of catabolism and absorption and this cannot be simulated in vitro. 
However, through this in vitro model, the elucidation of the pathway of the degradation 
process, types of breakdown products, rate of catabolism can be determined in a quick, 
reliable and an affordable manner (Edwards et al, 1996).
The most commonly applied ionization methods for the LC-MS are ESI and 
APCI. In this study, the ESI method was adopted for the detection of the flavonols, rutin
1 2 0
and quercetin while the APCI method was used for the detection of all the phenolic 
acids and taxifolin. ESI lacks sensitivity for the detection of phenolic acids as they are 
low molecular weight compounds and are not readily ionized by the ESI interface. The 
APCI interface, on the other hand has the ability to evaporate the samples by using 
temperatures up to 600°C after which they are ionised with a corona discharge. To 
optimize the detection of phenolic acids, the level of acid modifier in the mobile phase 
had to be reduced, as this suppresses ionization. However, at this level, the flavonols do 
not chromatograph, therefore two systems were used.
The results in this study were illustrated separately for each of the three faecal 
donors as they exhibited differences in both degree of catabolism and the resultant 
catabolite profile. Presumably this reflects variations in the gut micro flora of the three 
faecal donors.
4.5.2 Deglycoslyation of rutin
In the human colonic microflora, the presence of bacterial enzymes such as a- 
rhamnosidases and p-glucosidase, result in hydrolysis of rutin to release the rutinoside 
moiety fi-om quercetin (Aura et al, 2005). a-Rhamnosidases split off the rhamnose 
group fi'om the rutinosides leaving behind quercetin-3 -glucoside which is then acted 
upon by p-glucosidase which cleaves off the glucoside moiety. Alternatively, the 
rutinose sugar moiety may undergo a one step cleavage releasing quercetin.
In this study, although there was significant individual differences in the 
deglycoslation pattern of rutin, quercetin was detected in all the faecal samples. In 
contrast, similar studies carried out by other researchers have not always detected 
quercetin as indicated by Justeen et a l (2000). In other studies, the flavonol aglycone 
has appeared only transiently in the fermentation process (Aura et al, 2002). At the 
other extreme, more substantial quantities of quercetin were detected by Rechner et al 
(2004). The most plausible explanation for these discrepancies is that they are due to the 
use of different concentrations of the rutin substrate (Table 4.11). When lower doses of 
mtin are incubated with faecal preparations, quercetin tends not to accumulate. Highest 
levels of quercetin accumulation appear to be associated with the use of high doses of 
rutin. This indicates that deglycoslyation of mtin may occur more rapidly than 
catabolism of quercetin. This did not occur in the present study when glucose was added 
to the fermentation media. Although a high concentration of mtin was used in the
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present study, the addition of glucose enhanced not only the rate of deglycoslyation of 
rutin but also hastened the rate of quercetin catabolism such that quercetin only 
appeared transiently in the faecal samples. Without the addition of glucose, the 
degradation process appeared to be much slower and quercetin was found to accumulate 
in higher amounts in the case of donors B and C (Figure 4.5).
The addition of glucose in the fermentation media probably altered the 
microflora colony, encouraging the growth and the multiplication of bacterial strains 
that are responsible for both the deglycoslyation of rutin and the catabolism of the 
resultant quercetin. Other than having a direct effect via stimulation of the fermentation 
process, glucose could have also caused an alternation in the pH of the fermentation 
media, which in turn could have an effect on the ecosystem of the colonic microflora. 
The addition of glucose in the media was considered important in the present study as it 
was carried out to mimic in vivo conditions. The addition of glucose in vitro translates 
to dietary fibre intake in vivo where fermentation is stimulated by non-digested 
carbohydrate.
The degradation profile of rutin in faecal samples obtained from donor C was 
distinctly different from the other two donors; about 48% of the rutin still remained in 
the fermentation vessel 48 h after the onset of fermentation. A possible explanation 
could be that the bacteria responsible for the production of a-rhamnosidase were 
initially present at a low concentration which resulted in insufficient enzyme activity to 
completely degrade all the rutin added into the medium. Addition of glucose to the 
medium enhanced bacterial growth and seemed to overcome this effect as rutin 
disappeared more rapidly (Figure 4.5).
4.5.3 Radioactivity
The use of radioactive quercetin is advantageous in the identification the 
breakdown products and is particularly useful in the in vitro conditions as used in the 
current study. However, the correct positioning of the radiolabelled conpound can be 
crucial in trying to optimize the identification of breakdown products. In this study, the 
carbon was radiolabelled at the C4 position and the only catabolites that retained 
radioactivity were the oxidised forms of quercetin and taxifolin. The rest of the 
breakdown products, which either originated from ring A or C of the catechol structure 
lost their radioactivity due to the pattern of ring cleavage by the colonic microflora
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(Figure 4.14). Although the C4 position was not an ideal position for radiolabelling, 
position 2 would be better according to the ring cleavage pattern, but it did reveal the 
following:
• Instability of quercetin in the fermentation media -  quercetin was found to be
oxidised into various forms which the label helped detected and facilitate
MS  ^identification.
• The pattern of ring fission as suggested by earlier investigations can be 
confirmed, as explained below.
According to Justesen and Arrigoni (2001) and Rechner et al., 2004, the possible 
cleavage positions are
• between C2-ring oxygen and C3-C4 (blue dotted)
• between C2-ring oxygen and the C4 (red dotted)
OH
OH
OH
OH
Figure 4.14 [4-''^C]quercetin and possible types of ring fission by colonic 
catabolism. Adapted from Justesen et al 2001
If the carbon is labelled at the C4 position, during the degradation process, both types 
ring fission will result in the loss of radioactivity as observed in this study.
4.5.4 Intermediate products of the degradation of quercetin
When [*"^C]quercetin was used as a substrate, the main intermediate 
radio label led product detected was taxifolin (Figure 4.8). They appeared in highest 
amounts in faecal sample of donor B when incubated with glucose but were observed 
only transiently in all the other faecal samples (Table 4.4, Figure 4.9). Phloroglucinol,
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another intermediate was only detected in trace amounts in faecal samples of donor B 
and C, suggesting that both these intermediates were either produced by minor 
pathways or catabolised to other compounds very rapidly and therefore could not be 
detected within the 2 hour interval of sampling. Similar results have been obtained in 
other studies where phloroglucinol was detected only transiently in in vitro fermented 
human faecal samples (Schneider et a l, 1999) and also in pig caecum (Labib et a l, 
2004). Griffiths and Smith (1972) could not detect the presence of this metabolite in 
faecal samples and proposed that it may be rapidly metabolized to acetate and butyrate, 
which may correspond to the unidentified radioactive compounds detected in the current 
study (Figure 4.11). The low levels of taxifolin and phloroglucinol in in vitro fermented 
human faecal samples seemingly prevented their detection by Aura et al (2002); 
Rechner et al (2004); Justesen et al (2000) and Justesen & Arragoni (2001).
In the present study, three isomers of taxifolin were detected, all of which 
fragmented when analysed by HPLC-MS^, yielding identical MS  ^ spectra (Table 4.3). 
The first isomer, which had a retention time of 28.2 min is most probably alphitonin as 
suggested by Schoefer et al (2003) and Braune et al (2001) while the second isomer 
was identified as taxifolin. The third isomer, which has a slightly longer retention time 
could not be positively identified. Only taxifolin and the third isomer retained "^*C-label 
while no radioactivity was detected with alphitonin. Alphitonin could have lost its ^^ *0 at 
the 4 position during the ring opening and recyclization involved in its formation. 
Experiments were also carried out by other researchers to show that taxifolin is the 
initial product of quercetin degradation. In separate experiments, taxifolin was shown to 
be transformed to 3,4-dihydroxyphenylacetic acid by the human faecal bacteria 
Clostridium orbiscindens (Schoefer et al, 2003) and Eubacterium ramulus (Braune et 
al, 2001). In addition, alphitonin was also identified as an intermediate of the 
conversion of taxifolin to 3,4-dihydroxyphenylacetic acid (Braune et al, 2001).
4.5.5 Ring fission products
Five ring fission catabolites were identified in this study, namely; 3,4- 
dihydroxyphenylacetic acid, 3-hydroxyphenylacetic acid, 3,4-dihydroxybenzoic acid, 4- 
hydroxybenzoic acid and 3-(3-hydroxyphenyl)propionic acid. The composition of the 
phenolic acids present in the faecal samples of the three donors were found to be 
dependent on two main factors; the individual microflora profiles and the presence of 
glucose.
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The ring fission products obtained as a result of fermentation of quercetin were 
found to differ considerably in the faecal samples of donor C compared to those of the 
other two donors. This is probably due to differences in the profiles of the microflora in 
the individual faecal samples. In the samples of donor A & B, most of the quercetin 
(>60%) was converted to 3,4-dihydroxyphenyacetic acid which was subsequently 
degraded into 3-hydroxyphenylacetic acid. Only small amounts of 3,4-
dihydroxybenzoic acid, 4-hydroxybenzoic acid and 3-(3-hydroxyphenyl)propionic acid 
was detected here. However, in the faecal samples of donor C, the main ring fission 
product was 3,4-dihydroxybenzoic acid which was further degraded to 4- 
hydroxybenzoic acid. 3,4-Dihydroxyphenyacetic acid and its the subsequent 
degradation product, 3-hydroxyphenylacetic acid, were not detected. However, with the 
addition of glucose, the profile of the breakdown products were altered as both 3,4- 
dihydroxyphenyacetic acid and 3-hydroxyphenylacetic acid accumulated in the faecal 
samples of donor C. Glucose could have altered the composition of the microbial flora 
where it enhanced the growth and the multiplication of the bacterial strains responsible 
for the degradation of quercetin to 3,4-dihydroxyphenyacetic acid.
All other in vitro fermentation studies with human faecal samples were able to 
detect the major ring fission products identified in the current study but in most of the 
cases the percentage conversion of rutin to its catabolites after degradation was very low 
as indicated in Table 4.11. It was postulated that the remainder of the metabolite was 
either converted to other metabolites, which were below the limit of detection or were 
bound to faecal material and were thus not extractable by solvents (Aura et a l, 2002), 
converted to gaseous fermentation products (Walle et al, 2001) or converted to smaller 
molecular weight compounds such as butyrate and acetate (Schnieder et a l, 1999). The 
results of the current study give a more detailed picture of the mechanism of 
degradation of rutin/quercetin by colonic microflora. The loss of about 40 % of the 
radioactivity implies that the cleavage of the C ring could have resulted in the formation 
of the C-ring derived carbon dioxide while the 60 % retention of radioactivity 
could be due to the formation of low molecular weight compounds such as butyrate and 
acetate. Phloroglucinol, a phenolic fragment of the A-ring of quercetin was detected 
only transiently. B-ring cleavage results in the production of phenolic acids and in the 
present study, the main product to accumulate was 3,4-dihydroxyphenyacetic acid. In 
the presence of glucose there was 60-97% conversion of quercetin to 3,4-
125
dihydroxyphenyacetic in the faecal samples. This is in agreement with the report of 
Braune et ûf/.(2001), where the human faecal bacteria Eubacterium ramulus, brought 
about an 80% conversion of quercetin to 3,4-dihydroxyphenyacetic acid. In the current 
study, in addition to 3,4-dihydroxyphenyacetic acid, significant amounts of 3,4- 
dihydroxybenzoic acid and 4-hydroxybenzoic acid was also detected especially from 
the faecal samples of donor C suggesting that these compounds can also be important 
biodégradation products of the B ring of quercetin based compounds.
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4.5.6. Antioxidant activity
Catabolites of rutin/quercetin were analysed for antioxidant activity using the 
FRAP assay. Quercetin and 3,4-dihydroxyphenylacetic acid exhibited the highest 
antioxidant activity followed by rutin, 3,4-dihydroxybenzoic acid and taxifolin. No 
antioxidant activity was observed for phloroglucinol, 3-hydroxyphenylacetic acid and 3- 
(3-hydroxyphenyl)propionic acid. This indicates that the antioxidant activity of these 
compounds is correlated to their structure, specifically the presence of the 3', 4 -  
dihydroxy structure in a catechol group. Compounds without a 3'-hydroxyl group such 
as phloroglucinol, 3-hydroxyphenylacetic acid and 3-(3-hydroxyphenyl)propionic acid, 
have considerably reduced scavenging capacity. Flavonoids with both a 3-hydroxyl 
group and a 3',4'-dihydroxy structure are reported to be 10-fold more potent that 
ebselen (Figure 4.15), a known reactive nitrogen species (RNS) scavenger, against 
peroxynitrite (Heim et al, 2002). In addition to the 3-hydroxy and 3',4'-dihydroxy 
structure, the 2,3 double bond in conjugation with a 4-oxo function, and the presence of 
both 5- and 7-hydroxyl groups also contribute significantly to the antioxidant capacity 
of the molecule (Russo et al, 2000).
Figure 4.15. Ebselen (2-phenyl-l,2-benzisoselenazol-3(2H)) is a seleno-organic 
compound with high radical scavenging capacity (Heim et al, 2002).
Quercetin added at 55 pmoles to the 50 mL (1 mM/L) faecal slurry gave a 
FRAP value of 2.2 mM Fe^  ^but within just 15 min, the FRAP reading was reduced to 
an average of 0.5 mM Fe^ "^  due to the fact that quercetin was rapidly oxidised into 
quinine-type structures which are pro-oxidants. This is in accordance with the report of 
Babbs (1990) who demonstrated that dilution of faeces could produce radicals, as a 
result of bacterial oxidative metabolism and the catalytic action of available Fe^ .^ 
However, this was soon counteracted by the production of phenolic acids. With the 
degradation of quercetin and the production of colonic metabolites, the FRAP value
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increased to about 3.3 mM Fe^ ,^ suggesting that the colonic catabolites produced had 
significant antioxidant power (Table 4.7). The total colonic metabolites formed were 
found to be highly significantly correlated with the total antioxidant capacity of the 
fermented faecal samples with exception to that derived firom donor C in the absence of 
glucose. 3,4-Dihydroxyphenylacetic acid, the major catabolite formed was the main 
contributor to the total antioxidant activity of the faecal samples with its levels being 
strongly correlated with the total antioxidant activity of the faecal samples. The only 
exception to this was faecal samples derived firom donor C where the absence of the
3,4-dihydroxyphenylacetic acid accounted for low FRAP values during the first 24 h of 
the fermentation process after which a higher FRAP reading corresponded to the 
appearance of 3,4-dihydroxybenzoic acid (Table 4.9).
The intestine is unique among all fully differentiated organs as it sits at the 
interface between the organism and its luminal environment, it represents a critical 
defense barrier against luminal toxic agents. Thus, in addition to being exposed to 
luminal nutrients, the intestinal mucosa is constantly challenged by diet-derived 
oxidants, mutagens, and carcinogens as well as by endogenously generated ROS (Ames, 
1983). In addition to this, the intestinal epithelial cells are amongst the most highly 
proliferative tissues of the human body and there is a continuous need to preserve 
cellular integrity and tissue homeostasis through maintaining a reduced redox state. An 
oxidative shift in this potential can elicit growth arrest and cell transition to a 
differentiated or apoptotic phenotype. Tissue oxidative stress, which results from a 
disturbance in the cellular prooxidant-antioxidant balance in favour of prooxidants, is an 
important contributor to the genesis of gut pathologies such as inflammation and cancer 
(Aw, 2003). A change in the redox status of mucosal glutathione has been shown to be 
associated with inflammation and disease activity in ulcerative colitis in humans 
(Holmes et al, 1998). In a more recent study, the differences in the redox potential in 
the colon and the small intestine was used to explain the variation in cancer occurrences 
at these two sites (Sanders et al, 2004). Basal reactive oxygen species and antioxidant 
enzymes activity in the colon were found to be higher than the small intestine, which in 
tum was suggested to create an environment for more extensive oxidative damage. In 
addition to this Sanders et al, (2004) also suggested that the colon responds to oxidative 
stress less effectively than the small intestine and, thus, is more prone to cancer 
occurrences. This may relate to the fact that the lumen of the colon is normally highly
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reducing and anaerobic (-400mV) and that oxygen may be present only at the mucosal 
surface. The facultative bacteria mop up available oxygen and antioxidants molecules 
may have an important role in maintaining a healthy gut microflora and mucosa.
The feeding studies outlined in Chapter 3 indicate that rutin is not absorbed 
extensively in the small intestine and that sizable amounts pass into the colon. Rutin and 
its colonic catabolites, 3,4-dihydroxyphenylacetic acid and 3,4-dihydroxybenzoic acid 
may become concentrated in the colorectal lumen and, as such, would be well placed to 
interact with the mucosal cells of the distal gut. These compounds, therefore, may exert 
their antioxidant capacity to scavenge free radical cations in the colonic lumen thereby 
assisting in the maintainence of a reduced redox state especially in the mucosal cells. 
Other researchers such as Garsetti et ai, (2000), have shown that antioxidant levels in 
faeces can be much greater than in plasma (faeces 26.6 ± 10.5 (SD) and plasma 1.46 ± 
0.14 mM Trolox). In addition, the total amount of antioxidants excreted over 24 h was 
found to be significantly and positively correlated to the consumption of beverages rich 
in phenols (Garsetti et al., 2000). In addition to the antioxidant activity, the presence of 
rutin and quercetin in the gut suggests these compounds may also exert other protective 
effects. Both quercetin and rutin has also been suggested to be a potent inhibitors of 
inflammatory enzymes such as epidermal cyclooxygenase-2 and lipo-oxygenase (Lipkin 
et al., 1999; Kwan et al., 2005). In addition, quercetin has a broad range of other 
activities as it can inhibit Na+K+-ATPase, and various tyrosine kinases, all of which are 
elevated during carcinogen-induced colon neoplasias (Lipkin et al., 1999).
4.5.7 Proposed scheme of the colonic degradation of rutin and conclusion
As schematized in Figure 4.16, rutin is first deglycoslyated to produce 
quercetin by the P-glycosidase activity of the gut microflora, releasing quercetin for 
subsequent degradation (Aura et al, 2002 and Rechner et al, 2004). Quercetin being 
unstable in the faecal slurry, is oxidised to produce quinones and subsequently get 
attached to water molecules (Dangles et al, 1999). These ‘oxidised’ quercetin 
molecules act as the substrates for gut micro flora which cleave the flavonoid structure at 
the C ring as shown in Figure 4.14, resulting in the production of 3,4-dihydroxybenzoic 
acid and 3,4-dihydroxyphenylacetic acid from the B ring. In an alternative route, 
quercetin may undergo reduction of the double bond in the 2-3-position yielding 
taxifolin. This is most probably followed by a ring opening recyclization mechanism, 
forming an isomer of taxifolin, and a subsequent ring contraction to produce alphitonin
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(Braune et al., 2001). Taxifolin, and their isomers are then transformed to either of 3,4- 
dihydroxyphenylacetic acid or/and 3 (3-hydroxyphenyl)propionoc acid via fissions of 
the C-ring. Further dehydroxylation of 3,4-dihydroxyphenylacetic acid and 3,4- 
dihydroxybenzoic acid by dehydroxylases produced by the colonic microflora result in 
the formation of 3-hydroxyphenylacetic acid and 4-dihydroxybenzoic acid respectively. 
Phloroglucinol, on the other hand is derived from ring A of the flavonol structure.
The results presented in this study also indicate that modification of the 
structural properties of dietary polyphenols, rutin and quercetin by the colonic 
microflora can have a substantial effect on their subsequent biological activity in vivo. 
The structural modifications derived fi'om the C-ring cleavage may either increase or 
decrease the cation radical scavenging capacity depending on the retention of 3',4'- 
hydroxyl groups. Of the catabolites formed, only 3,4-dihydroxyphenylacetic acid and
3,4 dihydroxybenzoic acid retained this catechol structure and thus exhibit antioxidant 
activities. 3,4-Dihydroxyphenylacetic acid which accumulated in large amounts in the 
faecal samples was found to possess significant antioxidant activity and it may play a 
crucial role in the overall contribution of the antioxidant capacity of the colonic lumen.
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Chapter 5: Summary and Conclusion on Part I
The research presented in Chapters 3 & 4 concerns a series of studies 
undertaken in an effort to determine the absorption, metabolism and bioavailability of 
rutin. The aim of this chapter is to discuss and draw together the main conclusions 
arising from these two chapters, to compare the results obtained with that of an earlier 
feeding study carried out with quercetin glucoside-rich onions and finally to summarise 
the prospects for future research.
5.1 Unveiling the fate of rutin in humans
The underlying objective in Chapter 3 was to investigate the metabolism and 
absorption of rutin in vivo. As discussed in Chapter 3, rutin was found to be extensively 
metabolised and made bioavailable to humans following consumption of tomato juice 
spiked with 164 pmoles of rutin. The targets of this study were met by the identification 
of a huge array of phase II metabolites and catabolites of rutin. Isorhamnetin-3- 
glucuronide and quercetin-3-glucuronide are absorbed into the bloodstream from the 
large intestine following deglycosylation of rutin molecule presumably by glycosidase 
activity of the colonic microflora and/or the wall of the large intestine. Further 
metabolism of isorhamnetin-3-glucuronide and quercetin-3-glucuronide, probably in the 
liver and kidney, results in the formation of quercetin glucoside glucuronides, a 
quercetin diglucuronide, a methylquercetin diglucuronide, quercetin-4-glucuronide and 
quercetin-3-glucuronide, which although not detected in the circulatory system were 
excreted in the urine after the consumption of rutin. Indirect evidence of metabolism 
occurring in the large intestine, rather than the small intestine was the delayed 
appearance of rutin metabolites in plasma 4-5 h after intake and more direct proof was 
provided by ileostomy volunteers where 92% of the rutin was found to pass through the 
small intestine and emerged without modification in the ileal fluid.
Results from Chapter 3 also suggested that in the large intestine, the flux of the 
rutin metabolic pathway is directed towards catabolism rather than the production of 
conjugated quercetin metabolites. Following deglycosylation, only a small percentage 
of quercetin (0.01-0.06% of rutin intake) appears to be absorbed and proceeds to the 
production of phase II metabolites. A substantially larger percentage of quercetin 
produced is presumably rapidly acted upon by the colonic microflora leading to ring 
fission and production of phenolic catabolites. This is substantiated by a significant
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increase in the excretion of the catabolites in the urine of healthy volunteers post­
consumption of rutin. However, when considered with the data obtained from the 
ileostomy model, only three of the six phenolic acids excreted in the urine of healthy 
volunteers were postulated to be derived from the breakdown of rutin, namely, 3- 
hydroxyphenylacetic acid, 3,4-dihydroxyphenylacetic acid and 4-hydroxy-3- 
methoxyphenylacetic acid.
5.2 Role of colonic microflora in the catabolism of rutin
Further evidence of the role of colonic microflora in the breakdown of rutin is 
provided in Chapter 4. The accumulation of quercetin during in vitro fermentation 
provides direct proof that the initial step in the breakdown of rutin is deglycosylation. 
In Chapter 3, large individual variations were observed particularly in the production of 
the phase II metabolites and it was hypothesised to be due to the differences in the 
composition of colonic microflora. This was also reflected in the data presented in 
Chapter 4 where variations in deglycosylation profiles of rutin in the fermented faecal 
samples of the three individuals were observed, presumably because differences in 
microflora composition, resulted in quercetin accumulating in varying quantities.
The metabolic/catabolic pathways that dictate the fate of rutin in the colon is 
very much dependent on two main factors as revealed in the results of Chapter 4. The 
first is the composition of the colonic microflora. Inter-individual composition of the 
bacterial micro flora can either direct the catabolic pathway towards the production of 
hydroxyphenylacetic acid derivatives or towards the production of hydroxybenzoic 
acids. The composition of the colonic microflora of donor C directed the catabolism of 
quercetin towards the production of hydroxybenzoic acid while that of donors A and B, 
was towards the production of hydroxyphenylacetic acid derivatives. The latter pathway 
seemed to be a more common route in vivo as indicated by the results in Chapter 3 
where all the six volunteers excreted substantial levels of 3,4-dihydroxyphenyacetic 
acid, 3-hydroxyphenylacetic and 4-hydroxy-3 -methoxyphenylacetic acid but not 
hydroxybenzoic acids. The second factor that plays an important role in influencing the 
rutin catabolism pathway is the presence of glucose. The results in Chapter 4 imply that 
glucose stimulated the growth and the production of bacterial micro flora responsible for 
both the deglycolysation of rutin and catabolism of quercetin, which was indicated by a 
more rapid accumulation of quercetin and subsequently phenolic acids in the 
fermentation medium. The presence of glucose appeared to have a more pronounced
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effect on the bacterial strains responsible for the production of hydroxyphenylacetic 
acid derivatives rather than hydroxybenzoic acids. The pathway which was originally 
directed towards hydroxybenzoic acid in volunteer C was redirected towards the 
production of hydroxyphenyacetic acid derivatives in the presence of glucose. When 
this is translated to in vivo conditions, the food matrix associated with the production of 
glucose in the large intestine could have significant effects on the fate of rutin as it 
preferentially directs the catabolism towards the production of hydroxyphenylacetic 
acid deivatives. The presence of glucose in the large intestine, is the most probable 
cause as to why no hydroxybenzoic acids were excreted in the urine of all six volunteers 
after ingestion of rutin as reported in Chapter 3.
The in vitro study in Chapter 4 indicated a very high percentage of quercetin 
(60-97%) was converted to 3,4-dihydroxyphenylacetic acid. This was, however not 
reflected in the in vivo study where only 23 % of the ingested rutin was excreted as 
hydroxyphenylacetic acid derivatives. It is, therefore, feasible to assume that in vivo, a 
high percentage of rutin may have been catabolised to 3,4-dihydroxyphenylacetic acid 
in the large intestine but depending on a number of internal factors (such as mechanism 
of transport, intestinal transitional time, blood flow etc) which dictates bioavailability, 
only a proportion of it is absorbed and transported across the colonic lumen into the 
circulatory system. A clearer relationship between rutin catabolism and rutin uptake in 
the large intestinal may be resolved if the levels of phenolic acids in the plasma were 
analysed. As a result of time limitations, this was, however, not carried out in the 
present study because the HPLC-MS-APCI technique for the analysis of phenolic acids 
was only developed and put into routine use towards the end of this study. Further 
metabolism post absorption of phenolic acid in the liver may also alter the chemical 
structure either through méthylation as indicated by the presence of 4-hydroxy-3- 
methoxyphenylacetic acid in the urine of the six volunteers (Chapter 3). This phenolic 
acid was not detected in the in vitro fermentation study. In addition, further structural 
breakdown may occur in vivo to form other smaller molecular weight conpounds such 
as acetates and butyrates.
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5.3 Comparison of metabolism and bioavailability of rutin with 
that of quercetin glucoside.
The level of rutin used in Chapter 3 was chosen so that the p.moles ingested 
were similar to the intake of quercetin-4’-glucoside and quercetin-3,4’-diglucoside in an 
earlier study carried out by Mullen et al. (2005) when onions were ingested by healthy 
human volunteers. This enables direct comparisons to be made between the fate of the 
quercetin glucosides and rutin (quercetin-3-glucosylrhamnoside) in humans. Distinct 
differences in the plasma pharmacokinetic profiles of subjects after ingestion of onion 
and rutin were observed as indicated in Table 5.1. The longer Tmax about 5 h observed 
after ingestion of rutin implies that quercetin glucosides fi'om onions were absorbed in 
the small intestine while the absorption of rutin takes place in the more distal part of the 
GI, that is, the large intestine. The Cmax value of quercetin-3-glucuronide and 
isorhamnetin-3-glucuronide were about 30-fold higher when onions were consumed 
compared to the values obtained in the rutin study. The higher Cmax values indicate that 
absorption is much more effective in the small intestine compared than the large 
intestine. Two factors may complicate and reduce absorption of quercetin in the large 
intestine. Deglycosylation of quercetin glucoside occurs in the presence of P- 
glucosidase, which is present in relatively high amounts in the GI (Graefe et al, 2001). 
Rutin, on the other hand is dependent on two enzymes, p-glucosidase and a- 
rhamnosidases to release the quercetin moiety. a-Rhamnosidases, in contrast to p- 
glucosidase is not produced by the human body but by the colonic microflora and is 
produced in relatively small amounts (Graefe et al, 2001). In addition to this, the fact 
that the released quercetin can be catabolised by the colonic microflora restricts the 
amount of quercetin available for absorption which results in a lower Cmax value (Table 
5.1).
In addition to the low level of quercetin absorption in volunteers fed with 
rutin, reduced number of the phase II metabolites were produced coitq)ared to the 
metabolites obtained when onions were consumed (Table 5.2). In contrast to the 
seven metabolites detected in plasma of volunteers fed with onions, only two were 
found to accumulate in detectable quantities in plasma following rutin ingestion. 
Similarly, out of 18 metabolites excreted in urine post onion ingestion, only nine were 
detected in urine collected after rutin supplement. When rutin derived metabolites 
were compared as percentage of the level obtained fi'om onion, a range of 1.4 -  30%
136
was obtained (Table 5.2) which clearly demonstrates that phase II metabolism of 
quercetin is much more extensive when quercetin is ingested as quercetin glucosides 
as opposed to rutin. The higher recoveries of quercetin-3-glucuronide (30%) and 
quercetin-4-glucuronide in the rutin-fed subjects could be due to skewed data 
resulting from relatively high excretion of these metabolites in the urine of volunteer 
one as indicated in Chapter 3 (Table 3.6).
When comparing the metabolite profiles in Table 5.2, it is quite clear that 
the inter-individual variation, reflected in the standard errors, is much higher in 
subjects fed with rutin than it is after onion supplementation. This difference appears 
to be dependent of rutin metabolism, specifically the deglycosylation step, on the 
colonic microflora that differs considerably between individuals. Another striking 
difference that can be seen is the lack of quercetin sulphate conjugates in plasma and 
urine of rutin fed subjects. Quercetin-3-sulfate is the major plasma metabolite in 
onion fed subjects. Its appearance in the plasma 0.75 h after ingestion of onions 
suggest that deglycosylation and sulphation occurs in small intestine. Absence of 
sulphated quercetin metabolites in rutin fed volunteers could be due to a lack of 
flavonol-specific sulphotransferase in the colonic lumen as suggested by Harris et al 
(2000) and Liu and Hu (2002). In addition to this, the results obtained with the onion 
and rutin feeds imply that the site of quercetin sulphation is the enterocyte of the 
small intestine and the liver, contrary to the proposal of O’Leary et ah (2003), does 
not play an important role.
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Table 5.1. Pharmacokinetic parameters of quercetin metabolites in the plasma of human 
volunteers after the consunption of onions and rutin supplemented tomato juice
Source Metabolite Tm
Onions
Tomato juice spiked 
with rutin
Quercetin-3'-sulfate 665 ±82 0.75 ±0.12 1.7
Quercetin-3-glucuronide 351 ±27 0.60 ±0.10 2.3
Isorhanmetin-3-glucuronide 112 ±18 0.60 ±0.10 5.3
Quercetin diglucuronide 62 ±12 0.80 ±0.12 1.8
Quercetin glucuronide sulfate 123 ±26 2.5 ± 0.22 4.5
Quercetin-3-glucuronide 12 ± 2 4.7 ±0.3 5.7
Isorhamnetin-3-glucuronide 4.3:1 1.5 5.4 ±0.2 6.9
Cmax -  maximum concentration in plasma expressed in nM. Tmax -  time to reach Cmax expressed in h. Tm 
-  the elimination half-life of metabolites in h. Data presented as mean values ± standard error (n = 6). 
Pharmacokinetic data on onion metabolites from Mullen et al. (2005).
Table 5.2. Quercetin metabolites detected in plasma and urine after the 
consumption of fi'ied onions and rutin supplemented tomato juice by 
six human volunteers.
Compound
plasma from 
onion fed 
subjects
plasma from rutin fed 
subjects
urine from 
onion fed 
subjects
urine from rutin 
fed subjects
Quercetin diglucuronide n.d. n.d. trace n.d.
Methylquercetin diglucuronide n.d. n.d. 1003 ±156 25 ±21 (2.5%)
Quercetin glucoside glucuronide n.d. n.d. 163 ±23 39 ± 36 (24%)
Methylquercetin diglucuronide n.d. n.d. 426 ± 99 n.d.
Quercetin diglucuronide n.d. n.d. trace nd.
Quercetin glucoside glucuronide n.d. n.d. trace 22 ±21
Quercetin glucoside glucuronide n.d. n.d. trace 20 ±20
Quercetin diglucuronide 62±  12 n.d. 2223 ±417 32 ±28  (7.4%;
Quercetin-3 -glucuronide 351 ±27 \2 ± 2 (3 .4 % ) 912 ±149 270 ± 186 (30%)
Quercetin glucoside sulfate n.d. n.d. 393 ±60 n.d.
Quercetin glucuronide sulfate n.d. n.d. 1384 ±163 n.d.
Quercetin glucuronide sulfate 123 ±26 n.d. 1229 ±190 n.d.
Quercetin glucoside sulfate n.d. n.d. 821± 156 nd.
Isorhamnetin-3 -glucuronide 112±18 4.3 ±  1.5(3. 1789 ± 2 7 179 ±101 (10%)
Quercetin-4-glucuronide n.d. nd. trace 237 ±198
Quercetin-3 '-glucuronide trace n.d. 1845 ±193 220 ± 179 (72%;
Isorhamnetin-4'-glucuronide trace n.d. 700±11 n.d.
Quercetin-3 '-sulfate 665 ± 82 n.d. trace n.d.
Estimates of levels in plasma expressed as nM ± S.E. (n =6) at peak plasma concentration. Amounts in 
urine expressed as total amount excreted m nmoles ± S.E. over a 24 h period post-ingestion o f onions and 
rutin spiked tomato juice. Italicised figures in paraithesis represent rutin derived metabolites as 
percentage of the level obtained from quacetin glucosides in onions. Data on onion metabolites from 
Mullen et al. (2005).
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5.4 Health implications
Many of the biological actions of flavonoids have been attributed to their 
antioxidant properties through in vitro evaluation of aglycones or the glycosides that are 
present in food. However, recent studies have speculated that their classical hydrogen- 
donating antioxidant activity is unlikely to be the sole explanation for cellular effects of 
flavonoids (Williams et al, 2004). Flavonoids such as quercetin and rutin are 
extensively metabolised in vivo as indicated in Table 5.2, which will almost certainly 
result in a significant alteration in their redox potential. Further catabolism in the colon 
by the gut microflora to phenolic acids also adds on to their structural alterations. The 
in vivo results indicate that the phase II metabolites are present in very low amount and 
accounts for only 0.01-0.06% of rutin intake, which is probably too low to exert any 
biological effects. However, phenolic acids are present in more substantial amounts, as 
indicated by higher levels excreted in the urine, corresponding to 24% of rutin intake. 
These compounds may therefore be more bioavailable to the cells and tissues than the 
quercetin derivatives from which they originate and therefore, may have important 
physiological roles. In keeping with this possibility, 3,4-dihydroxyphenylacetic acid and 
4-hydroxyphenylacetic acid possesses more effective anti-platelet aggregation activity 
than their parent compounds, rutin and quercetin (Kim et a/., 1998). In a more recent 
study, 3,4-dihydroxyphenylacetic acid and 3,4-dihydroxybenzoic acid were found to 
exhibit anti-proliferative and apoptotic effects on T47D human breast cancer cell lines, 
indicating their potential protective role as anticancer agents (Kampa et a l, 2004).
The antioxidant and other protective effects of flavonols and phenolic acids 
could also occur before absorption, that is, within the gastrointestinal tract itself 
(Halliwell et al, 2005). Results in Chapter 4 indicated that rutin, quercetin and those 
phenolic acids that retained a 3',4-dihydroxyl structures, such as 3,4- 
dihydroxyphenylacetic acid and 3,4-dihydroxybenzoic acid, possess substantial 
antioxidant activity. Of these, quercetin and 3,4-dihydroxyphenylacetic are the strongest 
antioxidants. Substantial protective effects can be produced if these confounds are 
present in high amounts as indicated in the results from Chapter 4. The feeding studies 
outlined in Chapter 3 indicated that most of rutin pass into the large intestine 2-5 h after 
ingestion, implying that they were present in their natural intact form in the small 
intestines for the approximately 2 h during which they may have a favourable impact on 
the health of the small intestine before they enter the colon. A high proportion of the
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rutin was found to be catabolised to 3,4-dihydroxyphenylacetic acid, indicating that 3,4- 
dihydroxyphenylacetic acid is present in sizable amounts in the large intestines, prior to 
absorption and excretion in the urine, therefore, may play a crucial role in its 
contribution to the overall antioxidant capacity of the colonic lumen.
5.5 Conclusion
Figure 5.1 summarizes the possible metabolic fate of rutin in the human body 
after ingestion. It is clear that the GI, particularly the large intestine, plays a vital role in 
the metabolism and catabolism of rutin. Rutin passes into the large intestine, in 
substantial quantities and the first metabolic reaction begins with the deglycosylation 
step which involves p-glucosidase and a-rhamnosidases. On the release of the quercetin 
moiety, quercetin either can be absorbed directly into the colonic lumen or be subjected 
to further catabolism by the colonic microflora. On absorption into the lumen, 
glucuronidation and méthylation occur due to the presence of glucuronyltransferase 
(UGT) and methyltransferase (MT). This yields quercetin-3-glucuronide and 
isorhamnetin-3-glucuronide which then pass into the portal splanchnic vein into the 
liver. In the liver and possibly also other sites such as the kidneys, further metabolism of 
these two metabolites are believed to occur resulting in the production of a range of 
metabolites, including quercetin glucoside glucuronide, quercetin diglucuronide, 
methylquercetin diglucuronide, quercetin-4'-glucuronide and quercetin-3 -glucuronide. 
A large portion of the unabsorbed quercetin in the large intestine are catabolised, 
undergoing ring fission to produce 3,4-dihydroxyphenyacetic acid, 3- 
hydroxyphenylacetic and hydroxybenzoic acids. 3,4-Dihydroxyphenyacetic acid can 
either be methylated by the MT in the lumen of the colon or in the liver to produce 4- 
hydroxy-3-methoxyphenylacetic acid. Quercetin derived metabolites and catabolites 
which are not sequestered in cells and body tissues are excreted in the urine.
5.6 Future research
Improved knowledge of the consumption and bioavailability of dietary 
polyphenols is essential as many questions remain to be answered. Extending the work 
in this thesis on the identification and quantification of phenolic acids would provide 
valuable information on the extent of absorption and modification occurring in the large 
intestine following rutin consumption. Intravenous injection of metabolites compared to
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oral consumption of their parent compounds can also provide key answers on the extent 
of metabolism occurring in the gastrointestinal tract versus that in the liver and kidneys 
and the rate of turnover of these compounds in the circulatory system. Determination of 
the actual accumulation of rutin metabolites and catabolites in tissues may be just as 
more important, if not more so, than knowledge of their plasma concentrations. Data on 
this subject is very scarce, even in animals. Detailed information could be obtained by 
feeding [2-^ "^ C-]rutm to rats housed in metabolic cages. This methodology will enable 
valuable information to be generated by monitoring accumulation of all the metabolites 
and possible catabolites in the various organs and tissues following administration. By 
counting radioactivity in body tissues and fluids, using liquid scintillation counters, sites 
of accumulation of metabolites and catabolites can be readily detected. The identity of 
the individual compounds at each site can then be determined by HPLC with an on-line 
radioactivity detection coupled with MS .^ Preliminary studies in which [2-^ "^ C] 
quercetin-4-glucoside was fed to rats have demonstrated the value of this approach 
(Mullen et al, 2002 and Graefe Qt al, 2005). This approach is certainly more valuable 
than a recent study in which high doses of quercetin were fed to rats for 11 weeks and 
pigs for 3 days after which tissues and fluids were extracted and hydrolysed to release 
aglycones prior to the analysis by HPLC (de Boer et al, 2005).
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Chapter 6: Engineering Genistein Synthesis in Arabidopsis 
and Tomato
6.1 Introduction
In the past decade there has been a major shift towards food-for-health 
especially with the identification of bioactive ingredients in food. Since then, numerous 
investigations were carried out linking the bioactive compound with the prevention 
and/or treatment of degenerative diseases such as cancer, cardiovascular diseases and 
diabetes (Premier, 2002). Until recently, research has concentrated on producing new 
varieties that have a longer shelf life, higher production, better cosmetic value and 
higher resistance to pest and disease. However, with the advent of GM technologies 
together with the new focus on bioactive ingredients in food, there is pressure to 
reconsider plants for economic purposes. In line with this, molecular biologists, 
biochemists, botanists and medical researchers are linking in with plant breeding 
programmes to develop new varieties of fruit and vegetables that are tailor-made to 
produce higher levels of health-related bioactive confounds (Verrips et al., 2001). 
Research activities in producing ftinctional agrifood is becoming well established as 
new phytochemical-enhanced products such as broccoli, berries and tomato are being 
evaluated for commercial exploitation (Premier, 2002).
With respect to bioactive confounds, flavonoids especially the sub-class 
isofiavones are important since there is evidence that they protect against oxidative 
stress, coronary heart disease and other age-related diseases (Kuo, 1997, Yang et al., 
2001 and Ross and Kasum, 2002). In addition, isoflavone, as a phytoestrogen, has also 
been associated with reduced menopausal symptoms and reduced risk of some 
hormone-related cancers (Davis et al., 1999; Messina, 1999; Watanabe et al., 2002). 
The isoflavone genistein has been the subject of over 3,600 published studies in the last 
ten years. Since isofiavones are found primarily in leguminous species, there is an 
interest to direct synthesis of beneficial isofiavones through genetic manipulations in 
plants that do not synthesize them (Winkel-Shirley, 2001).
Many of the structural and some of the regulatory genes of the fiavonoid 
pathway have been cloned from several model plants, including maize. Antirrhinum, 
tobacco. Petunia and Arabidopsis (Holton and Comisch, 1995) and have been expressed 
in genetically modified model plants and micro-organisms (Dixon and Steele, 1999, 
Forkmann and Martens, 2001, Winkel-Shirley, 2001 and Hwang et al., 2003). The
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knowledge and availability of these genes provides the tools to genetically up-regulate 
the overall fiavonoid biosynthesis or to engineer new pathways towards production of 
elite fiavonoid species within crop plants.
In this study, we attempted to direct isoflavonoid synthesis towards branches 
that are normally not present in the host plant by introducing a foreign gene, isoflavone 
synthase (IFS) that branches off from the existing pathway towards the synthesis of the 
bioactive isoflavone, genistein. To date, some attempts have been made to produce 
isoflavonoids in non-legume plants such as Arabidopsis, tobacco and maize cell lines by 
over-expressing the soybean IFS gene (Liu et al., 2002, Yu et al., 2000). In the current 
study, a different crop model, tomato, was used. Tomato is an excellent candidate as it 
is not only one of the most-consumed foods but is also a reservoir of diverse antioxidant 
molecules, such as ascorbic acid, vitamin E, carotenoids and phenolic acids (Gahler et 
al., 2003). In addition to this, the skin from the tomato fruit contains high levels of the 
flavonol, rutin, which also possesses potential health benefits and is the subject of 
research in Chapter 3 & 4.
Therefore, the main aim of this study was to engineer genistein synthesis into 
tomato, with the aim of ultimately producing a crop with enhanced bioactive 
components. In order to develop methodologies and better understand the requirements 
and regulation of genistein production in the fiavonoid biosynthetic pathway, pilot 
studies were first conducted on Arabidopsis. Arabidopsis was chosen as it has a simpler 
genome that has been completely characterised and sequenced and it is therefore an 
easier model system for the introduction of genes than tomato.
144
6.2 Experimental approach
Isoflavonoids are synthesized from a branch of the phenylpropanoid pathway. 
IFS is the first committed enzyme in the isoflavone pathway and converts the flavanone 
naringenin to genistein or liquiritigenin to daidzein (illustrated by the green dotted lines 
in Figure 1.12). However, in non-leguminous plants, isofiavones are not among the 
complex array of secondary metabolites synthesized by the phenylpropanoid pathway 
due to the absence of IFS. Therefore to synthesize isoflavonoids in non-legume plants 
that lack the pathway, the introduction of IFS is crucial as it is the key entry point for 
isoflavonoid biosynthesis. With the recent identification of the IFS gene (Akashi et al., 
1999; Steele et al, 1999; Jung et a l, 2000), we were able to clone the IFS gene using 
RT-PCR from soybean and direct it in Arabidopsis and tomato
6.3 Materials and Method
6.3.1 Materials
6.3.1.1 Plant seed stocks
Wild-type Arabidopsis thaliana cv Columbia (Col 0) seeds were originally 
obtained from Nottingham Arabidopsis Stock Centre (ie. NASC, Nottingham, UK) 
(http://nasc.nott.ac.ukV Glycine max cv Envy (soybean) and Lycopersicum esculentum 
cv. Micro Tom (tomato) seeds were obtained from Nicky’s nursery (http://www.nickys- 
nurserv. co. uk/seeds .^
6.3.1.2 Chemicals
The chemicals used in this study were obtained from Sigma (Poole, Dorset) 
and Fisher Scientific (Loughborough, Leicestershire). Specialist chemicals and reagents 
were supplied as indicated.
6.3.1.3 DNA modifying enzymes
DNA restriction, synthesis and modification enzymes were purchased from 
Promega (Southampton, U.K.), New England Biolabs (Hitchin, Hertfordshire), and 
Roche Diagnostics (Mannheim, Germany) or as indicated. Enzymes were used in 
accordance with the manufacturer’s instructions.
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6.3.1.4 Plasmids and bacterial strains
The plasmids used in this study are
• 35S-pGlasglow. p-Glaslgow was derived from pJO530 binary vector [derivative 
of pBIN19 (D.Becker, NAR 18 203 (1991)], with the insertion of Luciferase 
and the Basta resistance gene (BAR) (A. Aakkha and J. Milner- unpublished) 
(Figure 6.8)
• pER8 plasmid (Zuo et al., 2000), genebank no. AF309825, an estradiol induced 
plasmid (Figure 6.9) was obtained from F. Auseabel, Harvard University.
• pCHF3 plasmid with a CaMV 35S full promoter and the RBCS terminator from 
pea (Figure 6.11).
All these plasmids were modified with the insertion of the c-DNA and then transformed
into Agrobacterium tumefaciens strain GV3101 (Koncz and Schell, 1986). The
Escherichia coli strain used was DH5a.
6.3.1.5 Antibiotics/pesticide
For bacterial or plant selection, the following antibiotics/pesticide were used:
Plasmid Bacteria Plant
pER-8 Spectinomycin Hygromycin
p-Glasglow Kanamycin Basta
pCHF3 Spectinomycin Kanamycin
The selection marker for A. tumefaciens strain GV3101 was gentamycin. Kanamycin 
and spectinomycin stocks were at 50 mg mL'* and used at a final concentration of 50 pg 
mL'\ Hygromycin and gentamycin stocks were at 25 mg mL‘^  and used at a final 
concentration of 25 pg mL'\ In cultured media, Basta (ammonium glufiisinate) stock 
was 10 mg mL'  ^ and used at a final concentration of 10 pg mL'\ To soil grown plants, 
basta was sprayed at 100 pg mL'  ^ in 0.005% Silvet L-77.
6.3.2 General Laboratory Procedures
6.3.2.1 pH measurement
The pH of solutions was measured using a Jenway 3320 pH meter and glass 
electrode (Jenway, Felsted, Essex).
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6.3.2.2 Autoclave sterilizatiou
Equipment and solutions were sterilized at 15 psi for approximately 30 min 
using benchtop (eg. Prestige Medical, Model 220140) or free-standing (eg. Laboratory 
Thermal Equipment Autoclave 225E) autoclaves.
6.3.2.3 Filter sterilizatiou
Heat labile solutions were sterilized by filtration through a Nalgene filter (pore 
diameter 0.2 pM) and collected in a sterile container.
6.3.3 Growth media
6.3.3.1 Liquid and solid bacterial growth
LB medium consisting of 1% tryptone, 0.5% yeast extract and 0.5% sodium 
chloride at pH 7.0 was used to grow E. coli. For plates, 15 g L'^  microagar was added to 
the media prior to autoclaving. Antibiotics were added after sterilisation, when the 
solutions have cooled to about 50°C. In growing agrobacterium, YEP medium, 
consisting of 1% tryptone, 1% yeast extract and 0.5% sodium chloride was used.
6.3.3.2 Solid plaut media
Solid plant media for growth of Arabidopsis plants consist of 1 x Murashage 
and Skoog (MS) salts + Gamborg’s Vitamin, 0.05% morpholinoethanesulfonic acid 
organic buffer (MES), 0.8% agar and 2% sucrose. The medium was sterilised and once 
cooled to 50°C, it was poured under sterilised conditions into 90 mm Petri dishes and 
allowed to set. For selection of transformants, 0.5 x Murashage and Skoog (MS) salts + 
Gamborg’s Vitamin was instead used. The appropriate antibiotic was added to the 
solution once it was cooled to 50°C.
6.3.3 3 Tissue culture media for tomato
a. Seed Germiuatiou media for tomato
The seed germination media of tomato consist 1 x MS salts, 1.5% sucrose, 
0.01% vitamin mix (consisting of thiamine, glycine, nicotinic acid, pyridoxine, folic 
acid, biotin and myo-inosital) at pH 5.7 and 0.7% agar.
b. Pre-culture media for ex-plants
The pre-culture media consist of 1 x MS salts, 3% sucrose, 0.01% vitamin
mix, 1 mg L^ benzylamino purine (BAP), 0.5 mg L^ naphthalene acetic acid
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(NAA), and 0.8% agar. pH was adjusted to 5.7 with KOH (before adding agar) and 
the medium was sterilized by autoclaving .
c. Shoot induction medium
The shoot induction media was prepared as above but instead of BAP and 
NAA, zeatin at 1 mg L'  ^ was added. The appropriate antibiotic was added to the 
solution once it was cooled to 50°C.
d. Shoot elongation medium
This media was similar to the shoot induction media but the quantity of 
sucrose and zeatin was reduced to 1.5% and 0.5 mg respectively. In addition to 
this, gibberellic acid (GA3) at 1 mg L'  ^ was added to the mixture. The appropriate 
antibiotic was added to the solution once it was cooled to 50°C.
e. Rooting medium
The rooting media was similar to the shoot elongation media but instead of 
zeatin and GA3, indole butyric acid (IBA) at 1 mg was added.
6.3.4 Plant growth and maintenance
6.3.4.1 Soil grown plants
Arabidopsis seeds were gown in autoclaved peat-based potting compost 
(Levington Horticulture Ltd.) that was pre-autoclaved and placed in trays soaked in 0.15 
g L'^  of a solution of the insecticide Intercept® (Scotts U.K., Bramford, Ipswich) for the 
control of aphids. The pots were then covered with cling film and vernalized for 2-3 
days at 4°C before transfer to growth conditions at 20°C under 16 hours daylength. 
Trays were maintained for three weeks at 100 pE m'  ^s'^  white light. Similar conditions 
were maintained for tomato but without vernalization and they were grown in pots.
Soybean seeds were pre-soaked in water for 5 h before placed on moist 
vermiculite in trays and placed in the growth chamber with similar conditions as above. 
The seedlings were harvested after seven days of sowing.
6.3.4.2 Surface sterilization of seeds
Seeds which were to be sown on sterile growth media or selection plates were 
surface sterilised.
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A. Arabidopsis
One CONCLOR 1000 tablet (Coventry Chemicals Ltd.) was dissolved in 35 
mL (IH2O, to which 2 drops of 1% (v/v) Tween 20 was added. Five mL of this stock 
solution was added to 95% ethanol. One mL of this sterilising solution was added to an 
appendorf tube containing 10-15 mg of Arabidopsis seeds. The tube sealed and inverted 
several times and left for 6.5 min. Further manipulations were carried out inside a sterile 
flow cabinet using sterile equipment and solutions, where the liquid was removed and 
washed twice in absolute ethanol. All traces of ethanol were removed and the seeds 
were allowed to dry for a further 30 min. Finally, the seeds were resuspended and 
washed five times in sterile water. The seeds were then distributed evenly on the agar 
plates. Agar plates were sealed with nescofilm and vernalized at 4°C for 2-4 days before 
being transferred to a growth chamber. The conditions of the growth chamber were 
similar to that of the soil grown plants. Seedlings were harvested and packaged into 
aluminium foil and frozen in liquid nitrogen before storage at -80°C.
B. Tomato
Tomato seeds were placed in a tea strainer and placed in a beaker with 70% 
ethanol and left for 1 min. Inside a sterile flow cabinet, the seeds were then sterilised 
with 5% sodium hypochlorite to which two drops of 1% (v/v) Tween 20 was added. The 
mixture was swirled occasionally for left for 20 min. The seeds were then transferred to 
agar plates using sterile forceps. The seeds were allowed to germinate at 20°C with 16 h 
photoperiod and at a light intensity of 100 pE m'  ^s '\
6.3.5 Plant treatments
6.3.5.1 UV-B illumination of plant material
UVB illuminations were carried out in controlled environment rooms at 20°C 
and the spectra were measured using a Macam Spectroradiometer SR9910 (Macam 
Photometries Ltd., Scotland). UV-B light was derived from Q-Panel UV-B 313 tubes 
(Q-Panel Co., U.S.A.). A cellulose acetate filter (Catalogue No. FLM400110/2925, 
West Design Products, Nathan Way, London) was used as standard and changed every 
24 h to eliminate any UV-C (wavelengths <280 nm) from the UV-B tubes (UV-C is 
therefore absent from the UV-B spectrum). Fluence of about 3 jxE m'  ^s'^  was achieved 
by varying both the number of fluorescent tubes used and the distance between the 
tubes and the plant material being illuminated. No white light was present. In addition
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to the Macam Spectroradiometer, a hand held RS232 meter, Skye Instruments (Powys, 
Wales) was also used to measure the UV-B (280-315 nm) with an SKU 430 sensor.
6.3.S.2 Basta selection
Selection of transgenics plants carrying the basta resistant genes was 
performed by sowing approximately 0.5 mL of seeds from infiltrated plants in soil trays 
(260 mm x 310 mm). Germination was synchronised by treatment at 4”C for 3-5 days. 
Trays were placed under long-day light at 21°C and seedlings sprayed first upon 
emergence and twice afterwards at 3-day intervals with 20% glufosinate ammonium. 
Basta-resistant plants were transferred to pots and grown to maturity. Plants were 
observed during growth for the presence of visible phenotypes.
6.3.6 Genomic DNA
6.3.6.1 Isolation of total DNA from plant material
(A) Arabidopsis
Approximately 100 mg of leaf tissue was harvested and DNA extracted from 
tissue using a Nucleospin kit (Clontech, Oxford, England). Leaves were ground in 
liquid nitrogen prior to addition to lysis buffer. DNA was then extracted and purified 
according to the manufacturer’s instructions.
(B) Tomato / soybean
For plants with higher tannin content, such as tomato and soybean, the 
GenElute Plant Genomic DNA miniprep Kit (Sigma-Aldrich, Poole, Dorset, UK) was 
used to extract the DNA. As above, 100 mg of the plant material were ground in liquid 
nitrogen before adding the lysis buffer. DNA was then extracted and purified according 
to the manufacturer’s protocol.
DNA was assayed spectrophotometrically on a Perkin Elmer Lambda 800 
spectrophotometer. The absorbance was measured between 260 nm and 280 nm against 
a sterile distilled H2O blank. The following formula was used to quantify the amount of 
DNA in the sample:
A260 X ( d i l u t i o n  f a c t o r )  x  50 ( c o n v e r s i o n  f a c t o r )  / pL = pg/pL
The integrity of the total DNA was determined by running 2 pL aliquots on agarose gel
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6.3 6.2 Agarose gel electrophoresis
Electrophoresis grade agarose (0.8-1.2 % (w/v) was added to 0.5 x TBE (44 
mM Tris-borate, 1 mM disodium EDTA, pH 8.0) for the gel cast. The suspension was 
heated in a microwave until the agaiose had completely dissolved. Once cooled to 
about 60°C, ethidium bromide was added to a final concentration of approximately 0.3 
pg mL^ and the gel solution poured into a casting tray. After the gel had set it was 
placed in the electrophoresis apparatus and submerged in 0.5 x TBE running buffer. 
DNA samples to be loaded were mixed with 1/10 volume of loading buffer (25% (v/v) 
glycerol, 5 mM disodium EDTA pH 8, 0.2% (w/v) bromophenol blue, 0.2% (w/v) 
xylene cyanol, 50mM Tris base) and applied to the gel with a pipette. Electrophoresis 
was allowed to proceed at 80-120 mA until the DNA molecules had been clearly 
separated. The gel was then visualized under UV light (transilluminator model TFM-20; 
Ultra-Violet Products, Cambridge, U.K.) and photographed using a Bio-Rad (Hemel 
Hempstead, Hertfordshire, U.K.) Gel Documentation System with Quantity One® 
(Version 4.3.0) Software. DNA Molecular Weight Marker X (catalogue No. 1498037, 
Roche Diagnostics, Mannheim, Germany) was used to calibrate DNA ft-agment sizes.
6.3.6.3 Oligonucleotide primers
The oligonucleotide primers used in this work were synthesized by MWG 
Biotech. The nested IFS primers were obtained from a published article (Jung et al., 
2000).
The nested primers were synthesised by MWG and their sequence are:
Forward: 5’- TGT TTC TGC ACT TGC GTC CCA C -  3’
Reverse: 5 - CCG ATC CTT GCA AGT GGA ACA A -  3'
Primer 3 (http: //www.basic. nwu. edu/biotools/Primer3.html) was used to design the full 
length IFS cDNA primers. Their sequences are
Forward; 5'- GTT ACC TCG GGA TCA CAG AAA CCA -  3’
Reverse. 5'- TCT AGA CCA GTA ACA CCT TAT TGA AAT GAT-3'
6.3.6.4 PCR
HotStarTaq master mix kit (Qiagen) was used with appropriate primers 
according to the protocol outlined by the manufacturers in Polymerase Chain Reaction 
to amplify cDNA fragments. The Polymerase Chain Reaction was carried out using 
DNA Engine PTC-200 Peltier Thermal Cycler (Genetic Research Instrumentation,
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Braintree, Essex, U.K.) machine. cDNA sequence comparisons were performed using 
the Basic Local Alignment Search Tool (BLAST) provided by The National Center for 
Biotechnology Information (NCBI) online (http://www.ncbi.nlm.nih.gov/blast/)
6.3.7 Genomic DNA
6.3.7.1 Isolation of RNA from plant material
Total RNA was isolated using the RNeasy Plant Mini Kit (Qiagen, West 
Sussex, UK). Young leaves were harvested and then quickly frozen with liquid nitrogen 
and ground to a fine powder using an RNase-free, chilled mortar and pestle on an ice 
bucket. Fine powder (approximately 100 mg) was transferred into a previously tared 1.5 
mL microfuge tube and the nitrogen liquid was allowed to evaporate, and then 450 pL 
RNeasy Lysis buffer (RLT) containing 1% 2-mercaptoethanol (BME, Fisher) was 
added. RNA was then extracted and purified according to the manufacturer’s protocol.
The absorbance (A) of the collected RNA was determined at 260 and 280 nm 
wavelengths using a Perkin Elmer Lambda 800 spectrophotometer and the following 
formula was used to quantify the amount of RNA in the sample:
A260 X (dilution factor) x 40 (conversion factor)/ pL = pg/pL 
The integrity and size distribution of the total RNA was determined by running 
1 pL and 2 pL aliquots of RNA on formaldehyde agarose (FA) gel. Two sharp RNA 
bands representing ribosomal RNA appearing on the stained gel indicate good RNA.
6.3.7.2 Formaldehyde agarose (FA) gel for RNA analysis
This method was used for gels that were to be blotted for Northern 
hybridization and to check the integrity of RNA extraction. Electrophoresis grade 
agarose at 1.2 % (w/v) was added to 72 mL of dH20. The agrose suspension was heated 
in a microwave until the agarose had completely dissolved. Once cooled to about 60°C, 
10 mL of 10 X MOPS (0.2M MOPS, 20 mM sodium acetate, 10 mM EDTA, pH 8.0) 
and 18 mL of formaldehyde (37% (v/v). Sigma) were added and the gel solution poured 
into a casting tray. After the gel had set it was placed in the electrophoresis apparatus 
and submerged in 1 x MOPS running buffer.
Total RNA, 5-10 pg per lane was added to equal volume of RNA loading 
buffer (100 pL of 5 X MOPS, 175 pL formaldehyde, 160 pL Ficoll dye, 10 pL ethidium 
bromide) and applied to the gel with a pipette. Electrophoresis was allowed to proceed
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in a fume hood at 50-70 mA until the RNA molecules have migrated to at least two- 
thirds down the gel. The gel was then visualized under UV light (transilluminator model 
TFM-20; Ultra-Violet Products, Cambridge, U.K.) and photographed using a Bio-Rad 
(Hemel Hempstead, Hertfordshire, U.K.) Gel Documentation System with Quantity 
One® (Version 4.3.0) Software.
6.3.7 3 RNA analysis by northern blot
A. RNA blotting
From the formaldehyde agarose gel, RNA was transferred to Hybond N 
membrane (Amersham, Bucks, England) according to the protocols outlined in 
Sambrook and Russell (2001) and fixed under UV-crosslink (Syngene Synoptics Ltd.).
B. Hybridisation, probes and phosphorimaging
(i) Pre-hybridisation
Membranes were placed in Techne roller hybridisation tubes (Techne, Stakks, 
UK) and covered with 15 ml of Northern Max hybridisation solution (Ambion, 
Huntingdon, Cambridgeshire, UK) containing denatured sheared salmon sperm 
(Ambion, Huntingdon, Cambridgeshire, UK) to a final concentration of 100 pg mL'\ 
Prehybridisation was carried out at 42°C for 18 h.
(ii) Probe
Denatured purified DNA fragments were labelled using using the Rediprime II 
DNA labeling system (Amersham Biosciences, UK), according to the manufacturer’s 
guidelines. The Rediprime II DNA labeling mixture consists of buffered solution of 
dATP, dGTP, dTTP, exonuclease free Klenow polymerase and random primers. Five 
pL of Rediprime mixture was added to a tube containing about 25 ng of denatured DNA 
and 50 pCi of a[32P]-dCTP (3000 Ci mmol'\ Amersham,UK). The labelling reaction 
progressed as outlined in the manufacturer’s protocol. The probe was then purified with 
Sephadex G50 Nick columns (Amersham, UK), which retains the unincorporated 
radiolabelled dCTP, but allows newly synthesised labelled DNA of greater than 50bp to 
pass through.
(iii) Hybridisation
The radiolabelled probe was boiled for 10 min, added to the filters and allowed 
to hybridise for 18 h at 42°C. Subsequently, the filters were subjected to SSPE washes
153
of different stringencies according to Sambrook and Russell (2001). Filters were then 
wrapped in cling film, placed in a cassette for phosphorimaging.
(iv) Phosphorimaging and quantification
Hybridization signals detected using a FLA 5000 phosphorimager (Raytek 
Scientific, Sheffield, United Kingdom). The total amount of RNA loaded onto each lane 
was quantified by pixel analysis of digitally reversed images of fluorescence, using 
Quantiscan for Windows (Biosoft, Cambridge, UK). The phosphorimages were scanned 
on a flatbed scanner (Hewlett Packard Scanjet 4470c), digitised and hybridisation was 
quantified by pixel analysis using Quantiscan for Windows.
6.3.7.4. Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
Following extraction of total RNA, a DNase treatment (DNA-free, Ambion, 
Huntingdon, UK) was used to eliminate contamination with genomic DNA according to 
the manufacturer’s protocol. First-Strand cDNA Synthesis was carried out using 
Superscript™ II reverse transcriptase (Invitrogen) according to the manufacture’s 
protocol. (http://www.invitrogen.conVcontent/sfs/manuals/superscriptll pps.pdf.). A 
20-pL reaction volume was used for 3-5 ug of total RNA and the reaction was allowed 
to proceed for 50 min at 42®C. Finally, the enzyme was inactivated by heating at 70°C 
for 15 min. The cDNA can now be used as a template for amplification in PCR.
6.3.8 Plasmid DNA
6.3.8.1 Isolation of DNA fragment from agarose gel
The DNA fragment of interest was initially separated from the residual DNA 
by agarose gel electrophoresis (section 6.3.6.2) and identified by comparing against I 
Kbp ladders (FMC, Surrey, UK). The appropriate bands were excised and the fragments 
were purified using a Quantum Prep Freeze-N-Squeeze Spin Column kit (Biorad, herts, 
UK).
6.3.8.2 Cloning of PCR products in plasmids
After purification the DNA fragment was inserted into pGlasglow and pER-8 
binary vectors by a series of digestion with restriction endonucleases followed by DNA 
ligations.
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(i) Digestion of DNA with restriction endonucleases
DNA restriction enzymes were used in accordance with the manufacturer’s 
instructions. DNA was prepared in a 1 x solution of the appropriate buffer (as 
recommended by the supplier) and approximately 5-20 units of restriction enzyme 
added to a concentration not exceeding 10 % (v/v). Reactions were incubated at the 
appropriate temperature overnight or for the required duration.
(ii) DNA ligations
After restriction endonuclease digestion and gel purification of DNA, the 
ligation reaction was as follows: The amount of insert needed = vector (ng) x kb size of 
insert/kb size of vector x molar ratio of insert/vector. Rapid DNA Ligation Kit (Roche 
Diagnostics, UK) consisting of T4 DNA ligase, T4 DNA Buffer and DNA dilution buffer 
was used to ligate the cDNA inserts in the pGlasglow, pCHF3 and pER- 8  vectors 
according to the manufacturer’s protocol. The plasmids were then checked by PCR 
using appropriate primers and by restriction digestion and gel electrophoresis, 
measuring the resultant fragments against a 1 Kb ladder.
6.3.S.3 Cloning of PCR products in Topo-vector
For the purpose of sequencing, PCR products were directly cloned into a 
plasmid vector, pCR®ll-TOPO and subsequently transferred to E. coli competent cells 
by One Shot® Chemical Transformation with the TOPO TA Cloning Kit (Invitrogen) 
as described in the manufacture’s manual.
6.3.S.4. Transformation of plasmids in E. Coli
For the purpose of amplification of the plasmid DNA, the pGlasglow, pCHF3 
and pER- 8  binary vector with the cDNA insert was transformed into E. coli DH5a cells 
using the methods described in Sections 6 .3.8 .5 -  6 .3.5.6.
6.3.S.5 Preparation of competent E. Coli cells
Chemical transformation was used to transform E. coli DH5a cells. DH5a 
cells were streaked onto a minimal plate (LB without antibiotics) and incubated at 37°C 
for 18 h. A five ml LB culture was inoculated with a single colony of the bacterial 
culture and incubated in a 2>TC shaking incubator ( 2 0 0  rpm) overnight. Two mL of this 
starter culture was then added to 100 ml of LB and allowed to grow until the absorbance 
at 650 nm reached about 0.5. The culture was centrifuged at 1000 g  for 10 min at 4°C
155
and the pelleted cells resuspended in 10 mL of pre-chilled Transfer Buffer 1 (consisting 
of 30 mM, potassium acetate, 100 mM rubidium chloride, 10 mM calcium chloride, 50 
mM manganese chloride and 15% glycerol at pH 5.8. After chilling on ice for 5 min, the 
culture was re-centrifuged and the pellet resuspended in 4 ml of Transfer Buffer II 
(consisting of 10 mM MOPS buffer, 10 mM rubidium chloride, 75 mM calcium 
chloride and 15% glycerol at pH 6.5). The cells were chilled on ice for a further 15 min 
and aliquots of it stored in -80"C until fiirther use.
6.3.8.6 Transformation of competent E. coli cells
Approximately 10-30 ng of binary vector plasmid DNA was added to thawed 
E. coli competent cells and left on ice for 20 min. The cells were then heat-shocked at 
42°C for 90 sec and returned to ice for a further 5 min. The cell suspension was then 
added to 5 mL of LB medium and incubated in a shaking incubator set at 200 rpm and 
at 37®C for 2 hours to allow expression of the antibiotic resistance encoded on the 
plasmids. Cells were then pelleted by centrifugation at 10,000 g for 1 min and the pellet 
resuspended in 150 pL of LB medium. 50-150 pL of the cell suspension was spread 
onto selective agar plates. The agar plates were incubated at 37°C and colonies appeared 
after 24 h.
6.3.8.7 Bacterial culture and isolation of plasmids
The E. coli stocks containing the vectors were grown under appropriate 
antibiotics according to Sambrook and Russell (2001). Bacteria was pelleted twice by 
centrifugation at 3000 g and resuspended in buffer PI of the QIAprep Spin Miniprep 
Kit (Qiagen, West Sussex,UK). The protocol outlined in the manufacturer’s manual of 
the QIAprep Spin Miniprep Kit was used to extract the plasmids.
6.3.8.8 Transformation of plasmids in agrobacterium cells
Since agrobacterium-mediated transformation will be adopted to transfer the 
cDNA of interest in tomato and Arabidopsis plants, the plasmids carrying the cDNA of 
interest was transformed into A. tumefaciens strain GV3101 using the methods 
described in Sections 6.3.8.8.1-6.3.8.8.2.
6.3.8.8.1 Preparation of competent agrobacterium cells
Five mL of YEP starter culture, containing 25 pg mL'  ^ of gentamycin was 
inoculated with a single colony of A. tumefaciens strain GV3101 and left to grow
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overnight at 28°C, shaking at 200 rpm. Two mL of this culture was added to 50 mL of 
YEP with 25 pgmL'^ of gentamycin in a 250 mL flask and left to grow at 28®C, and 
shaking at 200 rpm. Once the cultures reached an ODeoo of 0.5-1.0, they were chilled 
prior to centrifiigation at 3000 g for 5 minutes at 4°C. The pellets were resuspended in 
one mL of pre-chilled 20 mM calcium chloride. Aliquots of the agrobacterium cells 
were frozen in liquid nitrogen or dried-ice before storing at -80°C until further use.
6.3.8.S.2 Transformation of competent agrobacterium cells
Approximately 1 pg of binary vector plasmid DNA was added to thawed 
agrobacterium conpetent cells. The cells were frozen in liquid nitrogen and then thawed 
by incubating at 37°C for 3-5 min. One mL of YEP was added and the cells further 
incubated at 28^C for 2-4 h with gentle shaking to allow the cells to express the 
antibiotic resistance. The cells were centriftiged at 10,000 g  for 2 min and the pellet 
resuspended in 0.1 mL LB media. 50-100 pL of the cell suspension was spread onto 
selective agar plates. The agar plates were incubated at 28°C and colonies appeared after 
48 h.
6.3.9. Agrobacterium-mediated transformation into plants
A. Arabidopsis
The floral dip method was employed to produce Arabidopsis transgenic plants 
as outlined by Clough and Bent (1998). A. tumefaciens strain GV3101 was transformed 
with the plasmid pGlasglow, pCHF3 and pER-8 carrying the c DNA insert
B. Tomato
The tissue culture method as described by Oktem et al. (1999) was adopted to 
produce transgenic tomato plants. Once the tomato shoots have regenerated from the 
calli, they were transferred to the rooting media, which lacks the hormone zeatin, but 
contains Indol Butyric Acid (IBA) and the appropriate antibiotic for selection of 
transformants. Rooted plantlets were then transferred to boxes containing soil and kept 
covered with cling film in the growth chamber under low light intensity to acclimatise 
or "hardened o ff  for at least a week.
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6.3.10 Protein analysis
6.3.10.1 Total protein isolation
One g of freeze-dried plant tissue was homogenized in 5 mL of 1 x PBS 
solution to which protease inhibitor cocktail tablet (Roche Diagnostics, UK) was added. 
The homogenate was filtered through a 70 pm nylon mesh cloth and centrifuged at 
13,000 rpm for 10 min. The supernatant was collected and used for western blotting
6.3.10.2. Membrane protein isolation
One g of freeze-dried plant tissue was homogenized in chilled mortar on ice 
with 5 mL of homogenization buffer (consist of 25 mM MOPS, 0.25 M sucrose, 0.1 
mM magnesium chloride at pH 7.8). The homogenate was filtered through a 70 pm 
nylon mesh cloth and centrifuged at 8,000 g for 10 min at 4°C. The supernatant was 
removed to an ultra-centrifuge tube and centrifuged at 100,000 g for 1 h 15 min at 4°C. 
The pellet was then resuspended in 200 pL of resuspension buffer (250 mM sucrose, 4 
mM potassium nitrate and 5 mM potassium phosphate). This was then stored at -80°C 
in 20 pL aliquots.
6.3.10.3. Western blotting
An IPS antibody was prepared using a peptide sequence derived from the IFS 
coding region. The peptide NH2-DPKYWDRPSEFRPER (Yu et al., 2000) conjugated 
with KLH was produced by Davids Biotechnologie (Regensburg, Germany) and 
injected into a rabbit using their suggested immunization schedule. Serum from a bleed 
60 days after initial immunization, together with the extracted proteins from the 
transgenic plants was used to carry out westem-blot analysis according to Sambrook and 
Russell (2001). The membranes were wrapped in clingfilm, placed in a cassette and 
overlaid with Kodak MXB autoradiograph film in a dark room. The autoradiographs 
were exposed for an appropriate period and the film developed in an X-OMT Kodak 
developer.
6.3.11. Isoflavone analysis
Five hundred mg of frozen plant tissue samples were ground in liquid 
nitrogen, extracted with 80% (v/v) methanol. To hydrolyze any possible isoflavone 
conjugates, 1 mL of 6 M HCl were added to 5 mL of the extract and the sample was 
incubated at 90°C for 2 h. This was followed by partitionising into ethyl acetate. The
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ethyl acetate extract was then reduced to dryness in vacuo (Thermo Savant SPFD 
SpeedVac, Hampshire, UK). The dried extract was dissolved in 50 pL of 80% 
methanol. Ten pL aliquots of the centrifuged supernatant were analysed by HPLC- 
PDA-MS^. Separation was carried out using a 250 x 4.6 mm I D 4 pm Synergi Max-RP 
column and eluted with a 30 min gradient of 15-40% acetonitrile in 1% formic acid at a 
flow rate of 1 mL min'  ^ and maintained at 40°C. After passing through the flow cell of 
the diode array detector the column eluate was split and 0.3 mL min'  ^was directed to a 
LCQ DecaXP ion trap mass spectrometer fitted with either an ESI interface. Analyses 
utilised the negative ion mode for flavonoids. Analysis was carried out using full scan, 
data dependant MS  ^ scanning from m/z 100 to 1000. The capillary tenqjerature was 
250°C, sheath gas and auxiliary gas were 40 and 5 units respectively, and the source 
voltage was 5 kV for negative ionisation.
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6.4 Results
6.4.1 Detection of the IFS gene in Micro Tom tomato
The purpose of this study was to confirm earlier reports that the IFS gene is 
only found in the Leguminosae family and is not present in tomatoes. For this purpose, 
DNA of tomato was tested against the published nested IFS primers using PCR. Using 
the technique described in Section 6.3.6.1 tomato DNA was isolated and quantified at 
260 nm absorbance.
The nested primers were obtained from a published article (Jung et al., 2000) 
and synthesised by MWG. The nested primers are:
Forward: 5’- TGT TTC TGC ACT TGC GTC CCA C -  3'
Reverse: 5’- CCG ATC CTT GCA AGT GGA ACA A -  3'
DNA ranging from 74 -  300 ng pL'* was used. The thermal profile started with 15 min 
of dénaturation at 95 °C, followed by 30 cycles at 94 °C for 45 min, 50-54 °C for 1 min, 
72 °C for Imin 40 sec, and ended with an elongation step at 72 °C for 10 min. The gel 
electrophoresis indicated that PCR products were present with sizes of 700 bp and 1.5 
kb (Figure 6.1).
DNA was then extracted and purified from these two bands following the 
protocol described in Section 6.3.8.1 and cloned into the pCR 2.1 Topo vector using the 
TOPO TA Cloning® Kit for Sequencing (Section 6.3.8.3). Recombinant clones 
containing an insert of the correct size were selected and confirmed through PCR using 
colonies as template (Figure 6.2) and by restriction analysis (Eco Rl) on purified 
plasmids (Figure 6.3). The plasmids were then isolated and purified using the Qlprep 
Spin miniprep Kit as discussed in Section 6.3.8.7
The pCR4 TOPO vector-plasmids with the 1.5 kb and 700 bp fragments were 
sequenced. Blast was carried out on the above sequences using the pairwise and the 
standard nucleotide blast from NCBI (with the published IFS gene sequence Genebank 
no: AF195819). The pairwise blast revealed no homology to the published IFS 
sequence, suggesting that the IFS gene was not detected in tomato using the above 
nested primers. With the standard nucleotide blast, an 80% match was found between 
this sequence and the EST of tomato from cell culture (genbank no:BI209400) and an 
85% match with that of tomato radicle (genbank no: AW626375). This basically 
showed that the sequence identified is not IFS but another tomato gene.
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1.7 kb
700bp
Figure 6.1: Gel electrophoresis of PCR product after amplification o f tomato genomic DNA 
with nested IFS primers. 5 pL of the PCR product was used with 7 pL H2 O and 3 pL loading 
buffer for gel electrophoresis with 1% agarose C denotes negative controls, i.e., samples with 
distilled H2 O instead of genomic DNA as template. A & B are duplicate samples of tomato 
genomic DNA at varying concentration as indicated below:
Sam ple 1 2 3 4 C
T em p era tu re 50.0 °C 51 °C 52”C 54 °C 53 °C
DNA A 75 ng uL ' 150 ng uL ’ 210 ng uL ’ 300 ng uL ' 0
DNA B 110 ng uL ' 220 ng uL ’ 330 ng uL ' 440 ng uL ’ 0
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B1.5 kb 
fragm ent
S:iin|)lc.s
700 bp 
fragm en t
F igure 6.2: Gel electrophoresis o f  PCR product to confirm recombinant clones containing the 1.5 kb 
(A) and 700 bp (B) DNA fragment. 16 pL o f  the PCR product with 4 pL loading buffer was used for 
gel electrophoresis with 1% agarose. C denotes negative controls, i.e., samples with distilled H^O 
instead o f genomic DNA as template.
Plasmid DNA
950 bp 
450 bp
Plasmid DNA
7 0 0  bp
Sample 1
1 kb ladder
Figure 6.3: Gel electrophoresis o f  plasmid DNA containing the 1.5 kb (A) and 700 bp (B) 
fragment inserts after digestion witli Eco R l. 20 pL reaction m ixture was added to 5 pL o f  loading 
buffer for gel electrophoresis with 1% Agarose. There is an Eco R l digestion site in the 1.5 kb 
insert causing it to digest furtlier producing a 950 bp and 450 bp fragment.
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6.4.2 Designing primers for the full length sequence of the IFS gene
Primer 3 (http://www.basic.nwu.edu/biotools/Primer3.htmfi was used to 
design primers to clone the full length IFS cDNA based on the published IFS cDNA 
sequence from Glycine max (soybean), Genebank No:AF195798. Since efficacy and 
sensitivity of PCR largely depend on the efficiency of primers (He et ah, 1994), 
precaution was taken to ensure the following: primers were selected to have a G+C 
content of approximately 50% and had a melting tenqjerature (Tm) of 60°C. The 
difference in Tm between two primers within a primer pair was less than 3°C. Mis- 
priming was also minimized. Primers were synthesized by MWG Biotech. Since the 
purpose of the study is to clone IFS cDNA into a given vector for expression, short 
sequences with restriction sites were added prior to the 5' end of primer segments. The 
Hpa I  restriction site was added to the forward primer and the Xba I  was added to the 
reverse primer.
Their sequences are 5-GTT ACC TCG GGA TCA CAG AAA CCA-3' for the 
forward primer and 5'-TCT AGA CCA GTA ACA CCT TAT TGA AAT GAT-3’ for 
the reverse primer, respectively (The red letters denote the restriction sites). The primers 
were located 35 bp before the start codon and 65 bp after the stop codon on cDNA 
sequence (Appendix 1.1). The total length of the sequence is thus 1678 bp, of which 
1566 bp is the coding region (Appendix 1.2).
6.4.3 Detection and cloning qïIFS c D N A  from Glycine max cv. Envy (soybean)
The purpose of this study was to detect the expression of the IFS gene in the 
various plant parts and then to subsequently clone the soybean IFS gene using the full 
length IFS primers designed in section 6.4.2.
Using the technique described in Section 6.3.6.1, soybean RNA was isolated 
from the roots, stem, cotyledons and leaves of one week old soybean seedlings and 
subsequently quantified at 260 nm absorbance. The integrity of the RNA was checked 
by running the RNA on a formaldehyde (FA) agarose gel as indicated in Section 6.3.7.2 
(Figure 6.4). DNA was removed from RNA samples by using the DNA-free kit 
(Ambion) according to the manufacturer's instructions.
RT-PCR (as indicated in Section 6.3.7.4) was carried out to clone the IFS 
cDNA using oligo dT to prime the reaction and to generate a cDNA fragment 
containing the full coding region from the RNA. Following this, PCR of the cDNA was
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canied out using the following thermal profile: 15 min of dénaturation at 95 
followed by 30 cycles o f elongation at 94 "C for 45 min, 59-64 ”C for 1 min, 72 °C for 1 
min 40 sec, and ended with an elongation step at 72 "C for 10 min. To detect the 
presence of IFS cDNA in the PCR products, gel electrophoresis was can ied out. Only 
the roots had detectable IFS expression (Figure 6.5). The expression of IFS in the other 
plant parts may either be absent or too low for detection.
M— 50 m g-^  *4-200 m g-^  4  50 mg -► *4200 m g 4
F ig u re  6.4. FA  ag aro se  gel o f  R N A  ex trac ted  fro m  the  roo ts, stem , 
co ty ledons an d  leaves o f  o ne-w eek  o ld  so y b ean  seed lings. V ary in g  
am oun ts o f  p la n t tissu e  w as u sed  as  in d ica ted  in the  d iag ram .
1 7kb
Koot.s S tem i n l \  ledmi e ; i \e s L'diitrol
Fig 6 .5 . G el e lec trophoresis  o f  R T -P C R  p ro d u ct a fte r am p lifica tio n  of 
cD N A  from  vario u s tis su e  p a rts  o f  soybean  u s in g  ‘fu ll- le n g th ’ IFS  
p rim ers. 8 pL  reac tion  m ix tu re  w as ad d ed  to  7 p L  o f  w ate r and  7 p L  
o f  lo ad in g  b u ffe r in 1% agarose.
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DNA was then extracted and purified from PCR products of the root following 
the protocol described in Section 6.3.8.1 and cloned into the pCR 2.1 Topo vector using 
the TOPO TA Cloning® Kit for Sequencing (Section 6.3.8.3). Recombinant clones 
containing the IFS insert were selected and confirmed by PCR using positive colonies 
as template (Figure 6.6) and by restriction analysis (EcO Rl) on purified plasmids. The 
plasmids were multiplied and then isolated and purified using the Qlprep Spin miniprep 
Kit as discussed in Section 6 3.8.7. The pCR4 TOPO vector -plasmids with the IFS 
insert were sequenced with oligonucleotides M13Uni (-21) and M l3 Rev (-29). 
Sequence verification was perfbiTned using the NCBI Blast 2 Sequences engine 
(Tatusova and Madden, 1999) and compared with the Gen Bank database of published 
IFS cDNAsequence Genebank no;AF195819. We sequenced three independent clones, 
all were 99% identical to the published IFS sequence (Appendix 1.2) and showed 
differences in three nucleotides However none of these changes altered the derived 
amino acid sequence. These differences may have resulted either from a PCR error or 
more likely from polymoiphism differences between soybean cultivais.
Sam ples 
1 2 3 C
IFS (PC R  
p ro d u c t)  at 
1.7kb
1 kb ladder
F ig u re  6 .6 . G el e lec tro p h o resis  o f  P C R  p ro d u c t to  co n firm  rec o m b in an t c lones 
con ta in ing  IFS insert. 16 pL  o f  the  P C R  p ro d u c t w ith  4 p L  lo ad in g  b u ffe r  w as 
u sed  for gel e lec trophoresis  w ith  1% agarose. C  deno tes n eg a tiv e  con tro ls, i.e., 
sam ples w ith dH^O in stead  o f  g en o m ic  D N A  as tem pla te . O n ly  cD N A  of 
sam ple  3 h ad  the IFS insert.
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6.4.4 Construction of IFS plant expression vector
6.4.4.1 35S::IFS from pGlasglow
A schematic diagram of the construction of the plant expression vector 
35S. .IFS from pGlasglow is illustrated in Figure 6 .8 . In pGlasglow, the Luciferase gene 
was removed by restriction digestion at the Hpa I dsvAXba I site (Figure 6.7) according 
to the protocol outlined in Section 6.3.8.2. The full length IFS cDNA, was isolated 
from pCR 2.1 Topo vector using the same restriction sites. These digest were then run 
on an agrose gel and the IFS cDNA and the linearized vector was removed. T4 DNA 
ligase was used to join the compatible sticky ends of these two DNA fragments, and 
then transform the resulting recombinant plasmid into bacteria (Sections 6.3.8 . 2  and 
6.3.8 .6 ). The 35S:;/F5 binary vector derived from the pGlasglow contains a kanamycin 
resistance marker gene for bacterial selection and a Bar (BASTA) resistance marker for 
plant selection.
6.4.4.2 GlO-90: :IFS from pER8
A schematic diagram of the plant expression pER8  vector is illustrated in 
Figure 6.9. Xho I and Spe I were used to cut Topo-/FS' vector and the pER8  binary 
vector at the multiple cloning site. These digest were then run on an agrose gel and the 
IFS cDNA and the linearized vector was removed (Figure 6.10). T4 DNA ligase was 
used to join the conqjatible sticky ends of these two DNA fragments, and then transform 
the resulting recombinant plasmid into bacteria (sections 6.3.8 .2 and 6.3.8 .6 ). The GIO- 
9Q.:IFS from pER8  contains a spectinomycin resistance marker gene for bacterial 
selection and a hygromycin resistant marker for plant selection. In addition, GIO- 
90. .IFS also adopted the estrogen receptor-based chemical-inducible system (Zuo et al, 
2000).
6.4.4.3 3SSi:IFS from pCHF3
The binary vector pCHF3, which contains a CaMV 35S full promoter, the 
RBCS terminator from pea, and the kanamycin and spectinomycin resistance gene for 
plant selection and bacterial selection respectively was also used in this study. This 
vector was used to transform tomato as BASTA resistance is not a suitable selectable 
marker in this host. The pCHF3 plasmid was cut at the restriction digestion sites with 
Sma I and Xba I and the resultant linearized plasmid was ligated with the IFS cDNA, 
which was isolated from pCR 2.1 Topo vector (Figure 6 .1 1).
166
All these chimeric plasmids, containing the IFS cDNA insert, were confirmed 
by PCR using the IFS primers and by restriction analysis on purified plasmids. To 
confirm the conect orientation of the IFS cDNA insert, restriction fragment mapping 
analysis by further digestions with appropriate restriction sites were preformed as 
indicated in Figure 6.10. The plasmids were transformed into E. coli DH5a cells (as 
outlined in Section 6.3.8 6), multiplied and then isolated and purified using the Qlprep 
Spin miniprep Kit as discussed in Section 6.3.8.7
3 4 5
1 kb la d d er
Luciferase gene 
at 1.7 kb C ontro l
D ig ested  w ith  D ig ested  D igested
Xha I a n d  Hpa I w ith  Xba 1 w ith  Hpa I
Figure 6.7 Gel electrophoresis after digestion o f  pGlasglow  with Xba  I and Hpa I 
(lane 1) to remove the 1.7 kb Luciferase gene. Digestion with a single restriction 
enzyme (lane 3 and 4) resulted in no release o f  llie luciferase gene. Lane 5 is the 
undigested plasmid. 20 pL reaction m ixture was added to 5 pL o f  loading buffer in 
1% agarose.
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Figure 6.8. Construction of the 35S::/F5' from pG lasglow. The Luciferase gene was 
removed by restriction digestion at the Hpa I and Xba I site and the resultant linearized 
plasmid was ligated with the IFS cDNA, which was isolated from pCR 2.1 Topo vector. LB: 
left border; RB: right border, MCS, multiple cloning site; OSC: operator sequence
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L exA  VP16 OufxA-*^  M C S  ( G / = P )
Spa I
Figure 6.9. A schem atic d iag ram  of the  pE R 8 vector.
Only the region between tlie riglit and left borders is shown (not to scale). Pgio—90, a syntlietic 
promoter controlling XVE, XVE, DNA sequences encoding a chimeric transcription factor 
containing tlie DNA-binding domain o f  LexA (residues 1—87), the transcription activation domain 
o f  VP16 (residues 403—479) and the regulatory region o f  the human estrogen receptor (residues 
282-595); Tgg, rbcS E9 poly(A) addition sequaice; P„os, nopaline synthase promoter; HPT, 
hygromycin phosphotransferase 11 coding sequence; T„os, nopaline syntliase poly(A) addition 
sequence; Olcxa, eight copies o f  the LexA operator sequence; -4 6 , the - 4 6  35S minimal promoter, 
MCS, multiple cloning sites for target genes; Tja» rbcsS3A poly(A) addition sequence Arrows 
indicate the direction o f transcription (adapted from Zuo el al, 2000)
I Kt>
la d d e r
D ijieslw l w ith  I 
a n d  S //t' I
D i” i*ste<l wi t h  l l iu i  I
4 kb
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Figure 6.10. Gel electrophoresis after digestion o f  G10-90:://vS' from pER8 with 
Xho 1 and Spe 1 (lane 1-3) to remove the 1.7 kb IFS gene. Digestion witli Hpa I 
(lane 5-7) was to confirm tlie orientation o f  the IFS gene. With correct orim tation 
a 4 kb DNA fragment is released from tlie vector as observed above. 20 pL 
reaction mixture was added to 5 pL o f  loading buficr in 1% agarose.
Sma I Xba I
35 S
RB
u s c  DNA nm II
Figure 6.11. A schem atic d iag ram  of the  35S ::/F 5 ' from  pC H F 3
The pCHF3 plasmid was cut at the restriction digestion sites witli Sma I and Xha 1 site 
and the resultant linearized plasmid was ligated with tlie /FIS cDNA, which was isolated 
from pCR 2.1 Topo vector LB; left border; RB: right border; 35S, cauliflower mosaic 
virus 35S promoter, T, pea rubisco 3' terminator
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6.4.5 Introduction o f recom binant plasm ids into agrobacterium
The plant expression vectors 35S: JFS  from pGlasglow and pCHF3 and GIO- 
90 .IFS from pER8 were transformed into competent A. tumefaciens, strain GV3101 as 
outlined in Section 6.3.9. After transformation, the agrobacterium were plated out on 
gentamycin and kanamycin plates for 35S. .IFS from pGlasglow and on gentamycin and 
spectinomycin for 35S..IFS fiom pCHF3 and G10-90:.7F5' from pER8 Colonies were 
picked to inoculate LB medium, which was left to grow overnight Confirmation of the 
IFS inserts in the agrobacterium cultures were canied out by PCR using IFS primers 
(Figure 6.12). Positive cultures were used to proceed with the transformation of the IFS 
cDNA into plants
IFS al 1 7 Kb
I Kh Indue
IFS al 1.7 Kb—
Figure 6.12. Gel electrophoresis o f  PCR product to confirm 
recombinant plasmids clones containing IFS insert in agrobacterium 
A; agrobacterium-G 10-90; :/FS from pER8 ; B: agrobacterium- 
3SS::IFS from pGlasglow 16 pL o f  the PCR product with 4 pL 
loading bufTer was used for gel electrophoresis with 1% agarose.
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6.4.6. Agrobacterium-mediated transformation into Arabidopsis and tomato
6.4.6.1 Arabidopsis tansformation
The agrobacterium cultures with 35S;;/FS (from pGlasglow) and G10-90::/FS 
(from pER8) were used to transform Arabidopsis by floral dip method as outlined in 
Section 6.3.9. The Arabidopsis plants that were infiltrated with the agrobacterium were 
returned to the growth room and left to set seeds. After several weeks, the plants were 
left to dry and the seeds collected and surface sterilised as indicated in Section 6.3.4.2. 
The 35S: ./FS (from pGlasglow) seeds from agrobacterium-infiltrated plants were sown 
on soil and the transgenic plants were selected for basta resistance as outlined in Section
6.3.5.2. In contrast, G\0-90::IFS (from pER8) seeds from agrobacterium-infiltrated 
plants were sown on selection plates containing hygromycin. For both selections, a 
control. Col 0, the wild-type untransformed lines were also sown. After 2 weeks the 
robust-growing G10-90::/FS transformants were transplanted from the selection media 
onto soil.
6.4.6.2 Tomato transformation
In tomato, the tissue culture technique was adopted whereby cotyledons 
produced from sterile seeds were excised and used as explants following the protocols 
outlined in Section 6.3.9. The explants were cocultivated in agrobacterium containing 
the 35S.;/F<S (from pCHF3) and G10-90::/F5 plasmids. These explants were then placed 
on selection plates containing hygromycin or kanamycin for G10-90:;/FS and 35S::IFS 
transformants respectively. Carbencillin was also added onto the media to control the 
agrobacterium growth. Regenerated plants with shoot length of approximately 2-4 cm 
were excised from the callus and transferred onto a rooting medium in sterilized 
magenta boxes. The various stages of plant regeneration are illustrated in Figure 6.13.
Within four weeks, transformed shoots which developed good rooting system were 
transferred to soil. These plantlets were placed in trays and covered to increase humidity 
and reduce light intensity for at least a week before exposed to normal conditions.
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Figure 6.13. Various stages of tomato plant regeneration after infiltration with 
agrobacterium containing 35S;;1FS plasmids. A- one week old explants showing signs 
of callus induction, B- shoot formation on 2.5-week old explants ; C- shoot elongation 
and leaf production in 4-week old explants; D- root formation on 5.5-week old 
explants in majenta boxes
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6.4.7 Continuation of IFS transgenic plants
Genomic DNA was isolated from the leaves o f the primary (Tl) antibiotic- 
resistant plants using the protocol specified in Section 6.3.6.1. To detect the transgenic 
IFS lines, PCR was earned out using the IFS primers
A total of 98 PCR-positive IFS transformants lines were obtained from 
Arabidopsis and 4 PCR positive lines were obtained from tomato (Figure 6.14). No 
transformants were obtained in tomatoes when the pER8 binary vector was used. This 
may be due to the sensitivity of growth of tomato callus to the selection marker, 
hygromycin
IFS di 1.7 Kb
lFSd{ 1.7 Kb
IFS at 1.7 Kb
F ig u re  6.14. G el e lec tropho resis  o f  P C R  p ro d u cts  u sing  IFS  p rim ers  
o f  (A ) an tib io tic -resis tan t T l  A rab id o p sis  p lan ts  (B ) an tib io tic  
resistan t tom ato  p lan ts . 16 pL  o f  the  P C R  p ro d u c t w ith  4 p L  lo ad in g  
bu ffe r w as used  for gel e lec tro p h o resis  w ith  1% agarose . C  deno tes 
positive  contro l, i.e., sam ples w ith  3 5 S ::/F S  p la sm id  D N A  as tem p la te
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6.4.8 IFS  transgene expression
Independent PCR positive Arabidopsis transformants containing IFS were 
selfed, segregation ratios were determined based on their respective antibiotic/basta 
resistance, and then the process was repeated to identify lines homozygous for a single 
transgene locus. Seedlings of a homozygous line were germinated on the appropriate 
selective plates and were then transferred after 2 weeks to soil. 60 pM estradiol was 
sprayed to induce IFS transgene expression in pER8 Arabidopsis transformants. After 
24 h, leaves were harvested to investigate the IFS transgene expression. Total RNA, 
extracted fi*om leaves of the PCR-positive T2 /T3 transformants in Arabidopsis and Tl 
transformants in tomato (protocol outlined in Section 6.3.7.1) were used for Northern 
Blot analysis (protocol outlined in Section 6.3.7.3). In the Northern blots, full length 
IFS cDNA amounting to 50 ng pf* isolated from the 35S::IFS plasmid was used as the 
probe to hybridized the RNAs. RNA extracted from soybean was used as the positive 
control.
6.4 8.1. Quantification of IFS transgene expression
To offset the variation of the quantity of RNA loaded from lane to lane, for 
each lane, the quantity of hybridizing RNA was divided by the value of the total RNA. 
IFS transcript expression levels (arbitrary units) relative to the amounts of total RNA 
were then presented.
A. Arabidopsis
Out of the 20 PCR positive T2 homozygous 35S: :IFS lines (from pGlasglow), 
only one hybridised the IFS probe in the RNA leaf samples (Figure 6.15). In contrast, 
nineteen T2 homozygous lines out of thirty G10-90;:/FS' (from pER8) line exhibited 
transcripts levels of the IFS transgene as illustrated in the Northern Blot analysis (Figure 
6.17). No hybridisation was observed in any of the G10-90::/FS lines when no 
induction with estradiol was carried out (Figure 6.16), suggesting that the GlO-90 
promoter from pER8 activation system is tightly regulated and highly inducible in 
Arabidopsis (Zuo, et al, 2000). When the IFS transcript level of 35S::/F5 or GlO- 
90-. JFS were compared (in a single filter), a 3-10 fold higher expression level was 
observed in Arabidopsis transformed by pER-8 vector as indicated in Figure 6.18. In 
addition to this, the expression observed with the G10-90;:/F5 was also about 10-fold 
higher than that of soybean. These results indicate that in Arabidopsis, IFS transgene is
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effectively transcribed and pER8 is a better plant expression vector compared to 
pGlasglow. The moderate to highly expressed lines, that is, lines 13, 14, 15, 16 and 19 
were selected for the detection of the isoflavone, genistein.
B. Tomato
No hybridization was observed in all the four PCR positive tomato lines 
indicating very low IFS gene expression in tomato.
6.4.9 Phenotypical characterization of transgenic plants
Transgenic Arabidopsis plants overexpressing the IFS gene displayed no 
characteristic phenotype and they resembled the wild-type plants thoughout their life 
cycle.
Ll L2 L3 L4 L5 L6
-]U8 L9 LIO IJ l L12 control
F igure 6.15. Nortliem blot o f  T2 Arabidopsis 35S..IFS lines (from 
pGlasglow). Sample are applied in duplicates. Only line four (L4) exhibited 
transcript levels o f  the IFS fransgene. Control - positive control from 
soybean.
L1 L2 L3 L4 L5 L 6
control
F igure 6.16. Northern blot o f  Arabidopsis T2 G10-90;:/FS' lines (from 
pER8) before induction with estradiol. Sample are applied in duplicates. 
None o f  the line exhibited transcripts levels o f  the IFS transgene. Control - 
positive control from soybean.
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Figure 6.17. A: IFS transcript expression levels (arbitrary units) relative to the amounts o f  total RNA 
are presented for all the independent transgenic lines. Error bars indicate standard deviation.
B: Northern blot o f  Arabidopsis T2 G \0-90: JFS  lines. Samples are applied in duplicates. A total o f  19 
lines exhibited transcript levels o f  the IFS transgene. C is a positive control from soybean.
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Figure 6.18. Comparison of the IFS transcript expression levels (arbitrary units) relative to 
the amounts of total RNA are presented for soybean and the highly expressed Arabidopsis 
lines transformed by pERS and pGlasglow binary vectors. Northern blot indicating the 
expression levels of these transformants on the same filter membrane is also presented. Error 
bars indicate standard deviation.
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6.4.10 Flavonoid analysis
6.4.10.1. Detection of genistein in transgenic plants
G10-90;:/F5 (from pER8) lines, 13, 14, 15, 16 and 19 and the single 35S::IFS 
(from pGlasglow) that expressed the IFS transgene in Arabidopsis were ground to a fine 
powder in liquid nitrogen as outlined in Section 6.3.11 and analyzed for genistein 
accumulation by using the HPLC-MS^ and diode array detection. No fragmentation 
pattern or peak corresponding to the genistein standard was observed in any of these six 
independent transformant lines (Figure 6.19).
6.4.10.2. Induction of phenypropanoid pathway by UV-B
Availability of the naringenin substrate for IFS may be a factor limiting the 
synthesis of genistein in Arabidopsis as suggested by Jung et al. (2000). To further 
investigate the relationship of genistein production and phenylpropanoid pathway 
activity in Arabidopsis plants expressing IFS, the effect of stress induction of the 
pathway on the genistein production was investigated. As in other plant species, 
treatment of Arabidopsis plants with UV-B light has been shown to cause an increase in 
flavonoid accumulation in the leaves (Li et ah, 1993), indicating an increase in flux in 
the phenylpropanoid pathway, which in turn activates the production of the substrate 
naringenin.
The selected Arabidopsis transformants were placed directly under UV-B 
light for 6 hours following the protocol outlined in Section 6 3.5.1. Immediately 
following the UV-B treatment, the above-ground tissues of each UV-treated plant, as 
well as of untreated control plants, were ground to a fine powder in liquid nitrogen as 
outlined in Section 6.3.11, prior to analysis for genistein and naringenin accumulation 
by HPLC-MS^. No naringenin or genistein was detected in the control plants or in the 
IFS transformants after UV-B treatment. These results prompted us to investigate 
whether the IFS gene was functioning in vivo and synthesising the IFS protein.
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Figure 6.19. Comparison of a 15^0% gradient HPLC chromatogram of wild-type 
and transgenic Arabidopsis to a genistein standard and to soybean root samples. 
Genistein is only detected in soybean.
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6.4.11. IFS protein analysis
Presence of the IFS protein was assessed in leaves of the highly and 
moderately expressed transgenic Arabidopsis lines using an antibody raised to a 
synthetic peptide derived from the amino acid sequence of the IFS protein (Section 
6.3.10.3). Because the cytochrome P450 IFS is a membrane bound enzyme, both total 
protein and membrane protein isolation were carried out as outlined in Section 6.3.10.1 
and 6.3.10.2 on transformed Arabidopsis leaves. These were then used for westem-blot 
analysis.
The IFS antibody cross-reacted to a number of proteins of variable molecular 
sizes in both wild-type and transformed Arabidopsis as indicated in Figure 6.20. A very 
strong cross-reaction of IFS antibody with an unknown protein of about 250 kDa was 
observed in both the wild-type and transformed Arabidopsis (marked by a yellow arrow 
in Figure 6.20). The IFS antibody bound consistently to a band of 59 kDa in soybean, 
which is equivalent to the size of an IFS protein (Yu et al., 2000) in both the total 
protein and membrane protein extracts. A slightly larger protein of approximately 62 
kDa in two independent Arabidopsis transformed IFS lines (G10-90: :IFS) cross-reacted 
with the IFS antibodies which was absent from extracts of wild-type Arabidopsis 
(Figure 6.20-A, marked with a violet arrow). A corresponding higher IFS transcript of 
transformed lines was also observed in the Northern blots compared to that of soybean 
(Figure 6.20-C). The larger transcript seen here is presumably due to the extra addition 
base pairs added by the T-DNA of the vector pER8. This may have translated to a larger 
sized protein as observed in Figure 6.22-A. Similar size bands were however not 
detected in the transgenic lines when membrane protein isolation was carried out 
(Figure 6.20-B). These results tend to suggest that IFS protein did accumulate in the 
leaves of transgenic Arabidopsis but were not membrane-bound as it would be in its 
natural environment.
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Figure 6.20. Western (A, and B) and north mi (C) blots of Arabidopsis transformants compared to its 
wild-type and soybean. A was blotted with total proteins while B was blotted with membrane bound 
proteins.
In Blot A, an unknown protein of band size of approximately 250 kDa cross-reacted strongly 
with the antibody in Arabidopsis but very lightly in soybean, marked by the yellow coloured 
arrow.
In Blot A & B, there was a modest but consistent binding to a band of 59 kDa indicated by the 
blue coloured arrow in soybean (which is equivalent to the size of the IFS protein).
In Blot A, in the two independent pER8 transformant lines there was also reaction with the band 
of about 62 kDa which was absent from extracts of wild-type Arabidopsis, marked by a violet 
arrow.
In wild-type Arabidopsis, the antibody reacted with a protein which was also present in the 
transgaiic lines (Blot B), indicated by an orange coloured arrow.
The IFS transcripts in the northern blot (C) are slightly larger that the IFS transcript from 
soybean due to the extra base pairs added by the T-DNA of the pER8 vector. This may have 
translated to a larger protein size as seen in blot A indicated by the violet coloured arrow.
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6.5 Discussion
Two classes of genes can be distinguished within the flavonoid pathway: (a) 
the structural genes encoding enzymes that directly participate in the formation of 
flavonoids, and (b) regulatory genes that control the expression of the structural genes. 
Manipulation of the flavonoid pathway can be carried out by either down regulating or 
over-expressing these genes. In this study, manipulations were only carried out on the 
structural genes. A foreign structural gene from soybean, that is IFS was introduced and 
over-expressed in Arabidopsis and tomato to metabolically engineer a new isoflavonoid 
pathway that branches off from the existing phenylpropanoid pathway with the aim of 
leading to the production of isoflavones such as genistein.
6.5.1 IFS is not detected in tomato
Results from this study reveal that the IFS gene is not present in tomatoes. 
This is in accordance to the many reports that indicate isoflavonoids branch pathway is 
only prevalent in the Papilonoideae subfamily of the Leguminosae. (Dixon and Steele, 
1999, Graham, 1991). The absence of this branch pathway in most crops is due to the 
absence of the IFS gene. Although isoflavones such as genistein are formed from the 
flavanone, naringenin, which are ubiquitously present in plants, their formation involves 
an unusual aryl migration reaction, which is only catalyzed by the cytochrome P450 
enzyme, IFS enzyme (Steele et a/., 1999; Jung et ah, 2000).
6.5.2 Tissue specific localization of IFS gene expression
In this study, the full length IFS cDNA from soybean roots was cloned. IFS 
mRNA was not detected in the other soybean plant parts. This is consistent with the 
physiological roles of isoflavonoids as defense compounds against pathogens and signal 
molecules to symbiotic bacteria in soybean (Dixon & Steele, 1999). Recent 
investigation carried out by Subramanian et al. (2004a) provided direct genetic evidence 
that isoflavones are essential for nodule formation in soybean. In addition to this, the 
IFS expression was also found to be tissue-specific in response to both nodulation and 
defence signals. This was found to be due to the root-specific activity of the 
endogenous IFS promoter in soybean (Subramanium et a l, 2004b).
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6.5.3 Inducible versus a constitutive promoter
The availability of a broad spectrum of promoters that differ in their ability to 
regulate the temporal and spatial expression patterns of the transgene can dramatically 
increase the successful application of transgenic technology (Potenza et al., 2003). Due 
to this, two types of promoters were used, the CaMV 35S and an estrogen-inducible 
promoter G10-90. The CaMV 35S promoter is haboured in the pGlasglow and the 
pCHF3 plant expression vectors while the GlO-90 promoter is in pER8 inducible 
vector.
The CaMV 35S promoter is valuable not only because it delivers high 
expression in virtually all regions of the transgenic plant, but also because it is readily 
obtainable in research and academic settings, and available in plant transformation 
vector cassettes that allow for easy subcloning of the transgene of interest (Potenza et 
al, 2003). However, there are also a number of limitations in the use of virally derived 
promoter. When multiple copies of the transgene integrate into the genome, the 
probablity of transcriptional gene silencing is higher when viral promoters are used 
compared to constitutive promoters of plant origin (Meyer & Saedler, 1996; Potenza et 
al, 2003).
In some instances localized and targeted gene expression may also be more 
appropriate especially where the constitutive overexpression of transgenes may interfere 
with normal processes in a plant. This may be particularly important in the synthesis of 
genistein in non-legume crops. In their host plant, as metioned earlier IFS promoter is 
tissue-specific and is expressed mainly during root nodulation and pathogenic attack 
(Subramanium et al, 2004b). This together with the fact that genistein exhibits 
antimicrobial, anti-insecticidal and is a tyrosine kinase inhibitor (Dixon, 1999) indicate 
that the localization or spatial distribution of genistein is important. Exposure to 
genistein in all plant tissues over the life cycle of the plant may therefore have 
undesirable effects on the plant. Due to this an estrogen inducible GlO-90 promoter 
haboured in the pER8 vector was used.
6.5.4 Agrobacterium mediated transformation
This method takes advantage of the ‘natural’ plant genetic transformation 
system that evolved in agrobacterium The T-DNA is removed from agrobacterium and 
replaced with multicloning sites where genes of interest as well as dominant selectable
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markers are integrated. The agrobacterium harboring recombinant Ti plasmids can then 
be introduced onto wounded tissues (e.g.,leaf explants in culture) or even directly onto 
mature plant organs and in doing so, the bacterium will transfer the modified T-DNA to 
some of the cells of the host plant (Lessard et al, 2001). This system is relatively 
straightforward using the floral dip method as carried out in Arabidopsis. Using this 
method more than 90 PCR positive transformants were obtained, out of which 50 were 
selected for further investigation. However if complete regenerated plants are required 
as in tomatoes, then the process is complicated by the need for tissue culture-mediated 
plant regeneration. Despite considerable effort over the years, plant regeneration 
through tissue culture remains difficult, problematic, and time consuming. In some 
cases, unwanted somaclonal variation has been introduced through the tissue culture 
regeneration system (Lessard et al, 2001). In this study only 4 PCR positive 
independent tomato plants were regenerated through tissue culture. Most of the plants 
that regenerated on kanamycin (selection marker) were found to be false positives. 
When a more stringent marker, hygromycin, was used none of the callus regenerated 
into plantlets as observed with explants transformed with agrobacterium containing 
G10-90::/FiS' derived from pER8 vector.
6.5.5 p£R8 a better plant expression vector
Due to the nature of the pER8 construct and its promoter (Figure 6.9), a 3-10 
fold higher gene expression level was observed in Arabidopsis transgenic plants 
transformed by pER8 binary vector as compared to those transformed with pGlasglow 
(Figure 6.18). This is in keeping with the investigations carried out by Zoa et a l (2000) 
where upon induction, the pER8 promoter is capable of stimulating expression of a 
GFP transgene by eight folds higher than that obtained with a 35S::GFP transgene. In 
the present study, 63% of the PCR positive lines exhibited IFS transgene expression 
with the G10-90 promoter derived from pER8 vector. In contrast, only one line out of 
the 20 PCR positive lines exhibited IFS transgene expression when a 35S promoter was 
used. Similarly, when pCHF3 plasmid habouring the CaMV 35S promoter was used in 
tomatoes, very low gene expression was observed. A plausible explanation could be 
that due to the constitutive nature of the promoter, there may have been a natural plant 
defense mechanism by the host plant towards the introduced foreign DNA sequences 
and DNA modification such as:
• méthylation of the promoter and/or coding region (Scheid et al, 2002)
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• chromatin remodeling and excision of foreign DNA (reviewed in 
Kumpatlae^ fl/., 1998),
• homologous or ectopic pairing when multiple copies of the transgene 
integrate into the genome (Meyer & Saedler, 1996).
All these possibilities could have rendered inactivation of the transgene.
This study clearly indicates that the exogenous inducible promoter in the pER8 
plant expression vector was far more superior in inducing the IFS gene expression. In 
addition to reduced silencing, this system can also be applied at the discretion of the 
researcher to turn the transgene(s) on or off. This study also revealed that there was no 
basal level of gene expression in the absence of estrogen suggesting that the inducible 
promoter system in pER8 is a tightly controlled system.
6.5.6 Gene expressed but genistein not produced
Although very high levels of transcripts were obtained from the Arabidopsis 
transformants (Figure 6.17), no genistein was produced. This is in contradiction with the 
results obtained by other investigators (Yu et al., 2000; Jung et a l, 2000 and Liu et a l, 
2002) where trace amounts of genistein was found to accumulate in transformed 
Arabidopsis.
The lack of genistein obtained in this study could be due to a number of 
reasons. Varietal or ecotype differences may explain the contradicting results obtained 
as variation between plant species and cultivars have been demonstrated to lead to 
complications or unexpected results in pathway engineering (Lessard et a l, 2002). 
Genistein may have been produced in the IFS transgenic Arabidopsis with Col 0 
ecotype background but in very low amounts that were below the limit of detection. 
Other investigators used ecotype WS (Yu et a l, 2000; Jung et a l, 2000) and Landsberg 
Erecta (Liu et a l, 2002). Another plausible explanation is that genistein could be a 
transient intermediate, which were either rapidly metabolised or broken down to 
compounds that were not identified in this study.
The introduction of a new branch point within the existing pathway could 
interfere with endogenous flavonoid biosynthesis and/or fail to conçete with the 
endogenous pathway for common substrates such as narigenin, which may result in 
limited or no genistein production. Naringenin is the common substrate, which is shared
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between flavonoid and the isoflavonoid pathways. There are several other enzymes that 
utilize naringenin as a substrate. There are four known enzymes that use naringenin. In 
addition to F3H, flavone synthase (FNS), flavonoid 3'-hydroxylase (F3 H) and 
flavonoid 3 '5 '-hydroxylase (F3'5'H), all have been known to use naringenin to produce 
flavanones, flavones and precursors of flavones (Yu and McGonigle, 2005). 
Dihydroflavone reductase (DFR) can also directly use naringenin as a substrate to 
initiate the tissue-specific production of phlobaphenes (Grotewold et ah, 1994). In the 
present study, absence of naringenin in untreated control or IFS transgenic plants 
suggests that the endogenous amount of naringenin present may be insufficient for IFS 
to synthesise genistein. Alternatively, naringenin could also be a transient intermediate, 
which is rapidly metabolised and therefore does not accumulate in plant tissues. Direct 
evidence that naringenin was the rate-limiting step in transformed Arabidopsis lines 
were provided by Liu et al. (2002). Since F3H directly competes with IFS for the 
naringenin substrate, silencing of the F3H gene by the introduction of tt6/tt3 double 
mutant blocked a major portion of the flavonoid pathway and redirected the flow of 
substrate toward isoflavone biosynthesis and resulted in high levels of genistein (Liu et 
al., 2002).
Stress condition is known to activate the phenylpropanoid pathway, which 
could provide increased levels of the naringenin substrate. Therefore Arabidopsis 
transformants expressing the soybean IFS gene were exposed to UV-B irradiation for a 
specified length of time. However, no naringenin or genistein were detected in these 
treated Arabidopsis transgenic lines. This is in agreement with the investigations carried 
out by Yu et al, (2000) where UV-light treatment of /FS-transformed tobacco leaves to 
increase naringenin levels resulted in elevated flavonol levels but failed to enhance 
naringenin or isoflavone levels. It was, therefore, postulated that the flux through the 
phenylpropanoid pathway was tightly channeled to flavonol production, which in turn 
results in limited flux to the introduced isoflavone pathway (Yu & McGonigle, 2005).
6.5.7 IFS protein is formed but is not membrane bound
The evidence discussed earlier on the tightly regulated channeling towards the 
flavonol production tends to suggest that there is a closely regulated system of enzymes 
in the phenylpropanoid pathway. Winkel-Shirley, (1999) hypothesized that a physical 
complex exists between the following enzymes, CHS, CHI and F3H in non-legume 
crops In addition, 2 main types of CHIs have recently been discovered that is, type I
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and type II, and their distributions are highly family-specific (Shimada et at, 2003). 
Type 1 is present ubiquitously in most plants within the phenylproponoid pathway and 
isomerize only naringenin chalcone to naringenin while type II, is specifically 
distributed to only leguminous plants (Heller and Forkmann, 1993) and catalyses both 
naringenin chalcone to naringenin and isoliquiritigenin to liquiritigenin. Therefore, it is 
envisaged that, in leguminous plants both type I and type II CHIs participate in distinct 
enzyme complexes devoted to producing, for example, anthocyanin pigments and 
isoflavonoids in different organs and/or in different subcellular locations (Shimada et 
at, 2003). In the context of metabolic engineering, the utilization of the correct CHI in 
the production of isoflavonoids in transgenic plants can therefore be crucial. This was 
substantiated by the investigations carried out by Liu et al. (2002) where when IFS and 
type II CHI were introduced into a tt6/ttS double mutant background in Arabidopsis, 
genistein accumulation was enhanced by up to 30-fold as compared to plants expressing 
IFS alone. In total, these evidences tend to suggest that multienzyme complexes and 
protein-protein interaction between the key enzyme exist and they closely regulate the 
flux towards the isoflavonoid and flavonoid pathway. According to Dixon & Steele
(1999), these multienzymes conplexes sometimes maintain specific interactions and are 
even colocalized to defined regions in the cell to form dynamic complexes called 
“metabolons”. Metabolons facilitates rapid conversion of the product of one enzyme by 
the subsequent enzyme of the channel, which may overcome kinetic constraints imposed 
by the diffusion of metabolites within the cytosol. In addition, they can protect unstable 
intermediates from spontaneous breakdown or from potentially conpeting enzymatic 
reactions (Srere, 1987). However, metabolons can also confound attempts to engineer 
pathways by the introduction of transgenes that encode enzymes acting on intermediates 
that are channeled (Dixon, 2000).
In the present study, there is evidence indicating that the IFS protein is 
synthesized but the results also suggest that the protein is more likely to be free in the 
cytoplasm rather than membrane bound (Figure 6.20). In its natural environment, that 
is, in soybean, IFS is a membrane-bound protein and has been shown to be localized in 
the microsomes. In addition, IFS is closely associated with CHI II and isoflavone-O- 
methyltransferase (lOMT) and is postulated to form a mutienzyme complex as 
illustrated in Figure 6.21 (Liu & Dixon, 2001). The ‘free’ IFS detected in this study 
implies that IFS is not able to access the pre-existing multienzyme complex between
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CHS, CHI and F3H due to compartmentalisation and therefore is not able to synthesise 
genistein. Another possible explanation for the lack of genistein production in the 
transgenic plants is the absence of the legume CHI II, which may be important in 
forming enzyme complexes with IFS for the production of isoflavonols. Alternatively, 
failure to obtain genistein could also be due to the transport and accumulation processes 
rather than of biosynthesis per se (Dixon, 2005). This is also in keeping with the model 
of metabolons suggested by Liu and Dixon (2001) and Yu and McGonigle (2005). In 
this model the transient ER localization of IFS is important for the fonction of lOMT so 
that intermediates of the isoflavonoid pathway could flow rapidly from one enzyme 
center to the next, which may eventually fose with vacuoles (Figure 6.21). lOMT 
methylates the A-ring hydroxyl group, rendering the isoflavone more soluble for storage 
in vacuoles.
It is evident from the suggestion given above that the correct localization and 
transportation of IFS is crucial for the synthesis of genistein. The IFS protein has to 
migrate from its site of synthesis and orientate itself in the correct membrane. IFS being 
a membrane bound protein carries signals embedded within its structures that specify its 
subcellular distribution and endow it with the capacity to participate in regulated 
membrane trafficking processes. However, a matching sequence has to be present in the 
targeted membranes. A lack of recognition in the targeted membrane can result in the 
IFS being loose and not membrane-bound which could explain the results obtained in 
the present study.
Finally, there is also a possibility that some finer details in this pathway have 
not been unravelled. For entry into the isoflavone pathway, naringenin first undergoes 
abstraction of a hydrogen radical at C-3 followed by B-ring migration from C-2 to C-3 
and subsequent hydroxylation of the resulting C-2 radical, all of which is believed to be 
catalysed by IFS (Dixon, 2004). Before the production of genistein, an intermediate, 2- 
hydroxy-isoflavanone is formed. 2-Hydroxy-isoflavanone is unstable and readily 
undergoes dehydration to yield genistein at acidic pH. It has been suggested that a 
specific dehydrase enzyme catalyzes the 2-hydroxy-isoflavanone to isoflavone 
conversion in planta, and such an enzyme has been purified from Pueraria lobata, 
although it has not been characterized at the molecular level (Dixon, 2004). The absence 
of this enzyme in Arabidopsis may further reason for the failure to obtain genistein even 
though the introduced IFS enzyme is present.
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Figure 6.21. Proposed macromolecular complexes in the phenylpropanoid 
pathway. The isoflavonoid metabolon is shown on the left. The flavonoid 
metabolon after CHS is on the right. Arrows indicate metabolite flow (Adapted from 
Yu and McGonigle, 2005).
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6.6. Conclusion and further research
The success of metabolic engineering not only depends on the relative 
activities of all the enzymes that they comprise but also on the hidden more complex, 
non-linear, and largely unknown interactions of enzymes, regulators, and metabolites 
(Jung & Stephanopoulos, 2004). In addition, the level, timing, subcellular location, and 
tissue, organ and cultivar specificity that will be required from a transgene to ensure 
successful manipulation is also crucial (Lessard et al., 2002). Results from the present 
study indicates that correct choreographing of these factors is crucial in successfully 
engineering a foreign gene into plants.
Future research should be geared towards understanding these factors 
particularly of endogenous enzyme pathways which competes with introduced 
metabolically engineered enzymes. This can be an important factor when designing 
strategies for metabolic engineering. Beside this, not much is known about modifying 
enzymes and the corresponding genes that are responsible for glycosylation, 
méthylation and prénylation reactions that are important for flavonoid stability, cellular 
distribution, bioactivity and bioavailability. Many ‘failures’ in pathway engineering 
might also reflect a lack of understanding of transport and accumulation by these 
processes rather than of biosynthesis per se.
Alternative strategies for marker selection that will not have deleterious effect 
on the host plant especially during plant regeneration in the course of tissue culture 
should also be carried out. It will be even better, if resistance markers can be removed 
as this would also ease public concerns relating to the transfer of resistance markers to 
non-target species such as weeds or microbes (Lessard et al., 2002). Preliminary work 
on this topic involving the simultaneous but independent ‘co-transformation’ of plant 
cells with the marker gene on one DNA molecule and the desired second trait on a 
separate DNA molecule has been carried out by DeBlock and DeBrouwer (1991). 
Selectable markers were then removed from the whole plants via normal chromosomal 
segregation. However this technique is still at its infancy and needs to be fine-tuned 
before it can be used for plant transformation.
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Appendix 1.1 : Isoflane synthase c DNA from soybean Glycine max (Soybean)- 
AFl 95798.
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1 2 6 1 c a a g t a g g a a g g g a c c c c a a a t a c t g g g a c a g a c c a t c a g a a t t c c g t c c c g a g a g g t t c
1 3 2 1 t t a g a a a c t g g t g c t g a a g g g g a a g c a g g g c c t c t t g a t c t t a g g g g c c a g c a t t t c c a a
1 3 8 1 c t c c t c c c a t t t g g g t c t g g g a g g a g a a t g t g c c c t g g t g t c a a t t t g g c t a c t t c a g g a
1 4 4 1 a t g g c a a c a c t t c t t g c a t c t c t t a t c c a a t g c t t t g a c c t g c a a g t g c t g g g c c c t c a a
1 5 0 1 g g a c a a a t a t t g a a a g g t g a t g a t g c c a a a g t t a g c a t g g a a g a g a g a g c t g g c c t c a c a
1 5 6 1 g t t c c a a g g g c a c a t a g t c t c g t t t g t g t t c c a c t t g c a a g g a t c g g c g t t g c a t c t a a a
1 6 2 1 c t c c t t t c t t a a t t a a g a t a a t c a t c a t a t a c a a t a g t a g t g t c t t g c c a t c g c a g t t g c
214
1 6 8 1  t t t t t a t g t a  t t c a t a a t c a  t c a t t t c a a t  a a g g t g t g a c  t g g t a c t t a a  t c a a g t a a t t  
1 7 4 1  a a g g t t a c a t  a c a t g c a a a a  a a a a a a a a a a  a a a a
The red letters denote the location of the primers while the blue letters denote the start 
and the ends of the full length cDNA sequence
Appendix 1.2. IFS cDNA cloned from soybean
1 g t a a t t a a c c t c a c t c a a a c tc g g g a tc a c a g a a a c c a a c a a c a g t t c t t g c a c t g a g g t
6 1 t t c a c g a t g t t g c t g g a a c t t g c a c t t g g t t t g t t t g t g t t a g c t t t g t t t c t g c a c t t g
121 c g t c c c a c a c c a a g t g c a a a a t c a a a a g c a c t t c g c c a c c t c c c a a a c c c t c c a a g c c c a
1 8 1 a a g c c t c g t c t t c c c t t c a t t g g c c a c c t t c a c c t c t t a a a a g a t a a a c t t c t c c a c t a t
2 4 1 g c a c t c a t c g a t c t c t c c a a a a a g c a t g g c c c c t t a t t c t c t c t c t c c t t c g g c t c c a t g
3 0 1 c c a a c c g t c g t t g c c t c c a c c c c t g a g t t g t t c a a g c t c t t c c t c c a a a c c c a c g a g g c a
3 6 1 a c t t c c t t c a a c a c a a g g t t c c a a a c c t c t g c c a t a a g a c g c c t c a c t t a c g a c a a c t c t
4 2 1 g t g g c c a t g g t t c c a t t c g g a c c t t a c t g g a a g t t c g t g a g g a a g c t c a t c a t g a a c g a c
4 8 1 c t t c t c a a c g c c a c c a c c g t c a a c a a g c t c a g g c c t t t g a g g a c c c a a c a g a t c c g c a a g
5 4 1 t t c c t t a g g g t t a t g g c c c a a a g c g c a g a g g c c c a g a a g c c c c t t g a c g t c a c c g a g g a g
6 0 1 c t t c t c a a a t g g a c c a a c a g c a c c a t c t c c a t g a t g a t g c t c g g c g a g g c t g a g g a g a t c
6 6 1 a g a g a c a t c g c t c g c g a g g t t c t t a a g a t c t t c g g c g a a t a c a g c c t c a c t g a c t t c a t c
7 2 1 t g g c c t t t g a a g t a t c t c a a g g t t g g a a a g t a t g a g a a g a g g a t t g a t g a c a t c t t g a a c
7 8 1 a a g t t c g a c c c t g t c g t t g a a a g g g t c a t c a a g a a g c g c c g t g a g a t c g t c a g a a g g a g a
8 4 1 a a g a a c g g a g a a g t t g t t g a g g g c g a g g c c a g c g g c g t c t t c c t c g a c a c t t t g c t t g a a
9 0 1 t t c g c t g a g g a c g a g a c c a t g g a g a t c a a a a t t a c c a a g g a g c a a a t c a a g g g c c t t g t t
9 6 1 g t c g a c t t t t t c t c t g c a g g g a c a g a t t c c a c a g c g g t g g c a a c a g a g t g g g c a t t g g c a
1021 g a g c t c a t c a a c a a t c c c a g g g t g t t g c a a a a g g c t c g t g a g g a g g t c t a c a g t g t t g t g
1 0 8 1 g g c a a a g a t a g a c t c g t t g a c g a a g t t g a c a c t c a a a a c c t t c c t t a c a t t a g g g c c a t t
1 1 4 1 g t g a a g g a g a c a t t c c g a a t g c a c c c a c c a c t c c c a g t g g t c a a a a g a a a g t g c a c a g a a
1201 g a g t g t g a g a t t a a t g g g t a t g t g a t c c c a g a g g g a g c a t t g g t t c t t t t c a a t g t t t g g
1 2 6 1 c a a g t a g g a a g g g a c c c c a a a t a c t g g g a c a g a c c a t c a g a a t t c c g t c c c g a g a g g t t c
1 3 2 1 t t a g a a a c t g g t g c t g a a g g g g a a g c a g g g c c t c t t g a t c t t a g g g g c c a g c a t t t c c a a
1 3 8 1 c t c c t c c c a t t t g g g t c t g g g a g g a g a a t g t g c c c t g g t g t c a a t t t g g c t a c t t c a g g a
1 4 4 1 a t g g c a a c a c t t c t t g c a t c t c t t a t c c a a t g c t t t g a c c t g c a a g t g c t g g g c c c t c a a
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1 5 0 1  g g a c a a a t a t  t g a a a g g t g a  t g a t g c c a a a  g t t a g c a t g g  a a g a g a g a g c  t g g c c t c a c a
1 5 6 1  g t t c c a a g g g  c a c a t a g t c t  c g t t t g t g t t  c c a c t t g c a a  g g a t c g g c g t  t g c a t c t a a a
1 6 2 1  c t c c t t t c t t  a a t t a a g a t a  a t c a t c a t a t  a c a a t a g t a g  t g t c t t g c c a  t c g c a g t t g c
1 6 8 1  t t t t t a t g t a  t t c a t a a t c a  t c a t t t c a a t  a a g g t g t g a c  t g g t a c t t a a  t c a a g t a a t t
1 7 4 1  a a g g t t a c a t  a c a t g c a a a a  a a a a a a a a a a  a a a a
The red letters denote the location of the primers while the blue letters denote the start 
and the ends of the full length cDNA sequence. The pink letters denote the slight 
changes in the sequence when compared to the published sequence of soybean
21 6
